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Aggressive Non-Hodgkin lymphoma (aNHL) comprises a heterogeneous group of 
lymphatic malignancies. Although current treatment regiments can achieve high 
response rates, many patients do not achieve complete remission. Reliable and 
clinically applicable prognostic markers are needed to improve treatment strategies. 
Previous studies suggested a role for the cytokine interleukin 10 (IL10) for the 
initiation and progression of lymphomas. Conflicting data about associations of IL10 
gene variations or elevated IL10 serum levels with the clinical outcome of aNHL 
exists. Therefore, this study aimed at elucidating whether these two factors could be 
of prognostic relevance for aNHL outcome in independent larger clinical cohorts and 
to investigate molecular mechanisms contributing to this.  
Overall 1724 aNHL patients from three different clinical trials (NHL-B, RICOVER-60 
and MInT) have been included into this study. 604 patients were from RICOVER-60 
trial, of which sera were available from 523 patients. Survival analyses revealed that 
patients with low IL10 serum levels had a better treatment outcome compared to 
patients with elevated IL10 serum levels. This is also true for patients, treated with 
Rituximab in addition to chemotherapy, which is the current standard therapy. 
Therefore, circulating levels of IL10 could be of prognostic relevance for aNHL 
outcome. In addition, in vitro studies showed that IL10 treatment of target cells seems 
to reduce Rituximab-mediated antibody dependent cellular cytotoxicity (ADCC) but 
not complement dependent cytotoxicity (CDC). 
Furthermore, it was found that homozygous carriers the of IL10-11.668AA far distal IL10 
gene variation, located within an evolutionary conserved sequence, showed a better 
treatment outcome compared to carriers of the other two genotypes in the  
RICOVER-60 cohort (OS: HR=0.6; CI= 0.38-0.95; EFS: HR=0.6; CI= 0.41-0.87). 
Chromatin immunoprecipitation (ChIP) of modified histones revealed enhancer 
specific histone modifications around IL10-11.668G/A and other conserved sequences 
in transformed B cells. Therefore, they seem to be involved in IL10 gene regulation. 
Moreover, a very long non-coding RNA has been found to be transcribed from the 
IL10 gene locus. 
The results of this study confirm an important role for IL10 in the clinical course of 
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Malignant lymphomas comprise a group of hematological malignancies that usually 
form solid tumors in lymphatic organs due to uncontrolled clonal expansion. They 
often originate in the lymph node but can also affect other lymphatic tissues, i.e. 
thymus, spleen and bone marrow. The term Non Hodgkin Lymphoma (NHL) 
describes any kind of malignant lymphoma other than Hodgkin lymphoma (HL). NHL 
can be divided into aggressive (fast growing) and indolent (slow growing) types. This 
thesis concentrates on aggressive NHL (aNHL). Based on morphology, immunology, 
genetic aberrations and clinical aspects lymphoma entities can be described (Turner 
et al., 2010). The classification system has been adjusted regularly, based on new 
diagnostic tools. Today the classification system of the WHO is commonly used 
(Turner et al., 2010).  
In developed countries aNHL is the seventh most cancer diagnosed. The incidence 
of the disease has been increasing over the last decades (Jemal et al., 2011). This is 
probably in part caused by demographic changes as well as approved living 
circumstances and life expectancies in humans in developed countries. 
Despite therapeutic advances, many NHL patients do not achieve complete 
remission or they relapse after conventional chemotherapy and die of the disease. Of 
95 new cases (per 1000 of new cancer cases) in men and 84 new cases in women, 
37 and 33 deaths have been counted respectively in developed countries in 2008 
(Ferlay et al., 2010).  
New treatment strategies are required and a vast amount of new drugs has been 
developed during the last decades, based on an increasing knowledge about 
molecular mechanisms involved in lymphoma pathogenesis and progression. 
However, better prognostic factors, which are reliable and clinically applicable, are 




1.1 Non-Hodgkin Lymphoma 
Depending on their origination from B or T cells, aNHL is referred B- or T-NHL, 
whereby in developed countries approximately 90% of aggressive lymphoma are 
derived from B cells (Murawski and Pfreundschuh, 2010). NHL is found more 
frequently in men than in women and the relative risk to develop NHL is 10-100 or 
more times higher in people with immune deficiency due to immune suppressive 
therapy after transplantation or infection with HIV (Alexander et al., 2007; Grulich and 
Vajdic, 2005). 
The most common subtype of the very heterogeneous group of B-NHL is the diffuse 
large B cell lymphoma (DLBCL), which comprises approximately 30-40% of all NHL. 
DLBCL as well as other B-NHL arise from differentiating B cells during the germinal 
center reaction (1997; Kuppers, 2005). Most DLBCL are composed of cells 
resembling germinal center centroblasts (Friedberg and Fisher, 2008). A variety of 
chromosomal alterations, leading to aberrant expression of certain proto-oncogenes 
have been described for DLBCL, whereby translocations of BCL-6, a critical 
transcriptional repressor during germinal center formation, are the most common (Ci 
et al., 2008). Two molecular distinct subtypes of DLBCL have been identified via 
microarray-based gene expression profiling, the germinal center B-like DLBCL (GCB) 
and activated B-like DLBCL (ABC) (Alizadeh et al., 2000). 
Another aNHL is the Burkitt’s lymphoma (BL) which accounts for 2% of all NHL 
(Kuppers, 2005). Characteristic for the BL is a translocation of the proto-oncogene 
MYC into one of the immunoglobulin gene loci (Hummel et al., 2006). Different 
variants of BL exist. The endemic form, which is the most common malignancy in 
children in equatorial Africa, is associated with Epstein-Barr-Virus (EBV) infection. In 
developed countries the sporadic and the immunodeficiency associated forms of BL 
are predominant (reviewed in (Bellan et al., 2003)).  
T-NHL represent a rare and very heterogeneous group of NHL. T-NHL account for 
approximately 10% of all NHL, whereby a geographic variation in frequency could be 
observed for these lymphomas ranging from 1.5% (Vancouver, Canada) to 18.3% 
(Hong Kong, China). Compared to patients with B-NHL, a more aggressive clinical 
course and worse treatment outcome for patients with T-NHL is reported in most 
studies. The only exception is the anaplastic large cell lymphoma (ALCL), 
Introduction 
3 
overexpressing anaplastic lymphoma kinase (ALK) (Armitage et al., 2004; 
Gisselbrecht et al., 1998; Melnyk et al., 1997; Schmitz et al., 2010). 
Therapy of aggressive NHL 
For more than 25 years the cyclophosphamide, doxorubicin, vincristine and 
prednisolone (CHOP) has been standard treatment regimen for aNHL (Pfreundschuh 
et al., 2008). Due to an increasing knowledge about oncogenic pathways and 
molecules involved in pathogenesis and progression of distinct types of aNHL, 
obtained via gene expression profiling or other genomic and proteomic technologies, 
new therapeutic targets have been discovered and a vast amount of new drugs has 
been developed for the treatment of aNHL during the last decade (Mahadevan and 
Fisher, 2011; Murawski and Pfreundschuh, 2010). These include cytotoxic drugs, 
antibodies and other targeted therapies, targeting molecules or pathways 
characteristic for the lymphoma cells. These targeted therapies are thought to 
improve treatment responses especially in refractory and relapsed aNHL patients and 
to decrease side effects on normal tissue, thereby improving quality of life. Targets of 
these new drugs are for example certain receptor-associated kinases, histone 
deacetylases or molecules involved in the regulation of apoptosis, angiogenesis and 
immune modulation (Mahadevan and Fisher, 2011; Murawski and Pfreundschuh, 
2010).  
Due to these attempts to improve responses to chemotherapy a new standard 
therapy could be defined. The addition of Rituximab to conventional CHOP therapy 
significantly improved treatment outcome of young as well as elderly patients with 
aggressive B-NHL (Coiffier et al., 2002; Murawski and Pfreundschuh, 2010; 
Pfreundschuh et al., 2008; Pfreundschuh et al., 2006). Rituximab is a monoclonal 
chimeric antibody specifically targeting CD20 on the surface of normal mature and 
malignant B cells. How Rituximab mediates effects against malignant cells will be 
described in chapter 1.4. Several approaches have been undertaken to improve 
CD20 antibodies by humanization and/or glycoengineering. Antibodies which target 





Despite therapeutic advances, many patients with aggressive B-NHL do not achieve 
a complete remission with the so far best treatment regimen (Friedberg and Fisher, 
2008; Mahadevan and Fisher, 2011).  
Treatment of T-NHL remains a therapeutic challenge. Promising treatment strategies 
for B-NHL do not improve therapy of T-NHL patients (Nickelsen et al., 2009). Several 
new agents have been introduced in combination with CHOP therapy and/or stem 
cell transplantation, but most of them still need to be assessed in prospective clinical 
trials. In younger T-NHL patients the addition of etoposide to standard CHOP therapy 
(cyclohexamide, doxorubicin, vincristine, prednisolone), improved response rates 
(Schmitz et al., 2010). However, a more effective standard therapy for T-NHL has yet 
to be defined (O'Leary and Savage, 2008; Reimer et al., 2009). 
Good prognostic markers are essential to improve treatment strategies, to define 
patient subgroups and to compare different clinical trials. Today the International 
Prognostic Index (IPI), including the clinically relevant factors age, elevated lactate 
dehydrogenase (LDH), Ann Arbor stage, performance status and the involvement of 
extranodal sites is used to predict the outcome of NHL patients. Nevertheless, there 
is still a strong need to identify better prognostic markers in order to improve 
treatment strategies. 
Cytokines in aNHL 
Increasing evidence exists that the initiation or progression of aNHL is supported by 
certain cytokines, chemokines or their soluble receptors. Cytokines are important 
soluble mediators of low molecular weight, essential for the regulation magnitude and 
profile of innate and adaptive immune responses. They are produced by immune 
cells and facilitate communication between these cells. Cytokines can act in an 
autocrine, paracrine or endocrine fashion. They have pleiotropic properties, since 
they can affect the activity of many different cell types via binding to the respective 
receptors on the cell surface.  
Certain cytokines produced in the tumor microenvironment or by tumor cells can 
promote an enhanced tumor progression, invasion and metastasis for example by 
promoting inflammatory processes or by acting as paracrine or autocrine growth 
factors (Dranoff, 2004; Lin and Karin, 2007; Voorzanger et al., 1996). Context 
dependent certain cytokines also have the capacity to inhibit tumor development and 
progression (Dranoff, 2004).  
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Inherited gene variations or elevated secretion of certain cytokines have been 
frequently associated with susceptibility or disease outcome of aNHL and could 
therefore serve as prognostic factors in the future. In this context, pro- and anti-
inflammatory molecules such as TNF, Interleukin (IL)-4, IL6 or IL10 or their receptors 
are under investigation (Goto et al., 2006; Habermann et al., 2008; Hackstein et al., 
2001; Kube et al., 2008; Lech-Maranda et al., 2006; Skibola et al., 2007). Of 
particular interest for this thesis is the cytokine IL10. Therefore, it will be introduced in 
more detail in chapter 1.2. 
1.2 The cytokine Interleukin 10 
The active IL10 protein is a homodimer and each subunit consists of 178 amino acids 
and approximately 18kDa. IL10 is a highly conserved protein. 78% identity between 
the human and the mouse IL10 amino acid sequence can be observed. IL10 exhibits 
potent immunosuppressive and anti-inflammatory activity, repressing the expression 
of inflammatory cytokines such as TNF- (tumor necrosis factor-alpha), IL6 and IL1 
by macrophages (Fiorentino et al., 1991). In addition to this, IL10 induces the 
production of anti-inflammatory molecules. Therefore, IL10 is a cytokine with 
immune-modulatory functions, limiting inflammatory responses of the host (Moore et 
al., 2001). IL10 is secreted by a variety of immune cells including monocytes and 
macrophages, certain T cell subsets and B cells (Moore et al., 2001; Shoemaker et 
al., 2006). IL10 was first described as cytokine synthesis inhibitory factor (CSIF), due 
to its ability to inhibit activation of Th1 cells as well as production of cytokines like 
IFN- (Interferon-gamma) and TNF- by Th1 cells. This also lead to the 
characterization of IL10 as a Th2 (T helper 2 cells) cytokine, shifting the immune 
response from Th1 or T cell-mediated to a Th2 or humoral immune response 
(Mocellin et al., 2005). However, the down-regulation of cytokine production by T 
cells and also natural killer cells (NK cells) seems to be an indirect effect, mediated 
by inhibition of accessory cells like macrophages and monocytes (Moore et al., 
2001).  
IL10 is a potent growth factor for B cells by increasing the expression of the anti-
apoptotic gene Bcl-2 or by acting as a cofactor for proliferation of B cells after BCR or 
CD40 crosslink (Levy and Brouet, 1994; Rousset et al., 1992). 
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IL10 is thought to be involved in infectious and autoimmune diseases, transplantation 
tolerance and tumorigenesis (Moore et al., 2001). Due to its immunosuppressive 
properties or by stimulating cell proliferation and inhibition of apoptosis, it can 
promote tumor development and progression (Alas et al., 2001; Lu et al., 1995; 
Masood et al., 1995; Voorzanger et al., 1996).  
IL10 mRNA expression for example has been shown in tumor tissue samples derived 
from NHL patients an exogenous IL10 promoted proliferation of purified tumor cell 
preparations (Voorzanger et al., 1996). On the other hand, IL10 possesses 
immunostimulatory anticancer properties or inhibits angiogenesis (Cervenak et al., 
2000; Mocellin et al., 2005).  
IL10 signals through the IL10 receptor (IL10R). Two ligand binding subunits (IL10Rα) 
and two accessory subunits for signaling (IL10Rβ) form a functional IL10R. Binding of 
IL10 to the receptor leads to phosphorylation and activation of two receptor-
associated janus kinases, Janus Kinase-1 (JAK1) and Tyrosine Kinase-2 (TYK2), 
which in turn phosphorylates two tyrosine residues in the cytoplasmic tail of IL10Rα. 
Upon phosphorylation they form temporary docking sites for Signal Transducer and 
Activator of Transcription-3 (STAT3). STAT-3 binds via its Src Homology-2 (SH2) 
domain to the receptor and becomes phosphorylated by JAK1 and TYK2. STAT3 
forms homodimer, which translocate to the nucleus, where it binds to promoters of 
IL10 responsive genes (Donnelly et al., 1999). Therefore, phosphorylated STAT3 is 
the main transcription factor mediating IL10-induced signals. 
1.2.1 The IL10 gene locus and its regulation in immune cells 
The gene coding for IL10 is located on chromosome 1q31/32 and consists of 5 exons 
(Eskdale et al., 1997). Cytokine or cytokine receptor genes, as well as the IL10 gene, 
are frequently found in highly polymorphic „gene clusters“ (Keen, 2002). However, 
some regions within the IL10 gene locus show a high homology between species 
(Figure 1-1). Because these sequences are located within noncoding regions they 
are termed conserved noncoding sequences (CNS). This high conservation generally 





Figure 1-1 Evolutionary conserved noncoding sequences are located in the IL10 gene locus 
A comparison of the human IL10 gene locus (x-axis) and the opossum, rat, mouse and dog IL10 gene 
loci (y-axis) is shown. This comparison has been calculated using the browser for evolutionary 
conserved regions (ECR) (http://ecrbrowser.dcode.org). Sequences of similarity are marked by the 
height of the curves. A vertical axis cut-off of 50% to 100% identity is utilized to visualize only the 
significant alignments. Annotated genes (IL10) are depicted as a horizontal line above the graph. 
ECRs (pink rectangles on top of the plot), coding exons (blue), intronic regions (salmon-pink), 
transposons and simple repeats (green) and intergenic regions (red) are indicated. The CNS-12 and 
CNS+6 are indicated with black ovals. 
 
In addition, several single nucleotide polymorphisms (SNPs), microsatellites and one 
insertion/deletion variation have been described to be located within the IL10 gene 
locus (Figure 1-2). SNPs can be coding if they are located within the coding region, 
leading to an amino acid exchange or they can be regulatory (non-coding), if they are 
located within 5’- or 3’-regions or within introns of genes.  
Regulatory gene variations in the IL10 promoter are thought to influence the 
expression level of the cytokine, for example if they lie within transcription factor 
binding sites. This will be described in more detail in chapter 1.2.2. Moreover, certain 
IL10 gene variations have been associated with the outcome of aNHL and might be 





Figure 1-2 Scheme of the IL10 gene locus 
The human IL10 gene locus from -16.400bp till +6800bp on chromosome 1q31/32 is shown. Single 
nucleotide polymorphisms (SNP) and the insertion/deletion variation at -7400bp are indicated. In 
addition, the locations of two dinucleotide repeats IL10.R and IL10.G as well as one complex repetitive 
sequence, the IL10.D are indicated by red arrows. The IL10 gene and the position of the ATG are 
shown. UTR (yellow), exons (dark blue) and introns (white) are displayed.  
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Molecular mechanisms that contribute to the regulation of IL10 expression are still 
under investigation. Several studies examined these mechanisms in macrophages 
and DC (Dendritic cells) or T cells from mice. Thereby mechanisms have been 
revealed that are exclusive for one cell type, while others are common to all cell types 
investigated. For B cells the exact involved signaling pathways and molecular 
mechanisms remain elusive.  
IL10 expression in macrophages can be induced via inflammatory signals like the 
stimulation with LPS, whereas in T cells proliferative signals like the stimulation with 
PMA lead to IL10 expression. Notably, the induction of IL10 takes several hours (4-6) 
in both cell types. IL10 expression in macrophages and DC is induced via the 
activation of the extracellular signal-regulated kinase (ERK), p38 or nuclear factor-κB 
(NF-B) pathways (Boonstra et al., 2006; Dillon et al., 2004; Yi et al., 2002). ERK and 
p38 signals are mediated via the transcription factors CREB and AP1. IL10 
expression in different subsets of T cells is also ERK- but not p38-dependent and 
involves distinct signal transducer of activation (STAT) pathways. IL10 expression 
has been found to be accompanied by, and in the case of memory Th1 and Th2 
cells, also conditional on the expression of those cytokines characteristic for the 
respective subset (Chang et al., 2007; Saraiva et al., 2009; Shoemaker et al., 2006). 
IL10 itself provides a negative feedback loop controlling its own production (Hammer 
et al., 2005). 
In both macrophages and T cells many different transcription factors have been 
identified via mutagenesis or chromatin immunoprecipitation (ChIP). However, 
remodeling of the IL10 locus has been found to be required for transcription factor 
binding (Lucas et al., 2005; Shoemaker et al., 2006; Zhang et al., 2006).  
In eukaryotes DNA of the cell is found in the nucleus organized on separate 
chromosomes. In non-dividing cells the chromatin seems to be distributed throughout 
the nucleus and is organized into heterochromatin or condensed chromatin and the 
euchromatin, which resembles the more open confirmation (Felsenfeld and Groudine, 
2003). Chromatin is organized in nucleosomes, each containing 147bp of DNA 
wrapped around an octamer of the core histones (2xhistone 2A (H2A), 2xH2B, 2xH3 
and 2xH4), linked by 10-60bp of linker DNA. This “beads on a string” arrangement is 
folded into more condensed fibers of chromatin and stabilized by linker histones (H1 
and H5). Due to this organization of DNA into condensed fibers, posttranslational 
Introduction 
9 
modifications are necessary to make the DNA sequence accessible for other proteins 
like transcription factors. These posttranslational modifications include acetylation, 
methylation as well as phosphorylation of certain amino acids within the amino- or 
carboxy-terminal residues of the histones. Thereby, it seems that a pattern of histone 
marks determines whether these posttranslational modifications are associated with 
transcriptional activation or repression (Peterson and Laniel, 2004). 
By identification of DNaseI- hypersensitive sites (HSS), studies on IL10 regulation in 
T cells and macrophages revealed that the chromatin at the IL10 locus is remodeled 
in IL10 producing cells. These HSS can be inducible or constitutive (Im et al., 2004; 
Lucas et al., 2005; Wang et al., 2006). Most HSS are common to differentiated Th1, 
Th2 cells (but not naïve T cells) and macrophages, while others are unique to one 
cell type. HSS-4.5 for example is only found in macrophages and inducible by LPS 
stimulation. It is hyperacetylated upon LPS stimulation and comprises a binding site 
for NF-B (p65). Acetylation of certain amino acids within the amino-terminal 
residues of H3 and H4 is often associated with transcriptional activation (Li et al., 
2007; Peterson and Laniel, 2004). Inhibition of NF-B leads to reduction in IL10 
mRNA (Saraiva et al., 2005). 
Some of the HSS correlate with CNS (Figure 1-1). Several of these CNS function as 
enhancer elements in Th2 cells as shown by Jones and Flavell (Jones and Flavell, 
2005). The same group could show that some CNS possess promoter function and 
transcribe intergenic RNA in Th2 cells and in most cases also in Th1 cells, whereby 
the exact role of these RNAs for IL10 gene regulation remains to be elucidated. Two 
CNS, CNS-9 and CNS+6.45 were repeatedly emphasized not only by Jones and 
Flavell. CNS+6.45 for example has been shown to bind AP1 in Th2 cells. Later on, 
NFAT1 and IRF4 were shown to bind to CNS-9, preferentially in Th2 cells (Lee et al., 
2009a). CNS-9 is located 12kb downstream of the IL10 TSS (transcription start site) 
in the human genome and will therefore be referred to as CNS-12 for the human IL10 
gene in this dissertation. CNS+6.45 is located around 6kb upstream of the TSS and 
will be referred CNS+6 for the human IL10 gene (Figure 1-1). 
GATA binding protein 3 (GATA-3), a key main transcription factor needed for Th2 
differentiation, was found to regulate IL10 expression in Th2 cells. One binding site is 
located in CNS+6.45, and binding of GATA3 induces chromatin remodeling and 
histone acetylation at the IL10 locus (Shoemaker et al., 2006). For the induction of 
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IL10 expression additional stimuli are necessary, thus GATA-3 induces changes in 
chromatin structure at the IL10 locus, which are required for other transcription 
factors to bind to the DNA and induce IL10 expression. 
Similar mechanisms have been found to contribute to IL10 gene regulation in 
macrophages. Two stimuli are needed for full induction of IL10 expression. Fc-R 
ligation with immune complexes leads to activation of the mitogen activated protein 
kinases (MAPK) ERK and p38. This induces chromatin remodeling at IL10 gene 
locus, transient phosphorylation of histone 3 (H3) and increased accessibility, shown 
by DNAse I HSS. LPS stimulation then leads to activation of other transcription 
factors (Sp1 and STAT3), which are now able to bind to the IL10 promoter and to 
induce IL10 expression. Fc-R ligation alone does not induce IL10 expression (Lucas 
et al., 2005; Zhang et al., 2006). 
Therefore, one can conclude that both T cells and macrophages need two signals for 
IL10 induction. One signal that leads to an open chromatin confirmation and a 
second one that induces transcription factors (Lucas et al., 2005; Shoemaker et al., 
2006; Zhang et al., 2006) In macrophages the first signal seems to be provided by 
ligation of immune complexes to Fc-R, while the second signal is transmitted by 
inflammatory signals (Lucas et al., 2005; Zhang et al., 2006). In T cells the 
differentiation into Th2 or regulatory T cells (Treg) resembles the first signal. The 
second one is provided by signals inducing proliferation like PMA/Ionomycin 
stimulation (Jones and Flavell, 2005; Shoemaker et al., 2006). Nevertheless, even 
beside the nature of the two signals, there seem to be differences in IL10 regulation 
in T cells and macrophages.  
Little is known about the molecular mechanisms of IL10 regulation in B cells, even 
though IRF-1 and STAT3 seem to be involved in these processes (Benkhart et al., 
2000; Ziegler-Heitbrock et al., 2003). STAT3 is thought to be responsible for the 
induction of IL10 expression after LPS or INF- stimulation of the RPMI8226.1 B cell 
line, whereas IRF-1 is only induced after INF- stimulation of the same cell line. No 
other B cell lines were tested (Benkhart et al., 2000; Ziegler-Heitbrock et al., 2003). 
INF- down-regulates IL10 expression via STAT1 induction, which leads to a 




In the past it has been observed that the fact that several Burkitt’s lymphoma cell 
lines were positive for EBV (Epstein-Barr virus) is correlated to some extent with IL10 
expression and that one mechanism to induce IL10 expression in normal human B 
cells is by immortalization of these cells via in vitro EBV infection (Benjamin et al., 
1992; Burdin et al., 1993). B cells immortalized in vitro with EBV are termed LCLs 
(Lymphoblastoid cell lines). As a consequence of EBV infection, LCLs express 
several proteins, among them LMP1 (latent membrane protein 1), a protein 
significantly contributing to transformation and immortalization of B cells (Kaye et al., 
1993; Kilger et al., 1998). LMP1 activates NF-B, AP1 and mimics B cell activation 
processes which are physiologically triggered by CD40 signaling (Kieser et al., 1997; 
Kilger et al., 1998). Moreover, LMP1 has been shown to activate IL10 expression in 
Burkitt’s lymphoma cell lines through p38 activation but not in cell lines derived from 
other NHL or HL (Vockerodt et al., 2001). Reporter assays revealed positive and 
negative regulatory regions within the first 1100bp of the IL10 promoter in EBV 
positive Burkitt lymphoma cell lines (Kube et al., 1995). These regions seem to differ 
between EBV positive and negative cell lines with constitutive IL10 expression (Kube 
et al., 1999).  
As aNHL originates in 90% from B cells, knowledge about the regulation of IL10 gene 
expression and pathways involved in these processes in this cell type would be of 
great importance for the development of future therapeutic targets. So far, nothing is 
known about chromatin modification processes involved in IL10 gene regulation. 
1.2.2 Interindividual differences in IL10 production 
Twin studies indicated that 50 to 75% of interindividual differences in IL10 production 
are heritable (Reuss et al., 2002; Westendorp et al., 1997). Based on data obtained 
from in vitro studies of whole blood cultures or PBMCs stimulated with different 
agents, differences in interindividual IL10 production have been attributed to genetic 
variations, including the IL10 microsatellite alleles as well as SNPs or haplotypes 
formed by these gene variations in the 5’-region of IL10 (Crawley et al., 1999; 
Eskdale et al., 1998; Gibson et al., 2001; Mormann et al., 2004; Rieth et al., 2004; 
Turner et al., 1997).  
Some of the best studied gene variations are the SNPs IL10-1087A/G, IL10-824C/T,  
IL10-597A/C forming only three different haplotypes in Caucasian populations, ATA, 
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ACC and GCC (compare to Figure 1-1 and 1-3). Donors of the ATA haplotype    
(IL10-1087A, -824T, -597A) for example were described as „low IL10 producers”, while 
carriers of the GCC haplotype (IL10-1087G, -824C, -597C) have been considered as “high 
IL10 producers”, which is supported by studies of whole blood cultures and PBMCs 
as well as transient transfection studies (Crawley et al., 1999; Turner et al., 1997). 
This has been explained by the authors with data indicating that IL10-1087A/G occurs 
within a putative binding site for transcription factors from the Ets (E-twenty six) 
family of transcription factors. The other two polymorphisms lie in putative positive 
and negative regulatory regions, respectively and IL10-597A/C lies within a putative 
STAT3 binding site (Crawley et al., 1999; Kube et al., 1995). 
Later on, gene variations in the more distal parts of the IL10 gene have been 
proposed to be of higher importance (Gibson et al., 2001). The A-G/A-A haplotypes, 
formed by IL10-3538A/T, IL10-2812G/A and IL10-2726C/A showed lower IL10 production in 
whole blood cultures stimulated with LPS compared to the TGC haplotype (red box in 
Figure 1-3). Moreover, the GCC haplotype (IL10-1087G, -824C, -597C) was present in 
combination with A-G/A-A as well as TGC haplotype and not associated with high or 
low production of IL10 (green box in Figure 1-3).  
 
Figure 1-3 Distal IL10 haplotypes defined by Gibson et al. 
IL10 haplotype frequencies were defined in 52 Caucasian normal blood donors by Gibson et al. A 
scheme of the IL10 5’region is shown. The 7 SNPs genotyped in the blood donors as well as the two 
dinucleotide repeats IL10.R and IL10.D are indicated. The translation start site of the IL10 gene is 
indicated by ATG. Beneath the scheme the estimated haplotypes are shown. Frequencies are given 
for distal (red box) and extended haplotypes. The proximal haplotypes originally found to influence 
IL10 expression are emphasized by the green box. The figure is taken and modified from Gibson et al. 
2001 (Gibson et al., 2001). 
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However, depending on the stimulus used for the induction of IL10, different IL10 
gene variations seem to be of importance (Mormann et al., 2004). In line with this, 
homozygous carriers of the deletion of the insertion/deletion gene variation at 
position -7400 (IL10-7400In/Del, see Figure 1-2) were characterized by a significantly 
higher IL10 production capacity compared to the other two genotypes in PBMCs 
stimulated with LPS (Rieth et al., 2004). The same trend has been observed for 
cAMP stimulated PBMCs or EBV immortalization (LCLs). However, in these groups 
the trend was not significant, which might be due to the rare number of homozygous 
carriers of the deletion. Notably, the IL10-7400Del allele is in strong linkage 
disequilibrium to the IL10-1087G allele. Both have been described to be associated 
with high IL10 production.  
 
Taken together, the results of the implemented studies described above illustrate that 
regulatory gene variations within the IL10 promoter could influence interindividual 
differences in IL10 production. However, data are still incomplete and an ultimate 
answer to the question which gene variations and haplotypes influence IL10 
production under which conditions does not exist. 
Interindividual differences in IL10 production and therefore IL10 gene variations are 
thought to play a role for the establishment and outcome of certain diseases 
including aNHL. Therefore, a better knowledge and understanding of the influence of 
gene variations within the IL10 gene locus on interindividual IL10 production is 
mandatory for the interpretation of survival analyses revealing associations between 
certain gene variation and the outcome of aNHL. The role of IL10 gene variations as 
prognostic factors for aNHL outcome will be handled in the following chapter. 
1.3 Gene variations and serum levels of IL10 as prognostic factors for 
NHL outcome 
In recent years numerous studies have been undertaken to elucidate the role of gene 
variations in cytokine and cytokine receptor genes, possibly influencing the 
interindividual expression levels of the respective cytokine, for the susceptibility and 
the clinical course of malignant lymphoma as well as other types of cancer, 
autoimmune diseases or transplantation tolerance. Thereby numerous associations 
of gene variations with disease outcome have been reported.  
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In this context, the cytokine IL10 has been in the focus of a number of studies. Some 
reports provided evidence that the risk to develop lymphomas as well as the clinical 
outcome of aNHL patients could be related to some extent to defined IL10 gene 
variations. (Breen et al., 2003; Cunningham et al., 2003; Habermann et al., 2008; 
Kube et al., 2008; Lech-Maranda et al., 2004; Rothman et al., 2006). The IL10-1087G 
allele has been found to be associated with a superior clinical outcome in DLBCL 
patients (Domingo-Domenech et al., 2007; Lech-Maranda et al., 2004), which could 
not be confirmed in two independent aNHL patient cohorts (Berglund et al., 2005; 
Kube et al., 2007). Moreover, the TGCC haplotype formed by IL10-3538T, IL10-1087G, 
IL10-824C and IL10-597C has been associated with a 2.4 enhanced relative risk of 
shorter overall survival (OS) (Habermann et al., 2008). In 2006 two controversial 
studies related to the IL10-3538A/T gene variation were published. A report from the 
InterLymph consortium found the IL10-3538A allele to be associated with an increased 
susceptibility to aNHL and in particular to DLBCL (Rothman et al., 2006). The same 
effect could not be detected in another study of 710 lymphoma patients in 
comparison to 710 healthy controls from a German study cohort (Nieters et al., 
2006). These controversial results are probably caused by differences between the 
studied patient cohorts. They differed for example in study size, origin of population, 
histological subtypes and median age or other relevant clinical characteristics like an 
elevated LDH levels. This emphasizes the strong need for good, large prospective 
clinical trials to elucidate the role of IL10 gene variations for aNHL outcome. 
Furthermore, it is not clear whether the studies conducted so far focused on the 
“right” IL10 gene variations or if there might be other gene variations in linkage 
disequilibrium to the examined ones, bearing a higher value of information. 
In the most recent study of the working group in which this thesis was conducted, an 
increased risk for patients suffering from aNHL and carrying gene variation              
IL10-7400DelDel for a worse clinical outcome has been observed. This was estimated by 
a significantly shorter OS in a cohort of 500 equally treated aNHL patients (Kube et 
al., 2008). The number of homozygous carriers of IL10-7400DelDel was very low. 
Therefore, more distal gene variations of IL10, located in putative regulatory regions 
like the CNS, with a higher frequency might be more informative in terms of treatment 
outcome prediction.  
Little investigation has been conducted in the field of T-NHL, a very heterogeneous 
and very aggressive subgroup of NHL. Recently, significant associations between 
Introduction 
15 
IL10 gene variations and clinical outcome have been shown in an Asian cohort of 
108 T-NHL patients (Lee et al., 2007). Patients carrying at least one allele of the ATA 
haplotype (IL10-1087AG,-824CT,-597AC) showed better overall survival (OS) and failure-
free survival compared to those without ATA haplotype. The authors stated that even 
though a definite association with the response to chemotherapy was not proven, 
their data imply that IL10 may have some impact on the prognosis of T-NHL. This is a 
further crucial question, which should be answered in order to improve treatment 
strategies for this very aggressive NHL entity. 
In addition to IL10 gene variations the effects of IL10 serum levels prior to treatment 
has been assessed. In several studies, high levels of IL10 were associated with a 
poor outcome of lymphoma patients (Blay et al., 1993; Bohlen et al., 2000; Lech-
Maranda et al., 2006). Whereby, in other studies on NHL patients the same effect 
could not be observed (Cortes et al., 1995; Ozdemir et al., 2004; Stasi et al., 1994). 
Notably, the opposite effect of a better treatment outcome associated with elevated 
IL10 serum levels has not been reported. The studies differed with respect to 
histological subtypes of included lymphoma, the number of patients as well as the 
assay used for the detection of IL10 serum levels. Elder studies could not 
discriminate between viral IL10 and human IL10 and the detection limit of those 
assays was very high (Cortes and Kurzrock, 1997). Moreover, the study sizes were 
relatively small by today’s standards. Therefore larger trials are necessary to confirm 
the observation that elevated IL10 serum levels are associated with worse treatment 
outcome. Thereby, the question could be answered whether elevated IL10 serum 
levels could be used as clinically applicable prognostic markers for the outcome of 
aNHL or certain a NHL subtypes. 
As described in detail below (chapter 1.4) the CD20 antibody Rituximab has the 
potential to directly down regulate IL10 and therefore Bcl-2 (Alas et al., 2001). This 
raises the possibility that Rituximab could overcome the adverse prognostic features 
of elevated IL10 serum levels. As Rituximab together with CHOP is the current 
standard therapy it would be highly interesting to asses this question. So far studies 
analyzing the effects of IL10 gene variations or serum levels in patients treated with 
Rituximab are lacking. 
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1.4 Rituximab-mediated effects on immune responses against malignant 
cells 
The effects of Rituximab are mediated by various immune responses against the 
malignant cells, complement-dependent cytotoxicity (CDC), antibody dependent 
cellular cytotoxicity (ADCC) (Reff et al., 1994) or antibody dependent cellular 
phagocytosis (ADCP) as well as direct apoptosis through CD20 crosslinking (Glennie 
et al., 2007; Shan et al., 2000).  
CDC, ADCC and ADCP involve the binding of Fc-R to Rituximab antibodies bound 
to CD20 on the surface of B cells. In CDC Rituximab activates the complement 




Figure 1-4 Rituximab-mediated inhibition of p38 and IL10 induces chemosensitization 
The effects of rituximab treatment on inhibition of p38 MAPK activity and IL10 transcription and 
secretion in 2F7 AIDS derived DLBCL cell line are shown. CD20 crosslink by Rituximab antibody leads 
to inhibition of constitutively active Lyn kinase and p38 MAPK, resulting in down-regulation of IL10 
expression via inhibition of SP1 and NF-B. Decreased expression of IL10 leads to inhibition of 
constitutively active STAT3, through IL10 - IL10R interactions, and therefore inhibition of Bcl-2 
expression. This results in enhanced drug-induced apoptosis of the 2F7 cells. Lines ending in bars 
indicate inhibition. Arrows pointing downwards indicate down-regulation and arrow indicates activation. 




In ADCC the Fc-R of NK cells binds to the Rituximab antibody attached to the tumor 
cell. By monitoring human leukocyte antigen class I (HLA class I) expression on the 
surface of target cells, NK cells discriminate between self and non-self. The release 
of granules containing pore-forming perforin and the cytotoxic granzymes A and B is 
activated by the absence of inhibitory signals due to an altered or absent HLA class I 
on transformed cells. This leads to the destruction of the tumor cells. Inhibitory 
signals are mediated by interactions of killer immunoglobulin-like receptors (KIR) on 
the NK cell with HLA class I molecules (Vilches and Parham, 2002). In ADCP the 
Rituximab antibody is bound by Fc-R on the surface of monocytes and 
macrophages, which results in the engulfment of the antibody coated tumor cell 
(Ljunggren and Karre, 1990). 
 
Studies on a DLBCL cell line indicated that Rituximab treatment leads to an 
enhanced sensitivity to chemotherapeutic drugs in drug-resistant tumors (Demidem 
et al., 1997). Later on Bonavida and colleagues could show that Rituximab mediates 
inhibition of the p38 MAPK, ERK1/2 and Akt signaling pathways, leading to down-
regulation of the anti-apoptotic molecules Bcl-2 and Bcl-xl (Alas and Bonavida, 2001; 
Alas et al., 2001; Jazirehi et al., 2004; Suzuki et al., 2007; Vega et al., 2004). 
Inhibition of p38 MAPK signaling pathway, a pathway that induces IL10 via the Sp1 
transcription factor, resulted in inhibition of IL10 transcription and IL10 secretion in an 
AIDS related lymphoma cell line (Figure 1-4) (Vega et al., 2004). Inhibition of IL10 
expression leads to reduction of STAT3 phosphorylation and Bcl-2 expression (Alas 
and Bonavida, 2001; Alas et al., 2001). Notably, the same effect could not be 
observed in Ramos and Daudi cell lines (both human Burkitt’s lymphoma). In these 
cell lines Rituximab inhibits the ERK as well as the PI3K-Akt pathway, leading to a 
down-regulation of anti-apoptotic Bcl-xl (Jazirehi et al., 2004; Suzuki et al., 2007). 
Both of these pathways also seem to be involved in IL10 regulation (observation in 
macrophages). Due to the fact that the Ramos cell line does not express IL10 without 
prior stimulation (observation of working group) and Daudi cells express only very low 
levels of IL10 (Samanta et al., 2008), the effects on IL10 expression could not be 
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Aims of the Study 
In order to adjust individual treatment strategies of aNHL patients, reliable and 
clinically applicable prognostic markers are needed, which improve the prognostic 
value of the IPI factors. 
Previous studies suggested that the initiation or progression of lymphomas is 
supported by certain cytokines and their receptors, produced by lymphoma cells 
and/or cells in the tumor microenvironment. A number of studies have been 
performed to estimate the impact of inherited gene variations in cytokine or cytokine 
receptor genes on the susceptibility as well as clinical outcome of aNHL. In this 
context the anti-inflammatory cytokine IL10 has been investigated. Approximately 
90% of aNHL originate from B cells, on which IL10 acts as a potent autocrine growth 
factor. Associations of IL10 gene variations or elevated IL10 serum levels with the 
clinical outcome of aNHL have been assessed. However, results of these studies are 
controversial. 
The fundamental questions arising from these studies are whether IL10 gene 
variations and serum levels are predictive only for the clinical outcome of aNHL 
patients treated with CHOP or if they are also predictive for patients treated with 
Rituximab in addition to CHOP. Inherited IL10 gene variations, located in distal 
conserved regions of the IL10 gene locus, might be of prognostic relevance for 
treatment outcome. These gene variations might cause differences in interindividual 
IL10 production. Mechanisms contributing to IL10 gene regulation in B cells have not 
gained much attention in studies conducted so far.  
Therefore, this thesis aimed at answering the following questions: 
 What is the prognostic relevance of IL10 gene variations and IL10 serum 
levels for the outcome of aNHL in independent patient cohorts?  
 Does the addition of Rituximab to CHOP therapy overcome adverse 
prognostic features reported for elevated IL10 serum levels?  
 What is the effect of IL10 on lymphoma cells in Rituximab-mediated target cell 
killing? 
 How do IL10 gene variations affect interindividual IL10 production?  
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 Which molecular mechanisms contribute to the regulation of IL10 gene 
expression in human B cells? 
In order to answer these questions, DNA of aNHL patients derived from three 
different cohorts has to be genotyped on IL10 gene variations, including gene 
variations within putative regulatory regions shown to be located in conserved 
noncoding sequences (CNS). The obtained data have to be compared to respective 
clinical parameters. In addition, this study aims in assessing the prognostic relevance 
of IL10 serum levels for patients treated with or without Rituximab. 
EBV infected, immortalized lymphoblastoid cell lines (LCL) are characterized by 
different IL10 production. Therefore, this study examines the influence of IL10 gene 
variations on interindividual IL10 production using LCLs. 
To acquire a deeper knowledge about molecular mechanisms of IL10 gene 
regulation, different B cell lines with inducible or constitutive IL10 expression will be 
used for chromatin immunoprecipitation (ChIP) experiments. In addition to this, 
transcription of ncRNA from CNS will be examined. 
Moreover, this study aims in examining the influence of IL10 on lymphoma cells in 
Rituximab-mediated CDC and ADCC after preincubation with IL10 as well as in cells 
with different IL10 expression levels.  
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2 Material and Methods 
2.1 Biological Material 
2.1.1 cell lines 
Cell lines used for this thesis are listed in table 2-1. 
Table 2-1 Cell lines 
Cell line Source Reference 
Balm3 
B cell, diffuse lymphocytic lymphoma (EBV 
negative) 
(Lok et al., 1979) 
BHK baby (Syrian) hamster kidney cells  (Macpherson and Stoker, 1962) 
BHK-CD40L 
BHK, stably transfected with CD40L 
expression plasmid 
(Macpherson and Stoker, 1962) 
BJAB B cell, Burkitt’s lymphoma (EBV negative) (Menezes et al., 1975) 
BL2 B cell, Burkitt Lymphoma (EBV negative) 
(Kube et al., 1995; Nilsson and 
Ponten, 1975) 
Karpas422 B cell, Diffuse Large B cell lymphoma (Dyer et al., 1990) 
L428 Hodgkin lymphoma (Schaadt et al., 1979) 
MC116 B cell, lymphoma undifferentiated (Magrath et al., 1980) 
Ramos B cell, Burkitt Lymphoma (EBV negative) (Klein et al., 1975) 
SuDHL4 B cell, Diffuse Large B cell lymphoma  (Epstein et al., 1976) 
OCI Ly1 B cell, Diffuse Large B cell lymphoma  (Epstein et al., 1978) 
OCI Ly3 B cell, Diffuse Large B cell lymphoma  (Tweeddale et al., 1989) 
 
Lymphoblastoid cell lines (LCL) were obtained via immortalization of B cells with EBV 
using supernatant of the marmoset cell line B95-8 cell line as described in 2.9.2. 
Approximately 130 LCLs have been established in the context of previous studies 
from Prof. Dr. Kube (numbered 4/1-183/8). In addition 8 LCLs from the HapMap 
project were provided by Dr. Mladen Tzvetkov and 6 LCL were established during 
this thesis (numbered 191-202). 
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2.1.2 Lymphoma Patients 
For the analysis of the IL10 gene variations, DNA of aNHL patients from different 
trials conducted by the DSHNHL has been used. The NHL-B trial (Pfreundschuh et 
al., 2004a; Pfreundschuh et al., 2004b), The RICOVER-60 trial (Pfreundschuh et al., 
2008) and the MInT trial (Pfreundschuh et al., 2006). The study was conducted in 
accordance with the Declaration of Helsinki. The protocol was approved by the ethics 
review committee of each participating center. Patients were eligible if they had 
previously untreated, biopsy-confirmed aggressive non-Hodgkin lymphoma according 
to the Revised European-American Lymphoma Classification (translated into the 
World Health Organization [WHO] classification).  
The NHL-B trial can be divided into the NHL-B1 and NHL-B2 trial which aimed in 
elucidating whether the addition of etoposide to CHOP therapy improved treatment 
response in young (age≤60) or elderly (age>60) aNHL patients respectively. The 
RICOVER-60 trial aimed in elucidating the effect of the addition of Rituximab to 
CHOP therapy in elderly patients (age>60), while the MInT trial assessed the same 
question in young patients (age≤60). The patient cohorts used for genotyping 
analyses followed by survival analyses were representative for the complete trials in 
terms of clinical (table 3-1A and 3-1B) and histological (table A-1A and A-1B) 
characteristics. For this thesis the terms “trial” or “complete” are used for patients 
from the original trial and the terms “cohort” or “included” refer to patients included 
into the described analyses. A total number of 1724 patient DNA samples have been 
genotyped for IL10 gene variations. 942 patients included into these analyses were 
from the NHL-B; thereof 477 were from the NHL-B1 and 465 from the NHL-B2 trial. 
498 patients derived from the NHL-B trial have been analysed previously with respect 
to IL10 gene variations (Kube et al., 2008). The remaining 444 patients are described 
here as NHL-B_CCR-excluded cohort. 604 patients were from the RICOVER-60 trial 
and thereof 301 patients have been treated with CHOP and 303 have been treated 
with R-CHOP. In addition 178 patient DNA samples from the MInT trial have been 
analysed.  
Patients included into the analysis of T-NHL patients were from the NHL-B and 
RICOVER-60 trials. 197 patients with mature nodal or extranodal biopsy-confirmed T 
cell or NK cell lymphoma were included within prospective clinical trials of the 
DSHNHL as described recently (Pfreundschuh et al., 2008; Pfreundschuh et al., 
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2004a; Pfreundschuh et al., 2004b; Schmitz et al., 2010). Based on quality and 
availability of respective material 117 patients have been included into this study. 
Clinical and histological characteristics of the patients eligible for this study are 
shown in Table A-2. 
2.2 Chemicals and Consumable supplies 
Chemicals are listed in table 2-2. Chemical inhibitors are listed in table 2-3 and 
Consumables are listed in table 2-3. 
Table 2-2 Chemicals 
Chemical Manufacturer 
4-IPBA Sigma-Aldrich, Munich GER 
Agarose Sigma-Aldrich, Munich GER 
Acrylamid/Bisacrylamid 40% BioRad, Munich GER 
Ammonium sulfate Merck, Darmstadt GER 
Bradford solution RothiQuant-Roth, Karlsruhe GER 
Bromphenol Blue Sigma-Aldrich, Munich GER 
BSA Serva, Heidelberg GER 
Chelex 100 BioRad, Munich GER 
Cyclosporin A  Bayer, Leverkusen GER 
DEPC Roth, Karlsruhe GER 
3,3′-Dioctadecyloxacarbocyanine 
perchlorate (DiO) 
Sigma-Aldrich, Munich GER 
DMSO Sigma-Aldrich, Munich GER 
dNTP (dATP, dCTP, dGTP, dTTP) Primetech LTD, Minsk Belarus 
Ethanol (100%) J.T. Baker, Deventer NL 
Ethidiumbromid Sigma-Aldrich, Munich GER 
EDTA Riedel-de Haën, Seelze GER 
Fetal bovine serum (FBS) for cell culture 
medium A,C,D  
Sigma-Aldrich, Munich GER 
FBS for cell culture medium B Sigma-Aldrich, Munich GER 
Ficoll separating solution Invitrogen, Karlsruhe GER 
Full Range Rainbow Molecular Weight 
Markers RPN800 
GE Healthcare, Munich GER 
Formaldehyde Sigma-Aldrich, Munich GER 
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Chemical Manufacturer 
Formic acid Merck, Darmstadt, GER 
G418 Roche, Mannheim GER 
Glycerol Roth, Karlsruhe GER 
Glycin Roth, Karlsruhe GER 
Glyco Blue
TM
 Applied Biosystems, Foster City USA 
HEPES Sigma-Aldrich, Munich GER 
HiDi - Formamid Applied Biosystems, Foster City USA 
Iscove’s modified Dulbecco’s medium 
(IMDM) 
Pan Biotech, Aidenbach GER 
Isopropanol Sigma-Aldrich, Munich GER 
L-Glutamine Sigma-Aldrich, Munich GER 
Luminol Sigma-Aldrich, Munich GER 
LymphoPrep (Ficoll) PROGEN Biotechnik GmbH, Heidelberg GER 
Methanol 100% (p.a.) J.T. Baker, Deventer NL 
Milk powder Roth, Karlsruhe GER 
MTT (3-(4,5-Dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide) 
Sigma-Aldrich, Munich GER 
Nonidet P-40 (Igepal) Sigma-Aldrich, Munich GER 
Penicillin/Streptomycin Sigma-Aldrich, Munich GER 
Phorbol 12-myristate 13-acetate (PMA) 
(Approx. 99% TLC) 
Sigma-Aldrich, Munich GER 
Phosphatase inhibitor Phospho- STOP Roche, Mannheim GER 
PMSF  Sigma-Aldrich, Munich GER 
Ponceau S Sigma-Aldrich, Munich GER 
Protein A Sepharose GE Healthcare, Munich GER 
Propidium iodide  Sigma-Aldrich, Munich GER 
Proteaseinhibitor-Mix Complete™  Santa Cruz biotechnology, Heidelberg GER 
RPMI Lonza, Basel CH 
SDS  Merck, Darmstadt, GER 
Sodium butyrat Sigma-Aldrich, Munich GER 
Sodium chloride Merck, Darmstadt, GER 
Sodium deoxycholat  Merck, Darmstadt, GER 
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Chemical Manufacturer 
Sodium pyruvate Sigma-Aldrich, Munich GER 
Sodium vanadate  Sigma-Aldrich, Munich GER 
Spectra Multicolor Broad Range 
Protein Ladder 
Fermentas, Frankfurt GER 
SybrGreen Roche, Grenzach GER 
TEMED  Sigma-Aldrich, Munich GER 
Thymidin-5’-
3
H  GE Healthcare, Munich GER 
Trehalose  Roth, Karlsruhe GER 
Trisbase  Sigma-Aldrich, Munich GER 
Triton-X-100 Roth, Karlsruhe Germany 
Trypanblue 0.4% in PBS GIBCO BRL, Life Technologies, Eggenstein GER 
Tween-20  Merck, Darmstadt GER 
Water HPLC grade Merck, Darmstadt GER 
 




Chemical Inhibitors   
Bisindolylmaleimide I (PKC) Calbiochem/Merck, Darmstadt, GER 10nM 
Ly294002 (PI3K) Calbiochem/Merck, Darmstadt, GER 10µM 
U0126 (ERK1/2) Sigma-Aldrich, Munich GER 10µM 
Recombinant Proteins   
recombinant human IL10 Peprotech, Hamburg GER 100ng/ml 
Enzymes    
EcoRV 
New England BioLabs, Frankfurt am 
Main GER 
 
HOT FIREPol (Hotstart DNA 
Polymerase) (5U/µl) 
Solis Biodyne, Tartu Estonia  
Taq Polymerase (5U/µl) Invitrogen, Karlsruhe GER 0.5 U/25µl 
Taq Polymerase (5U/µl) Primetech LTD, Misk Belarus 0.5 U/25µl 
PlatinumTaq Polymerase (5U/µl) Invitrogen, Karlsruhe GER 0.5 U/25µl 
Proteinase K Invitrogen, Karlsruhe GER 20µg/ml 
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Table 2-4 Consumables 
Consumable Manufacturer 
ABI PRISM® 384-well clear optical 
reaction plate 
Applied Biosystems, Foster City USA 
ABI PRISM® 384-well reaction plate Applied Biosystems, Foster City USA 
ABI PRISM® Optical Adhesive Covers Applied Biosystems, Foster City USA 
Cell culture flasks Sarstedt, Nümbrecht GER 
Cryo Box Nunc, Wiesbaden GER 
Cryotubes Nunc, Wiesbaden GER 
Diethylaminoethyl-Cellulose Whatman®, International Ltd UK 
Falcon Tubes 15 ml Sarstedt, Nümbrecht GER 
Falcon Tubes 50 ml Sarstedt, Nümbrecht GER 
Filter Tips, 10 µl, 100 µl, 200µl, 1000 µl Starlab, Ahrensburg GER 
Flat bottom tube (screw cap) Nunc, Wiesbaden GER 
Heparin Monovettes Sarstedt, Nümbrecht GER 
MicroAmp Optical 96-well reaction plate Applied Biosystems, Foster City USA 
Sterling Nitrile Powder-Free Examination 
Gloves 
Kimberly-Clark, Zaventem, Belgium 
Pasteurpipettes Sarstedt, Nümbrecht GER 
Pipette Tips (wo filters) 100µl, 1000µl Sarstedt, Nümbrecht GER 
Plate septa 96-well Applied Biosystems, Foster City USA 
Reactiontubes 0.5ml Sarstedt, Nümbrecht GER 
Reactiontubes 1.5ml Sarstedt, Nümbrecht GER 
Reactiontubes 2.0ml Sarstedt, Nümbrecht GER 
Serological pipettes 5 ml Sarstedt, Nümbrecht GER 
Serological pipettes 10 ml Sarstedt, Nümbrecht GER 
Serological pipettes 25 ml Sarstedt, Nümbrecht GER 
Tissue culture plates, 6 well Nunc, Wiesbaden GER 
Tissue culture plates, 12 well Nunc, Wiesbaden GER 
Tissue culture plates, 24 well Nunc, Wiesbaden GER 
Tissue culture plates, 96 well, round 
bottom 
Nunc, Wiesbaden GER 
Tissue culture plates, 96 well, flat bottom Nunc, Wiesbaden GER 
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2.3 Buffers, Solutions and Media  
Buffers, solutions and media used for this work are listed in table 2-5. 
Table 2-5 Buffers, Solutions and Media 
Buffers, solutions and media Receipt / Manufacturer 
1x TE 
10mM Tris/HCl (pH 7.4) 
1mM EDTA 
2x SDS loading dye 
4% SDS 
0.12 M Tris/HCl (pH 6.8) 
200mM DTT 
Pipette Tip of 1% Bromphenolblue 
4x loading buffer Roti®-Load Roth, Karlsruhe GER 
Cell culture medium A 
(Balm3, BHK,  BJAB, Karpas422, 
LCLs, MC116) 
RPMI-1640  
10% (v/v) FBS  
200U/ml Penicillin + 
200μg/ml Streptomycin 
4mM L-Glutamine  
Cell culture medium A for BHK-
CD40L 
Cell culture medium A supplemented with 100µg/ml G418 
Cell culture medium B 
(L428) 
RPMI-1640  
10% (v/v) FBS 200U/ml Penicillin + 
200μg/ml Streptomycin 
4mM L-Glutamine 
Cell culture medium C 
(Ramos, Bl2) 
RPMI-1640  
10% (v/v) FBS  
200U/ml Penicillin + 
200μg/ml Streptomycin  
4mM L-Glutamine 
50 µM α-Thiolglycerol  
20 nM BCS, 1 mM Sodium pyruvat 
Cell culture medium D 
(OCI Ly 1 and OCI Ly 3) 
IMDM  
10% (v/v) FBS for OCI Ly 1 
20% FBS for OCI Ly 3 
200U/ml Penicillin + 
200μg/ml Streptomycin  
4mM L-Glutamine 
ChIP Nelson buffer modified   
50mM Tris/HCl (pH 7,5) 
150mM NaCl  
20mM EDTA (pH 8)  
0.5% NP-40 (IGEPAL) 
1% Triton-X-100  
20mM NaF (only necessary for phosphorylation) 
 
add 0.5mM DTT fresh 
add Roche Protease inhibitor cocktail fresh 
add inhibitors fresh 
ChIP Gomes Lysis buffer 
50mM Tris/HCl (pH 8)  
150mM NaCl  
20mM  EDTA (pH 8)  
1% v/v NP-40 (IGEPAL) 
0.5% w/v sodium deoxycholate 
0,1% w/v SDS  
20mM NaF (only necessary for phosphorylation) 
 
add Roche Protease inhibitor cocktail fresh 
add inhibitors fresh 
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Buffers, solutions and media Receipt / Manufacturer 
ChIP Gomes Wash buffer 
100mM Tris/HCl (pH 8.5)  
500mM LiCl  
20mM  EDTA (pH 8)  
1% v/v NP-40 (IGEPAL) 
1% w/v sodium deoxycholate 
20mM NaF (only necessary for phosphorylation) 
ChIP SDS-Lysis buffer 
50mM Tris/HCl (pH 8.1) 
10mM EDTA 
1% w/v SDS 
 
add Roche Protease inhibitor cocktail fresh 
add inhibitors fresh 
Enhanced Chemiluminescence 
solution (ECL), self-made 
Luminol-solution+ Peroxide-solution (1:1) 
EDTA cell culture grade 0.5 M, Sigma-Aldrich, Munich GER 
Freezing medium 
90% (v/v) FBS (Biochrom, Berlin GER) 
10% (v/v) DMSO (Sigma-Aldrich, Munich GER) 
LB-agar 1.5% (w/v) Agar in LB-medium 
LB-Medium 
0.5% (w/v) Sodium Chloride 
0.5% (w/v) Yeast Extract  
1% (w/v) Bacto-Trypton 
100µg/ml Ampicillin 
Laemmli buffer (2x) 
187.5 mM Tris/HCl (pH 6.8) 
6.0% (w/v) SDS 
30.0% (v/v) Glycerin 
0.01% (w/v) Bromphenolblue 
10% (v/v) ß-Mercaptoethanol 
Luminol-solution (for ECL) 
100mM Tris/HCl (pH 8.8) 
2.5mM Luminol 
4mM 4-IPBA, dark 4°C 
MTT solution I 
5mg/ml MTT in PBS  
store at 4°C, dark 
MTT solution II 
33% DMSO 
5% formic acid 
62% Isopropanol 
store at RT, dark 
PBS pH 7.4  (cell culture grade) Lonza, Basel CH 
Peroxide-solution ( for ECL) 
100mM Tris/HCl (pH 8.8) 
10.6mM H2O2, dark 4°C 
Ponceau-S 
5 % (v/v) glacial acetic acid 
0.5 % (w/v) Ponceau-S 
RIPA buffer 
1x PBS pH 7.4 
1% (v/v) Igepal 
0.5% (w/v) Sodium-deoxycholat 
mg/ml PMSF (solved in isopropanol) 
1 mM Soduim-Orthovanadat 
Complete-Solution (40 μl stock solutiuon for 1 ml RIPA; 
stock solution: 1 tablet for 1.5ml H2O,   
Running buffer (1x): 
25mM Tris-Base 
192mM Glycin 
34.67 mM SDS 
Separation Gel Mix 
31.3 % (v/v) Acrylamid/Bisacrylamide Solution (40 %) 
332 mM Tris Base, pH 8,9 
3.33 mM EDTA 
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Buffers, solutions and media Receipt / Manufacturer 
Stacking Gel Mix 
15 % (v/v) Acrylamid/Bisacrylamid Solution (40 %) 
125 mM Tris Base pH 6.8 
0.1 % (w/v) SDS 
5 mM EDTA 
SYBR Green Mix 
1x SYBR Green PCR buffer 
3mM MgCl2 (supplied with HOT FIREPol®) 
1:80000 SybrGreen 
0.2 mM dNTP each 
20 U/ml Hot FIREPol® 
0.25 % TritonX-100 
0.5 mM Trehalose, in 10mM Tris-HCl pH 8,0 
SYBR Green PCR-buffer 10x 
750 mM Tris-HCl pH 8.8 
200 mM Ammonium sulfate 
0.1% Tween-20 
in depc water 
TAE (10x) 
400mM Tris 
0.01M EDTA (pH 8.3) 
TBS (1x) 
20mM Tris-Base, 
137mM Sodium Chloride (pH 7.6) 
TBS-T 
1x TBS 




15% (v/v) MeOH 
2.4 Equipment 
Table 2-6 Equipment 
Instrument Manufacturer 
Genetic Analyser 3130 Applied Biosystems, Foster City USA 
ABI PRISM 7900HT  Applied Biosystems, Foster City USA 
Accu-jet Brand, Hamburg GER 
Biofuge Pico Heraeus Instruments, Hanau GER 
Biorupter™ Next Gen Diagnode, Liège, Belgium 
Biometra TI 3 INTAS, Göttingen GER 
Electrophoresis Power Supply Invitrogen, Karlsruhe GER 
FACSCanto
TM
 Flow Cytometer Becton Dickinson, Heidelberg GER 
Freezer -20 Liebherr GER 
Freezer -150 Ultra low VIP+ Sanyo, San Diego USA 
Fridge 4°C Linder 
IKA KS 260 shaker IKA, Staufen GER 
IKAMAG RCT magnetic stirrer IKA, Staufen GER 
Incubator Heracell Heraeus Instruments, Hanau GER 
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Instrument Manufacturer 
Incudrive incubator Schütt Labortechnik, Göttingen GER 
Inotech Cell Harvester,  Wallac Distribution Freiburg 
LAS-4000 Image Reader Fujfilm, Düsseldorf GER 
Microcoolcentrifuge 1-15k Sigma, Munich GER 




Neubauer Counting Chamber Improved Lo Labor Optik, Friedrichsdorf GER 
Power Pac 300 Power Supply Bio-Rad, München GER 
Robocycler Gradient 96 Agilent Technologies, Waldbronn GER 
Roller Mixer RM5 Hecht Assistant, Sondheim GER 
Stuart SRT 6 horizontal roller  Sigma-Aldrich, Munich GER 
Sunrise
TM
 Microplate Reader Tecan, Crailsheim GER 
Televal 31 inverse light optical microscope Zeiss, Jena GER 
MaterCycler Eppendorf 384-well gradient Eppendorf, Hamburg GER 
Thermocycler T3000 Biometra, Göttingen GER 
Thermomixer Compact Eppendorf, Hamburg GER 
Vortex Genie 2 Schütt Labortechnik, Göttingen GER 
Water bath Köttermann Labortechnik, Hänigsen GER 
 
2.5 Oligonucleotides 
Primers used for qRT-PCR are listed in Table 2-7 (chapter 2.5). Primers used for 
Taqman assay are listed in Table 2-8. Primers used for Snap-shot are listed in Table 
2-9. 
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Gene Oligonucleotide 








































































-7400forward IL10 fwd 5’-GAAGGAACATCTGAGCTGAGAGCT-3’ 
-7400reverse neu rev 5’-TTGAACTCCTAGGCTCAAGTAATCCT-3’ 
 
Table 2-8 Primers used for Taqman genotyping assay 
gene 
variation 











































* Applied Biosystems Darmstadt Germany; Custom made assay,  
** Applied Biosystems Darmstadt Germany; Validated assay,   
*** Eurogentec Seraine Belgium 
 
Table 2-9 Primers used for SNaPshot assay 
gene 
variation 
rs-number alleles Assay details / Primers  





fwd: 5’-CTGTCCCAGCTCACAGATCA-3’  
rev: 5’-GTTTCACGAAAGCGGCTAAG-3’ 
* 


































































Primer 3’  
5’-GATCCTGGTTTCTCTTCCTAAGAGTATTTG(T/C)-3’ 
** 
*IBA Göttingen Germany 
**MWG Ebersberg Germany 
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2.6 Antibodies  
Antibodies used for Immunoblot analysis, ChIP and FACS are listed in Table 2.10. 
Table 2-10 Antibodies 
Antibody Manufacturer Working Dilution 
ChIP 
anti IgG ChIP grade (ab46540) abcam, Cambridge UK 2µg/IP 
anti acH3 ChIP grade (06-599) Millipore, Schwalbach GER 2µg/IP 
anti H3K4me1 ChIP grade 
(ab8895) 
abcam, Cambridge UK 
2µg/IP 
anti-H3K4me3 (07-473) Millipore, Schwalbach GER 2µg/IP 
Immunoblot 




1:5000 in 3% milkpowder in 
TBS-T 
rabbit anti p-STAT3 (Ser727) 
(#9134) 
Cell Signalling/ New England 
Biolabs, Frankfurt am Main 
GER 
1:1000 in 3% BSA  in TBS-T 
rabbit anti-STAT3 (#9132) 
Cell Signalling/ New England 
Biolabs, Frankfurt am Main 
GER 
1:1000 in 3% BSA  in TBS-T 
anti-LMP1 
Cell Signalling/ New England 
Biolabs, Frankfurt am Main 
GER 
1:1000 in 3% BSA  in TBS-T 
FACS 
anti-mouse HRP polyclonal 
goat (D1609) 
Santa Cruz, Heidelberg GER 
1:5000 in 3% milkpowder in 
TBS-T 
anti-rabbit HRP polyclonal goat 
(E1710) 
Santa Cruz, Heidelberg GER 
1:1000 in 3% BSA  in TBS-T 
anti-CD20 FITC 
Becton Dickinson, Heidelberg 
GER 
1:20 in Medium 
anti-CD56  BD Biosciences Heidelberg GER 1:20 in Medium 
anti-CD3 PE 
Beckmann Coulter, Krefeld 
GER 
1:20 in Medium 
anti-CD16 PE BD Biosciences Heidelberg GER 1:20 in Medium 
anti-HLA PE, Monoclonal 
Mouse Anti Human HLA-ABC 
Antigen/RPE clone W6/32 
Dako, Stockport UK 
1:20 in Medium 
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2.7 Plasmids 
Plasmids used for qRT-PCR as Standards are listed in Table 2-11. 
Table 2-11 Plasmids 
Plasmid Description 
pCR2.1 Topo-IL10e1-2 control vector for qRT-PCR containing PCR product of qRT-IL10-e1-2 
pCR2.1 Topo-β2m control vector for qRT-PCR containing PCR product of β2m primers 
2.8 Ready to use Reaction Systems 
In Table 2-12 the used ready to use reaction systems are listed. 
Table 2-12 Ready to use reaction systems 
Description Manufacturer 
BigDye Terminator Cycle Sequencing-Kit v1.1,  Applied Biosystems, Foster City USA 
EndoFree® Plasmid Maxi Kit Qiagen, Hilden GER 
Human IL10 ELI PAIR Diaclone, Giessen GER 
innuPREP DYEpure Kit  Analytik Jena, Jena GER 
NK cell isolation Kit II Miltenyi Biotec, Bergisch Gladbach GER 
Nucleo Spin RNA II Machery+Nagel, Düren GER 
Rneasy® Plus Mini Kit Qiagen, Hilden GER 
Superscript II™ RT Kit  Invitrogen, Karlsruhe GER 
TOPO TA cloning® Kit Invitrogen, Karlsruhe GER 
QIAamp® DNA Mini Kit Qiagen, Hilden GER 
QIAEX II Agarose Gel Extraction Kit  Qiagen, Hilden GER 
QIAGEN Plasmid Mini Kit Qiagen, Hilden GER 
QIAshredder Qiagen, Hilden GER 
QIAquick PCR purification Kit Qiagen, Hilden GER 
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2.9 Cell Biology  
2.9.1 Cell culture techniques 
All cell lines were cultured at 37°C, 5% CO2 and were splitted every second day 
according to proliferation rate, observed via cell density. If not otherwise indicated     
B cell lines were cultured in cell culture medium A (for detail see table 2-5) in a 
density between 5x105/ml- 1x106/ml. The Hodgkin cell line L428 was cultured in cell 
culture medium B in a density between 5x105/ml- 1x106/ml. Burkitt’s lymphoma cell 
lines were cultured in cell culture medium C in a density of 3x105/ml- 1x106/ml. OCI 
Ly1 and OCI Ly3 were cultured in cell culture medium D supplemented with 10% 
FBS or 20% FBS respectively in a density between 5x105/ml- 1x106/ml. The adhesive 
cell line BHK was cultured in cell culture medium A, supplemented with 100µg/ml 
G418 for BHK-CD40L for selectively culturing neomycin resistant cells. Cells were 
counted in a Neubauer counting chamber diluted 1:1 with PBS 0.4% Trypanblue. 
To freeze cells, approximately 1x107cells were sedimented (centrifugation 
250xg/8min/RT) and resuspended in 1ml freezing medium. Cryo boxes containing 
isopropanol were used for a constant cooling of 1°C/min till -80°C. Frozen aliquots 
were stored at -150°C. To thaw cells for cultivation, a frozen aliquot was thawed and 
washed in 10ml of RT cell culture medium. The cells were sedimented as described 
above and resuspended in 5-10ml of the respective cell culture medium. 
2.9.2 EBV immortalization of B cells 
For the establishment of lymphoblastoid cell lines (LCLs), peripheral blood 
mononuclear cells (PBMCs) were isolated from peripheral blood of voluntary donors 
(buffy coats) and immortalized by EBV infection. Peripheral blood of voluntary donors 
(50ml) was separated by centrifugation (1300xg/10min). PBMCs interphase (white 
ring) were transferred to a new tube and diluted with 0.9% sodium chloride. 15ml 
ficoll separating solution was overlayed carefully with 35ml diluted PBMCs and 
centrifuged at 850xg for 20 min. The interphase, containing PBMCs was transferred 
to a new tube (without toxic ficoll). After centrifugation at 90xg for 10min the 
supernatant was discarded and the cells were washed twice in 35ml 0.9% sodium 
chloride. In a final step the cells were resuspended in cell culture medium A in a 
density of 1x106
 
cells/ml. 1ml of PBMCs suspension was placed into a flat bottom 
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tube and 1ml of sterile filtered (0.2μm) Epstein-Barr-Virus (EBV) supernatant from a 
B95-8 marmoset cell line was added (incubation at 37°C, 5% CO
2 
overnight).  
On the next day 1.4ml fresh cell culture medium A, supplemented with 2μg/ml of 
Cyclosporin A was added for 7 days culture. Cyclosporin A suppresses T cell growth, 
preventing the elimination of EBV infected  B cells. Approximately after 7 days half of 
the supernatant was discarded and filled up with fresh cell culture medium A 
supplemented with 1μg/ml of Cyclosporin A. As soon as LCLs formed clusters and 
grew densely, they were transferred into 25 cm2 culture flasks. Cultivation continued 
for several weeks by using cell culture medium A.  
2ml of the peripheral blood were used for DNA preparation (2.11.1).  
2.9.3 Stimulation of L428 cell line with PMA 
PMA (powder) had to be dissolved in 100% Ethanol with a final concentration of 
1mg/ml and aliquots were stored at -20°C. Directly prior to stimulation PMA was 
diluted 1:100 in respective cell culture medium (10ng/µl). 
24h prior to stimulation, cells were seeded in an optimal cell density in fresh cell 
culture medium. This was 5x105 for L428 in cell culture medium B (incubation 37°C, 
5% CO2). After 24h cells were sedimented (centrifugation 250xg/8min/RT), counted 
and adjusted to a density of 5x105/ml in fresh medium. A respective amount of cells 
(i.e. 1x106 cells for RNA preparation) was stimulated with 2µl PMA/ml cells (20ng 
PMA/ml cells) or left untreated for control. Enough cells for each required time point 
had to be stimulated. In case of chromatin immunoprecipitation (chapter 2.11.10) 
stimulation was conducted in separate flasks. The cells were incubated for 1h at 
37°C and 5% CO2. Subsequently, they were sedimented (centrifugation 
250xg/8min/RT) and resuspended in fresh medium in a density of 5x105/ml. If very 
high amount of cells were used, the control samples were resuspended in (1h) old 
medium. This was followed by cultivation of cells for indicated times (counted from 
stimulation of the cells). Subsequently, cells were harvested according to the 
respective application.  
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2.9.4 CD40 crosslink using BHK-CD40L 
BHK cells were cultivated in Cell culture medium A, supplemented with 100µg/ml 
G418 for BHK-CD40L. In this medium, only stably transfected cells with neomycin 
resistance were able to proliferate. Prior to usage of BHK-CD40L cells for stimulation, 
two passages without G418 should have been done. Adherent BHK cells were 
splitted by adding 1ml 5mM EDTA in PBS to cells, after taking away all cell culture 
medium. Cells were incubated approximately 1min at 37°C and rinsed from the 
bottom of the cell culture flask with 10ml PBS. After sedimentation (300xg/5min/RT) 
cells were resuspended in 10ml cell culture medium. A respective amount of cells 
was seeded into a fresh cell culture flask.  
For stimulation, 5x105 cells were seeded on 6 well plates in 3ml of cell culture 
medium A, 24h prior to stimulation. At the same time point, cell lines that had to be 
stimulated were seeded in an optimal cell density in fresh medium. This was 3x105/ml 
for Ramos. On the next day medium was taken away from BHK cells carefully and 
1x106 Ramos cells were added in 3ml fresh cell culture medium B. Cells were 
harvested for RNA preparation (2.11.6) after the indicated time points. 
2.9.5 Inhibitor treatment 
For analyses of pathways involved in IL10 gene regulation in L428, cells were treated 
with inhibitors listed in table 2-3. 
24h prior to stimulation, L428 cells were seeded in a density of 5x105/ml. On the next 
day, 3ml L428 in a density of 5x105/ml were treated with 10nM (1:242) 
Bisindolylmaleimide I (PKC Inhibitor), 10µM U0126 (ERK Inhibitor) or Ly294002 
(PI3K Inhibitor) or respective dilutions of the solvent DMSO as a control for 3 h prior 
to PMA stimulation. Cells were stimulated with PMA and washed after one our 
according to procedure described in 2.9.3. After the washing step, fresh inhibitor and 
DMSO were added to the cells. After 12h PMA stimulation, cells were harvested for 
RNA preparation (2.11.6) and Immunoblot analyses (2.10.3) to check pathway 
activity. 
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2.9.6 Treatment with IL10 
24h prior to stimulation with IL10, cells have been seeded in an optimal cell density 
(3x105/ml for Burkitt’s lymphoma cell lines, 5x105/ml for DLBCL cell lines) in fresh cell 
culture medium. For IL10 stimulation cells have been sedimented (centrifugation 
250xg/8min/RT), resuspended in fresh medium in required densities and stimulated 
with 100ng IL10/ml cells (stock 5ng/µl). 
2.9.7 Rituximab treatment of B cell lines 
24h prior to stimulation with Rituximab, cells have been seeded in an optimal cell 
density (3x105/ml for Burkitt’s lymphoma cell lines, 5x105/ml for DLBCL cell lines) in 
fresh cell culture medium. For Rituximab stimulation, the cells have been sedimented 
(centrifugation 250xg/8min/RT), resuspended in fresh medium in required densities 
and stimulated with indicated amounts of Rituximab (stock 10mg/ml). If necessary, 
Rituximab has been diluted in the respective cell culture medium prior to use.  
2.9.8 MTT viability assay 
MTT is a colorimetric assay for measuring the activity of enzymes that reduce MTT in 
living (viable) cells. 24h prior to MTT assay cells were seeded in optimal densities 
(3x105 Burkitt’s lymphoma cell lines and 5x105/ml for all other cell lines). On the next 
day cells were sedimented (centrifugation 250xg/ 8min/ RT) counted and 
5x105cells/ml were resuspended in respective cell culture medium. Respective cell 
culture medium was supplemented with human serum instead of FBS. 100µl cells 
were seeded on a round bottom 96-well plate. 100ng/ml of IL10 was added to 
respective samples as indicated (see 2.9.6). Indicated amounts of Rituximab were 
added (see 2.9.7). Plates were incubated at 37°C and 5% CO2. 20h, 44h and 68h 
later 10µl MTT solution I was added to all samples and plates were incubated for 
another 4h at 37°C and 5% CO2. During this time the yellow MTT was converted into 
blue formazan by mitochondrial reductases. Subsequently, the plates were 
centrifuged to pellet the cells and supernatant was removed carefully. 100µl of MTT 
solution II were added to each well. Plates were rocked until all cell agglutinations 
were solved. Viability of cells was determined by measuring the absorbance in 
SunriseTM Microplate Reader at 540nm with reference of 655nm. 
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2.9.9 Proliferation assay 
The proliferation of cells has been determined using the 3H-thymidin incorporation 
method. The radioactive nucleoside 3H-thymidin is incorporated into new strands of 
chromosomal DNA during replication. Therefore radioactivity is proportional to the 
number of proliferating cells. 
Cells have been prepared as for the MTT (see 2.9.8) but instead of a round bottom 
96-well plate a flat bottom 96-well plate was used (incubation 37°C, 5% CO2). 16h 
before the end of incubation 0,5µCi Thymidin-5’-3H in 30µl cell culture medium have 
been added to each well. For harvesting the cells have been transferred on a filter 
paper, which was dried subsequently for 1h at 60°C. Radioactivity was estimated 
using a Liquid Scintillation-Counter. 
2.9.10 Flow cytometry 
Flow cytometry is used to analyse properties of cells. A laser beam of a specific 
wavelength is directed onto the single cells within a carrier liquid. The emitted 
fluorescent of each single cell is measured by detectors. The size of the cell is 
determined by the forward scatter and the granularity by the sideward scatter. 
Fluorescent dyes bound to the cell via specifically labeled antibodies can be excited 
and emit light of a specific wavelength. Fluorescent dyes used were Fluorescein 
(FITC; absorption maximum at 494nm; emission maximum of 521nm) and 
Phycoerythrin (PE; absorption maximum at 495nm; emission maximum at 575nm). 
For the characterization of cell populations prior to ADCC, the cells were stained with 
respective antibodies (see table 2-10). 5µl antibody was added to 100µl cells 
(5x105/ml for cell lines, 1x106/ml for NK cells). For ADCC propidium iodide (PI 
0.1µg/ml) was added to the cells to detect lysed/dead cells. 
2.9.11 ADCC 
NK cell purification 
CD56+ and CD3- NK cells have been purified from peripheral blood of voluntary 
donors. NK cells were immunomagnetically selected using the NK cell Isolation Kit II. 
By use of this kit non-NK cells, i.e., T cells, B cells, stem cells, dendritic cells, 
monocytes, granulocytes, and erythroid cells, are magnetically labeled by using a 
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cocktail of biotin-conjugated antibodies and the NK Cell MicroBead Cocktail. Isolation 
of highly pure NK cells is achieved by depletion of magnetically labeled cells. 
Therefore, peripheral blood was diluted 1:1 with PBS. Leukocytes were obtained via 
Ficoll (LymphoPrep) separation. Peripheral blood/PBS was given to the same 
amount of Ficoll and centrifuged 800xg, 20min without brake. The Phase containing 
leukocytes was taken off and washed once with PBS (centrifugation 250xg/10min) 
and MACS buffer (300xg/10min). 1x108cells were resuspended in 400µl MACS 
buffer. 75µl of biotin-conjugated antibody mixture from the Kit was added to the cells 
and binds to all non-NK cells (rock 10min/ 4°C). 300µl MACS buffer together with 
150µl magnetic-beats (Kit) were added (rock 15min/ 4°C). Mixture was washed with 
25ml of MACS buffer meanwhile the column (LS. Kit) was equilibrated with MACS-
buffer. Sample was diluted in 500µl MACS buffer and added on the column. Elution 
of NK cells was done three times with 3.5ml MACS-buffer. NK cells were sedimented 
and resuspended in cell culture medium in a density of 5x106/ml. To increase 
cytotoxic activity of NK cells, they were cultivated with 5µl IL2/ml cells overnight 
(37°C, 5% CO2). Purity of NK cells has been assessed by Flow cytometry (see 
chapter 2.9.10). NK cells had to be CD56+, CD3-, CD20- and CD16+.  
Target cell incubation with IL10 
Karpas422 and Ramos were sedimented (centrifugation 250xg/8min/RT), counted 
and resuspended in fresh cell culture medium in a density of 3x105/ml (Ramos) or 
5x105/ml (Karpas422) for 24h. For IL10 treatment, cells were sedimented 
(centrifugation 250xg/ 8min/ RT), counted and 2x 5x106-1x107 cells were 
resuspended in fresh cell culture medium in a density of 5x105/ml (Ramos) or 
1x106/ml (Karpas422) for stimulated and unstimulated cells. 100ng IL10/ml cells was 
added to one of two prepared flask with cells. After 12 hours cells were analysed by 
flow cytometry and had to be CD20 and HLA I positive. Target cells were 
subsequently stained with green fluorescence DiO. 1x106 cells were resuspended in 
1ml PBS. 5µl DiO (3mM) was added to cells (rock, 20min, 37°C). Cells were washed 
twice with PBS and resuspended in cell culture medium in a density of 1x106/ml. 
Cytotoxicity assay 
NK cells were incubated with DiO-labeled target cells in a ratio of 2:1 (50µl NK cells 
(2x106/ml) + 50µl target cells (1x106/ml)) at 37°C and 5% CO2 for 4h. Rituximab and 
IL10 were added as indicated in results. In addition target cells were incubated 
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without NK cells for determination of spontaneous lysis. NK cell-mediated cytotoxicity 
was assessed with flow cytometry after propidium iodide staining (50µg/ml). Lysed 
cells were propidium iodide positive, DiO stained target cells. Specific lysis was 
calculated as specific lysis (%) = (lysis of sample % -spontaneous lysis %) / (100-
spontaneous lysis %) x100. ADCC was calculated as ADCC (%) = (specific lysis of 
sample incubated with Rituximab % - specific lysis of sample incubated without 
Rituximab %) / (100- specific lysis of sample incubated without Rituximab %) x100. 
2.10 Protein Biochemistry 
2.10.1 Preparation of cell lysates 
For preparation of cell lysates for Immunoblot, cells were sedimented 
(250xg/10min/4°C) and washed in PBS, complemented with 100mM sodium 
orthovanadate. If not processed immediately, pellets were frozen at -20°C. 
Pellets were thawed on ice and cells were suspended in RIPA buffer (see table 2-5) 
for lysis and incubated for 30min on ice. This was followed by centrifugation to 
sediment cell debris (14.000xg/15min/4°C). The protein concentration of the 
supernatant was determined via Bradford assay (Bradford, 1976) using a ready to 
use Bradford solution and photometrical quantification with the SunriseTM Microplate 
Reader and MagellanTM software. 
2.10.2 SDS-PAGE 
For separation of proteins SDS-PAGE was used. Proteins get negatively charged 
through sodium dodecyl sulfate (SDS) treatment and can be separated by size using 
polyacrylamide gelelectrophoresis (PAGE).  
Polyacrylamide gels comprised of a separation gel containing 10% and a stacking gel 
with 5% Acrylamide have been prepared using the BioRad System (München, GER). 
After pouring the separation gel, it was covered by Isopropanol to get a smooth 
surface and to protect it from drying out. After polymerization of the separation gel, 
the isopropanol was removed and the stacking gel was poured. 10-30µg of protein 
samples was suspended in 4x Roti®-Load loading dye buffer, denaturized for 5 min 
at 95°C and loaded onto the gel. The Fullrange rainbowTM marker was loaded in 
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addition for later determination of protein sizes. For the first 15min, a current of 20mA 
was used until all probes reached the border between stacking and separation gel. 
Subsequently, the current was set to 40mA for separation.  
The Immunoblot technique was used to transfer separated proteins onto a 
nitrocellulose membrane. Separation gel, Nitrocellulose membrane (Hybond™-
C extra, GE Healthcare, München GER) and whatman paper were equilibrated into 
transfer buffer and arranged in a pile as follows: Cathode (-), 2 whatman papers, 
separation gel, nitrocellulose membrane, 2 whatman papers, Anode (+). Using a 
Tank Blot system (BioRad, München GER) the proteins were blotted (100V, max. 
300mA, 300W, 1h) onto the nitrocellulose membrane.  
Subsequently, equal loading was controlled by staining the proteins with Ponceau S. 
To remove the stain, the membrane was washed with TBS-T and blocked with 5% 
milk powder in TBS-T for 1h at RT. Staining with primary antibodies was done by 
incubation at 4°C overnight. On the next day, the membrane was washed three times 
for 10min in TBS-T and incubated with the respective secondary antibody for 1h at 
RT. After washing the membrane three times for 10min with TBS-T, it was incubated 
with self-made ECL (see table 2-5) for 1min at RT. Proteins were detected using the 
chemiluminescence camera LAS-4000 Image Reader. 
2.10.3 Enzyme-linked Immunosorbent Assay (ELISA) 
To estimate the amount of human IL10 in sera derived from LCLs or patients, ELISA 
has been used. Sera derived from LCLs were stored at -20°C, patient sera at -75°C 
and have been thawed on ice directly before the analysis. For the detection of IL10 
the Eli-pair ELISA, specific for human IL10, with a detection limit of 5pg/ml has been 
used according to the manufacturer’s protocol. The absorption of the samples has 
been detected at a wavelength of 450nm using the SunriseTM Microplate Reader and 
MagellanTM software. 
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2.11 Molecular Biology  
2.11.1 Isolation of genomic DNA  
For the isolation of genomic DNA from blood samples or cell lines, the QIAamp® 
DNA Mini Kit was used. The procedure has been performed according to the 
manufacturers’ protocol. To enhance the amount of isolated DNA, the amount of 
used samples was doubled compared to the manufactures’ protocol. DNA was eluted 
in 200µl H2O and the concentration was determined using the NanoDrop. DNA was 
stored at 4°C. 
2.11.2 Allelic discrimination via Taqman assay 
Allelic discrimination via Taqman assay was used for the determination of certain 
single nucleotide polymorphisms (SNP) of IL10. In addition to two locus-specific 
primers, two fluorescence labeled probes are included into the PCR-reaction. These 
probes differ with respect to the nucleotide at the position of the SNP and the 
fluorescent label at the 5’-end (FAM or VIC). Both probes carry a quencher at the 3’-
end. If the quencher is located close to the fluorescent dye, the fluorescence signal is 
repressed. The probes bind to the DNA template, containing the respective SNP. 
During the elongation step of the PCR the Taq polymerase destroys the probe by 5’-
3’ exonuclease activity and the fluorescent dye is released. Thereby, the fluorescent 
intensity of the respective dye increases and can be measured by the instrument 
(ABI PRISM 7900HT). Depending on the genotype the free fluorescent dyes FAM, 
VIC or both (heterozygous) are accumulated. 
Assay and primer details for each analysed SNP are listed in table 2-8. The reaction 
has been performed on a 384-well plate in a volume of 5µl. The following reaction 
has been used.  
Applied Biosystems mix: 2.5µl Taqman Genotyping Mastermix (2x), 0.25µl Taqman 
SNP genotyping assay, 1.25µl H2O, 1µl genomic DNA (10ng/µl). 
Self-made Mix: 2.5µl Taqman Genotyping Mastermix (2x), 0.20µl of each primer 
(22.5µM) and each probe (5µM), 0.7µl H2O, 1µl genomic DNA (10ng/µl). 
The following PCR-program has been used for the reaction (ABI PRISM 7900HT): 
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Table 2-13 PCR program Taqman 
Initial denaturation 95°C 10min  
Denaturation 95°C 15s  
40 cycles Annealing/Extension 60°C 1min 
 
2.11.3 SNaPshot  
The SNaPshot® Multiplex System (Applied Biosystems) was used for the 
determination of certain IL10 SNPs. Therefore, DNA from patients and cell lines was 
used to amplify three different fragments containing the SNPs of interest (IL10-12kb, 
-3kb or +4kb). These PCR fragments were used in a primer extension reaction with 
fluorescent-labeled ddNTPs. SNP-specific primers of different length with the 3’-end 
directly adjacent to the respective gene variation were used. The analysis was than 
done using the AB3130 Genetic Analyser from Applied Biosystems. 
The following reactions were used for the PCR of SNP containing fragments: 
Table 2-14 PCR reaction Mix for SNaPshot 
2.5µl  10xPuffer (10x supplied with Taq polymerase) 
0.75µl MgCl2 (50mM supplied with polymerase) 
0.5µl  dNTPs (10mM each) 
0.5µl  rev. Primer (10µM) 
0.5µl  fwd. Primer (10µM) 
0,1 µl  Taq Polymerase (Invitrogen, Karlsruhe GER) 
ad.  24µl  H2O 
plus 25-50ng genomic DNA 
 
For the PCR fragment containing IL10-11.668G/A, IL10-11.777A/G and IL10-12.806C/T, the 
following PCR program was used (Thermocycler T3000): 
 
Table 2-15 PCR program used for amplification of the IL10-12kb fragment 
Initial Denaturation 95°C 4min  
Denaturation 94°C 45s  
 
10 cycles 
Annealing  63°C 1min 
Elongation 72°C 5min 
Denaturation 95°C 45s  
 
25cycles 
Annealing 57°C 1min 
Elongation 72°C 2min 30s 
Elongation 72°C 1h  
Pause 4°C  
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For the PCR fragment containing IL10-3538A/T, IL10-2849G/A, IL10-2763C/A, the following 
PCR program was used (Thermocycler T3000): 
Table 2-16 PCR program used for amplification of the IL10-3kb fragment 
Initial Denaturation 95°C 5min  
Annealing  58°C 3min  
Elongation 72°C 3min  




Annealing 58°C 1min 
Elongation 72°C 2min 




Annealing 56°C 1min 
Elongation 72°C 2min 
Elongation 72°C 10min  
Pause 4°  
 
For the PCR fragment containing IL10-4259A/G and IL10+5876C/T, the following PCR 
program was used (Thermocycler T3000): 
Table 2-17 PCR program used for amplification of the IL10+5kb fragment  
Initial Denaturation 95°C 5min  
Annealing 65°C 3min   
Elongation 72°C 3min  
Denaturation 95°C 30s  
 
40cycles 
Annealing 65°C 1min 
Elongation 72°C 2min 
Elongation 72°C 10min  
Pause 4°C  
 
After the PCR, the PCR-fragments had to be purified. This was done according to 
table 2-18. 
 
Table 2-18 Purification of PCR fragments for SNaPshot reaction 
1,5µl Shrimp Alkaline Phosphatase Reaction buffer  10x  (10xRxBuf) 
3,3µl Shrimp Alkaline Phosphatase (SAP) 1u/µl 
0,2µl Exonuclease I (Exo I) 10u/µl 
5µl PCR-fragment -12kb PCR-fragment -3kb 
5µl PCR-fragment +4kb PCR-fragment TNF 
Thermocycler T3000: 
Digestion 1h bei 37°C,  
heat inactivation 15min 80°C 
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Pooled primer mixes (table 2-19), using primers listed in table 2-9 and the SNaPshot 
reaction mix (table 2-20) were prepared, before the SNaPshot reaction (table 2-21). 
Table 2-19 Pooled primer mixes 
 Pooled primer Mix IL10 -12800/+4259 Pooled primer Mix TNF/IL10 
   
90µl H2O H2O 
2,5µl SNaPshot IL10-12806CT (100µM)  
2µl SNaPshot IL10-11777AG (100µM) SNaPshot IL10 -3538 (100µM) 
2µl SNaPshot IL10+545Ex5 (100µM) SNaPshot IL10 -2849 (100µM) 
2µl IL10 rs3024505 (100µM) SNaPshot TNF -308 (100µM) 
  SNaPshot TNF -238 (100µM) 
1,5µl SNaPshot IL10 -11668 (100µM) SNaPshot IL10 2763 new (100µM) 
100µl total total 
 
Table 2-20 SNaPshot reaction mix 
1,86µl H2O 
0,64µl SNaPShot Multiplex Ready Reaction Mix 100 RXN (Applied) 
0,5µl Pooled Primer Mix 
2µl purified PCR fragement 
→ 384 well plate  
 
Table 2-21 PCR programs for SNaPshot reaction 
Denaturation 96°C 10s  
 
24cycles 
Annealing 50°C 5s 
Elongation 60°C 30s 
Pause 4°C  
For the purification after SNaPshot reaction the following mix was prepared. 
Table 2-22 Purification of SNaPshot reaction 
0,5µl 10xRxBuf  
0,5µl SAP  
1µl total 
add to each well from SNaPshot reaction 
Mastercycler ( 384 well) 
digestion 1h at 37°C,  
heat inactivation 15min 80°C 
 
For the analysis, 10µl Formamid, supplemented with 0.1µl GeneScan120 LIZ size 
standard (Applied Biosystems Part No: 4322362) have been mixed with 1µl Snapshot 
reaction product on a 96-well plate . This was denatured at 95°C for 10min. The 
SNPs are subsequently determined according to the fluorescent labeled fragments of 
different sizes using the AB3130 Genetic Analyser and Gene MapperID Version 3.2. 
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2.11.4 Fragment length analysis of IL10-7400In/Del 
Fragment length analysis was used to determine, if the insertion or the deletion at    
IL10-7400In/Del or both were present in genomic DNA samples.  
Table 2-23 Fragment length analysis of IL10-7400In/Del 
Reaction Mix PCR-program 
30ng  DNA 96°C 30s  
 
25 cycles 
2,5µl  PlatinumTaq buffer (10x) 64°C 20s 
2µl MgCl2 (25mM) 72°C 15s 
0,5µl dNTP (10mM each) 96°C  
 
10 cycles 
0,4µl -7400forward (5µM) 60°C 
0,4µl -7400reverse neu (5µM) 72°C 
0,1µl (5U/µl)  PlatinumTaq 72°C 1h 
ad 25µl  H2O 4°C  
Fragment length has subsequently been determined, by mixing 10µl Formamid with 
0.15µl ROX500 (Applied Biosystems) and 1µl PCR product using the Genetic 
Analyser 3130 with Gene MapperID Version 3.2. 
2.11.5 Sequencing 
For the analysis of nucleotide sequences, fluorescent labeled ddNTPs were used 
(BigDye Terminator Cycle Sequencing-Kit v1.1) according to the procedure described 
in table 2-24. 
Table 2-24 Sequencing Mix 
Reaction Mix PCR-program 
100-500ng DNA  
2µl sequencing buffer (5x) 95°C 30s  
 
25 cycles 
1,5µl sequencing mix 50°C 15s 
5pmol Primer 60°C 4min 
ad 10µl H2O 4°C   
Subsequently, the reaction mix had to be purified. Therefore, the innuPREP DYEpure 
Kit has been used according to the manufacturers’ protocol. 10µl of eluted purified 
PCR product of sequencing reaction have been mixed with 10µl Formamid. 
Sequencing analysis has been conducted using the AB3130 Genetic Analyser with 
Sequencing Analysis Version 5.2.  
2.11.6 Isolation of RNA and Reverse Transcription 
Cells for RNA Isolation were harvested via sedimentation (210xg/10min/4°C) and 
washed once with PBS (1000xg/4°C/ 10min). For the Isolation of RNA the RNeasy 
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plus Mini Kit (Qiagen) together with QIAshredder or the Nucleo Spin RNA II Kit 
(Machery & Nagel) were used according to the manufacturers’ protocols. RNA has 
been eluted in 40µl RNAse free water. RNA concentrations were determined using 
the NanoDrop. 
For the reverse transcription from RNA into cDNA, the SuperScript II Reverse 
transcriptase (Invitrogen) was used. Reverse transcription was performed with 
random hexamer primers or oligo dT primers.  
2µl of random hexamer (100µM) or oligo dT (50µM) was added to each cup. 1-3µg 
RNA was added in 10µl H2O. This mix was denatured for 10min on 70°C in a 
Thermocycler. Subsequently samples have been cooled on ice and 8µl of the Master 
Mix have been added to each sample. Depending on the oligonucleotide primers, a 
respective program was used for reverse transcription in the Thermocycler 
(Biometra) (table 2-25). 
Table 2-25 Reverse Transcription 
Master Mix rnd hexamer oligo dT 
4µl 5x first strand buffer   
2µl DTT (0.1M) 25°C 10min  
1µl Super Script II 42°C 60min 42°C 60min 
1µl dNTPs (10mM each) 65°C 10min 70°C 15min 
→ 8µl per sample 4°C  4°C  
 
2.11.7 quantitative Real-Time PCR (qRT-PCR) 
For the quantification of transcripts, a SYBR® Green based system was used. 
SYBR® Green is a cyanine-dye, which intercalates with double stranded DNA. Upon 
binding to DNA, the dye absorbs blue light (λmax = 488 nm) and emits green light 
(λmax = 522 nm). Therefore, this system can be used to quantify the amount of double 
stranded PCR products. The number of PCR cycles at which an exponential increase 
of fluorescence can be detected (Cycle Threshold= Ct-value) correlates to the 
amount of DNA templates within the PCR. A self-made SYBR Green Mix (see table 
2-5) was used for this purpose. The PCR has been conducted using 384-well clear 
optical plates. For each reaction a total volume of 10µl was used with 5.6µl SYBR 
Green mix and 0.3pmol/µl of each primer. An amount of cDNA has been used that 
corresponds to 20ng RNA. Each analysis has been conducted in triplets. 
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Table 2-26 qRT-PCR program 
Initial Denaturation and activation of HOT 
FIREPol® 
95°C 12min 
Denaturation 95°C 15s  





Pause 4°C  
 
To determine the relative expression of each analysed gene, the Ct-values of each 
triplet were normalized to the mean Ct-value of a housekeeper gene (abl or β2m see 
table 2-7). 
Ctspez. – Cthousekeeper = Ct 
To compare gene expression of a control sample to a modified sample the CT was 
calculated.  
Ctmodified sample – Ctcontrol = CT 
The ∆∆CT is a value which shows whether the expression of a certain gene is higher 
or lower compared to the control sample. For example if IL10 expression changes 
after a respective stimulation of the cells. Based on the ∆∆Ct the fold change could 
be calculated as  
fold change = 1/ (2∆∆CT) 
If the gene of interest was not expressed in the control sample, the fold change could 
not be calculated and the respective normalized Ct-value was used. 
2.11.8 PCR for ncRNA 
The transcription of ncRNA has been assessed by SYBR Green PCR or conventional 
PCR. As template cDNA was used, which was reverse transcribed with random 
hexamer or oligo dT (see 2.11.6). As a control for DNA contamination cDNA reverse 
transcribed without reverse transcriptase has been used. As positive control for the 
PCR, DNA of the respective cell line was used. For SYBR Green PCR the above 
described protocol (see 2.11.7) was used with primers originally designed for ChIP 
(table 2-7). 
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For conventional PCR the same primers have been used but in different 
combinations, as indicated below the respective figures. The following reaction mix 
was used. 
Table 2-27 Reaction mix for ncRNA detection 
Master Mix  
cDNA (or DNA 50-100ng) 300ng (based on used RNA) 
10xPCR buffer K (supplied with Taq) 5µl 
MgCl2 (50mM supplied with Taq) 1.5µl 
dNTPs (10mM each) 1µl 
Primer forward (10µM) 1µl 
Primer reverse (10µM) 1µl 
Taq Polymerase (Primetech LTD, Belarus) 0.2µl 
ad 50µl H2O  
Depending on the length of the PCR product different PCR-programs have been 
used. 
Table 2-28 PCR programs used for the detection of ncRNA via conventional PCR 
 length of PCR fragments 
 100-500bp approx. 3kb approx. 4kb 
Initial Denaturation  95°C 5min 95°C 5min 95°C 5min 
Annealing 60°C 3min 60°C 3min 60°C 3min 
Elongation 72°C 3min 72°C 3min 72°C 3min 
Denaturation 95°C 30s 95°C 1min 95°C 1min 
40 
cycles 
Annealing 60°C 30s 60°C 1min 60°C 1min 
Elongation 72°C 1min 72°C 3min 72°C 5min 
Elongation 72°C 10min 72°C 10min 72°C 10min 
Pause 4°C  4°C  4°C  
 
2.11.9 Chromatin immunoprecipitation and Sonication test  
Chromatin immunoprecipitation (ChIP) can be used to detect binding of transcription 
factors or specific histone modifications at defined regions of the genome. For this 
purpose, proteins bound to DNA are crosslinked using formaldehyde. Subsequently, 
the DNA is sheared by sonication. The protein-DNA complexes can be 
immunoprecipitated, using antibodies specifically binding modified histone 
modifications or transcription factors of interest. In a final step, the crosslink is 
reversed and the DNA fragments, which were immunoprecipitated due to their 
binding to respective proteins are analysed by qRT-PCR. Thereby, the binding 
regions of the respective proteins can be defined. Buffers used for ChIP are 
described in table 2-5. Used inhibitors were sodium butyrate (5mM) and Protease 
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inhibitor cocktail (Roche). This is indicated by ++. The procedure has been conducted 
using the following protocol, adjusted from the ChIP protocol from the Laboratory of 
Junior Professor Dr. Steven Johnsen. 
For each ChIP 5-6x106 cells have been prepared (e.g. stimulation with PMA), 
depending on the question of interest. Three biological replicates were analysed in 
parallel. 1x106 cells per immunoprecipitation (IP) (5-6x106 per previously sample) 
have been crosslinked according to the best conditions for the respective cell line (for 
all cell line used here: 0.5% Formaldehyde in PBS for 10min at RT). Quenching of 
formaldehyde has been performed by adding 1ml 1.25M Glycine and incubation for 
5min at room temperature. Cells were washed twice in ice-cold PBS and twice in 
Nelson buffer modified++ (12,000 g, 1 min., 4°C). The nuclear pellet was resuspended 
in 300µl (for 5-6x106 cells) SDS lysis buffer. Sonication of the samples has been 
performed using the Biorupter™ Next Gen for 3 x 10min (Settings: 10 sec on/off duty 
time at high power). Preclearing has been performed with 80-100µl Protein A-
Sepharose (50% slurry in Gomes lysis buffer++) for 1h at 4°C. The samples were 
centrifuged at 12,000xg/10min/4°C and the supernatant was used for IP. An amount 
of 50µl chromatin containing supernatant derived from approximately 1x106cells has 
been used per IP and the input sample. 2µg of respective antibodies were added to 
each sample, including an anti-IgG antibody as negative control (table 2-10) and 
each sample was filled up to a volume of 500µl with Gomes lysis buffer++. The input 
DNA has been precipitated with 100µl 100% Ethanol and 1µl GlycoBlueTM overnight 
at -20°C. Protein A-Sepharose has been blocked overnight with salmon sperm DNA 
and BSA. On the next day, the samples have been incubated for 1h at 4°C with 30µl 
Protein A-Sepharose (50% slurry in Gomes lysis buffer++, washed three times after 
blocking). Immune complexes have been washed twice with Gomes lysis buffer, 
three times with Gomes wash buffer and once with 1xTE (centrifuge at 
2,000xg/4°C/2min). After the last washing step, as much supernatant as possible has 
been removed. The input DNA has been sedimented (12,000xg/20min/4°C) and 
washed twice with 500µl 70%EtOH (12,000xg/5min/4°C). For DNA Isolation 100µl 
10% Chelex 100 slurry has been added to the washed beads and the input DNA, 
vortexed briefly and heated up to 95°C for 10min. Subsequently, samples have been 
treated with proteinase K for 30min at 55°C. Proteinase K has been inactivated by 
incubating samples at 95°C for 10min. Samples have been centrifuged 
(12,000xg/1min/4°C). 70µl of supernatant have been transferred to a new tube, 
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without transferring any Chelex as this inhibits PCR-reactions. The DNA has been 
stored at -20 °C. 
For PCR analysis all samples including the input have been diluted 1:10. A dilution 
series of a pooled input mix has been prepared for use as standard in the PCR. The 
PCR has been conducted using the SYBR Green system (see 2.11.7). For each 
tested primer pair (see table 2-7 and Figure 3-16) the input standard, the input and 
each sample has been analysed in triplicates. The amount of bound DNA was 
estimated as % of input. 
2.11.10 Transformation of E.coli 
E.coli bacteria were used for the amplification of plasmid DNA. For the transformation 
of plasmid DNA into E.coli, the chemically competent DH5α cells were used, which 
were stored at -80°C. Cells were thawed on ice for 5-10min. 4-10µl of a ligation 
reaction or 50ng purified plasmid DNA was added to the cells without pipetting up 
and down. After 30min incubation on ice a heat shock at 42°C for 42s was 
performed. The bacteria were kept on ice for another 10min. Subsequently, cells 
were suspended in 250µl SOC medium and incubated shaking for 1h at 37°C. For 
selection of transformed cells, the bacteria were plated on LB-agar plates containing 
100µg/ml Ampicillin. These plates were incubated at 37°C overnight. On the next 
day, individual colonies have been transferred into 2ml of LB-medium containing 
Ampicillin for preparation of plasmid DNA (see 2.11.11) for sequencing analysis (see 
2.11.5). Of these cultures, glycerol stocks have been established for cryo-
conservation by mixing 200µl of the bacterial suspension with 200µl Glycerol (storage 
-80°C). 
2.11.11 Isolation of Plasmid DNA 
For isolation of small amounts of plasmid DNA, 2ml of bacterial culture have been 
incubated at 37°C shaking overnight. Isolation has been performed using the 
QIAGEN Plasmid Mini Kit according to the manufacturers’ protocol. These have been 
used for sequencing analysis (2.11.5). For high amounts 110ml bacterial culture have 
been incubated overnight at 37°C shaking and isolation of plasmid DNA has been 
performed using the EndoFree Plasmid Maxi Kit according to the manufacturers’ 
protocol. Plasmid DNA has been resolved in endotoxin free water at 4°C overnight 
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and concentration of DNA was measured using the NanoDrop. Plasmid DNA has 
been stored at 4°C. 
2.11.12 qRT-PCR for IL10 expression on LCLs /using Standard Plasmids 
For the comparability of different qRT-PCRs, conducted to analyse IL10 expression 
of LCLs, a standard has been developed. The PCR products of both primers used, 
qRT-IL10-e1-2 for IL10 expression and β2m the housekeeper (see table 2-7) have 
been inserted into the pCR2.1 Topo. 
Therefore, the PCRs have been conducted on DNA derived from LCL 183/2 using 
the Thermocycler T3000. The PCR program also used for the detection of ncRNA 
fragments of 100bp-500bp has been used (see table 2-28). Subsequently, the PCR 
products have been separated on a 1% Agarose gel. The PCR products have been 
cut from the Gel and purified using the QIAEX II Agarose Gel Extraction kit according 
to the manufacturers’ protocol. 
To insert the PCR products into the pCR2.1 Topo, the TOPO TA Cloning® Kit has 
been used according to the manufacturers’ protocol. This ligation reaction has been 
used for transformation (see 2.11.10), followed by isolation of plasmid DNA from a 
2ml culture (see 2.11.11), which has been used for sequencing (see 2.11.5). 
After sequencing, one correct plasmid has been used for Maxi plasmid preparation 
using the EndoFree® Plasmid Maxi Kit according to the manufacturers protocol. The 
plasmids have been linearized by digesting them with EcoRV. 5µl buffer 3 (NEB), 
5µg of the respective plasmid and 1µl EcoRV have been incubated in 50µl total 
Volume for 2h on 37°C. 
4µl Shrimp Alkaline Phosphatase (SAP) from the SNaPshot assay has been added 
to both samples after controlling digestion on 1% Agarose gel. This was incubated for 
1h on 37°C, followed by heat inactivation of SAP for 15min on 65°C. 
For purification the QIAquick PCR purification Kit was used according to the 
manufacturers’ protocol. 
According to the number of base pairs of each plasmid, the molecular weight has 
been calculated. Dilutions of each plasmid of 1x107 to 1x102 molecules/2µl have 
been prepared. These have been tested in qRT-PCR analyses (see 2.11.4). The 
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estimated slope of the SDS 2.1 software had to be -3.32. Plasmid dilutions have 
been aliquoted and stored at -20°C. 
2.12 Definitions and statistical Analyses/ 
2.12.1 Survival Analysis 
For a first analysis of genotyping data of aNHL patients (for details of patients see 
chapter 2.1.2), the GENEPOP software was used (Version 3.4 
http://genepop.curtin.edu.au/). These analyses included tests for Hardy-Weinberg 
equilibrium, genotypic and allelic differentiation. For the reconstitution of haplotypes, 
the haplotype estimation software was used (MDC, Berlin http://www.bioinf.mdc-
berlin.de/projects/hap/). Later analyses were made by Dr. Mladen Tzvetkov using the 
Phase software (http://depts.washington.edu/uwc4c/express-licenses/assets/phase/). 
Clinical characteristics between included patients and patients of the complete trials 
were estimated using the  2-test, and if required, Fisher´s exact test. 
Overall survival (OS) was defined as time from first day of therapy (NHL-B1/B2) or 
random assignment (RICOVER-60) to death from any cause. Event-free survival 
(EFS) was defined as time from first day of therapy (NHL-B1/B2) or random 
assignment (RICOVER-60) to progressive disease under therapy, or failure to 
achieve complete remission, additional therapy in excess of that prescribed in the 
protocol, relapse or death from any cause, whatever came first. Patients without an 
event in EFS or OS were censored at the last day with valid information for the 
respective endpoint. EFS and OS were estimated according to Kaplan-Meier and 
compared by log-rank trend test. Multivariate analyses were performed with the use 
of Cox proportional hazard models to estimate hazard ratios for evolving an event. 
The analyses have been conducted without adjustment for multiple comparisons. 
Therefore, only the most prominent aspects have been extracted. Statistical analyses 
were performed with R-2.6.2. by Markus Kreuz (IMISE, Leipzig). 
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2.12.2 LCLs  
The analyses of associations between IL10 expression or IL10 secretion of LCLs with 
IL10 genotypes has been conducted assisted by Hans-Joachim Helms (Department 
of Medical Statistics, UMG, Göttingen).  
Values estimated for IL10 expression (see chapter 2.11.8) were not normally 
distributed and have therefore been ranked. This means the LCL with the lowest     
IL10 expression was ranked 1 and the LCL with the highest IL10 expression was 
ranked 111. Due to the fact that qRT-PCR has been conducted on different qRT-
plates a two-way ANOVA has been conducted. Thereby, the influence of IL10 gene 
variation and the qRT-plate as independent variables on IL10 gene expression as the 
dependent variable as well as the interaction between the two independent variables 
has been estimated. These analyses have been conducted using the SAS software. 
Pair-wise comparisons have been conducted for IL10 gene variations with significant 
results. A Wilcoxon-Test adjusted for Bonferroni has been done using the 
STATISTICA software (www.statsoft.de).  
Values estimated for IL10 secretion (see chapter 2.10.4) were also not normally 
distributed and have been ranked prior to following analyses. Variance analyses 
have been conducted using Kruskal-Wallis ANOVA and STATISTICA software. 
LCLs have been grouped into high and low IL10 expressing and IL10 secreting cells 
according to the respective median (median expression: 0.000762 NSM          
IL10/NSM β2m; median secretion 737pg IL10/ml). These groups have been 
compared in a two-way summary table and Pearson Χ2-test has been conducted 





3.1 Characterization of Interleukin 10 gene variations and serum levels 
in aNHL patients 
To answer the question about the prognostic relevance of IL10 gene variations in 
aNHL, IL10 gene variations were analysed in relation to OS or EFS of aNHL patients 
treated within three different prospective clinical trials from the DSHNHL (Deutsche 
Studiengruppe für hochmaligne Non-Hodgkin-Lymphome) (see Material and Methods 
2.1.2). For a better understanding of this and the following chapters, the most 
important characteristics are summarized here. 
942 patients were from the NHL-B trial. Patients within this trial have been treated 
every second or third week with CHOP or CHOP plus etoposide (Pfreundschuh et al., 
2004a; Pfreundschuh et al., 2004b). The trial can be divided in a younger cohort, 
NHL-B1 (age≤60) with 477 patients and an older cohort, NHL-B2 (age>60) with 465 
patients included into this study. 498 of these patients have been included into a 
previous study on IL10 gene variations (Kube et al., 2008). Therefore the 942 
patients are an enlargement of the previous study analysed for an extended number 
of IL10 gene variations in the present study. The cohort termed “CCR-excluded” 
represents those 444 patients not included into the previous study. From the 
RICOVER-60 trial DNA of 604 patients has been available for respective analyses. 
This trial showed that the outcome of patients treated with Rituximab in addition to 
conventional CHOP therapy (R-CHOP) is superior compared to the outcome of 
patients treated with CHOP alone in elderly aNHL patients (age≥60) (Pfreundschuh 
et al., 2008). 301 patients out of the 604 patients have been treated with CHOP, 
while 303 have been treated with Rituximab in addition to CHOP (R-CHOP). The 
same effect as in RICOVER-60 was tested in younger patients within the Mab Thera 
International Trial (MInT) (Pfreundschuh et al., 2006). In this trial the same effect of 
superior survival for patients treated with Rituximab has been observed. However the 
general outcome in this young patient group is much better compared to the elderly 
patients. 178 patient DNAs from the whole MInT trial were available for our analyses. 
In total, DNA of 1724 patients with aNHL has been genotyped for IL10 gene 
variations. The clinical characteristics of the patients, of which respective material for 
genotyping analyses was available (included), have been compared to those from 
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the complete trials (complete). The clinical characteristics of patient of each individual 
trial are summarized in table 3-1A and table 3-1B. Notably, the patients included into 
the NHL-B and the CCR-excluded cohorts are from the same trial. Therefore the 
clinical characteristics for the complete trial are listed only once.  
Patients included into our analysed cohorts are representative for the complete trials 
and the different arms of NHL-B and RICOVER-60. The only exception is the CCR-
excluded cohort in which the median age differs significantly from the complete trial 
(difference=2 years). Nevertheless this cohort was evaluated, as it was important for 
the validation of the effects observed in the previous study on 498 aNHL patients 
(Kube et al., 2008). 
 
Genotyping has been done for 12 gene variations located in the 5’ flanking region of 
IL10, with the most distal variation at -12.806bp from the transcriptional start site, one 
variation within the 3’-UTR (IL10+4259A/G) and 1 variation in the proximal 3’region 
(IL10+5876C/T), assisted by Frederike von Bonin and Angela Lenz. The genotyping 
was performed using the respective Taqman SNP genotyping assays for the gene 
variations IL10-6752A/T, IL10-6208G/C, IL10-3538T/A, IL10-1087A/G, IL10-824C/T and       
IL10-597C/A or a fragment length analysis for IL10-7400In/Del. The gene variations     
IL10-12806C/T, IL10-11777A/G, IL10-11668G/A, IL10-2812G/A, IL10-2726C/A, and              
IL10+4259A/G and IL10+5876C/T were analysed using SNaPshot-assay. IL10-3538T/A was 
genotyped with both methods as a cross reference. In addition to those gene 
variations analysed in a previous study on 498 aNHL patients (Kube et al., 2008), the 
gene variations IL10-12806C/T, IL10-11777A/G, IL10-11668G/A, IL10+4259A/G and          
IL10+5876C/T have been included into the analysis due to their localization within 
evolutionary conserved regions and their recent functional description relevant for 
IL10 expression (Jones and Flavell, 2005; Shoemaker et al., 2006), whereas          
IL10-2812G/A, IL10-2726C/A have been described to affect inter-individual differences in 









Table 3-1A Clinical characteristics of the NHL patient subgroup analysed for IL10 gene variations 
This table shows a comparison of the clinical characteristics of patients from the whole NHL-B trial, the young patients from the NHL-B1, the elderly patients 
from the NHL-B2 trial and the T-NHL patients. “Included” refers to the patients included into our analyses based on availability of respective material and 
“complete” refers to patients included into the original clinical trials. * IPI= International Prognostic Index LDH >N, age >60 years, ECOG >1, stage III/IV, and 




































































Age Median (Min.;Max.) 60 (18;75) 58 (18;75) 60 (18;75) 49 (18;60) 48 (18;60) 67 (61;75) 67 (61;75) 58 (18;78) 61 (18;78) 
IPI* 
          low (IPI=0,1) 
          intermediate low (IPI=2) 
          intermediate high (IPI=3) 














































Serum LDH > N 214 (23%) 92 (21%) 316 (23%) 0 (0%) 0 (0%) 214 (46%) 316 (46%) 22 (19%) 45 (23%) 
Age Older than 60 y 465 (49%) 194 (44%) 689 (49%) 0 (0%) 0 (0%) 465 (100%) 689 (100%) 50 (43%) 99 (50%) 
Performance status ECOG > 1 106 (11%) 42 (10%) 163 (12%) 24 (5%) 38 (5%) 82 (18%) 125 (18%) 13 (11%) 31 (16%) 
Ann Arbor stage III,IV 376 (40%) 175 (40%) 567 (41%) 149 (31%) 217 (31%) 227 (49%) 350 (51%) 47 (40%) 85 (43%) 
No of extranodal sites >1 186 (20%) 82 (19%) 276 (20%) 67 (14%) 104 (15%) 119 (26%) 172 (25%) 23 (19.7%) 36 (18.3%) 
Bulky tumor (>7,5 cm) 319 (34%) 156 (35%) 467 (33%) 133 (28%) 197 (28%) 186 (40%) 270 (40%) 30 (25.7%) 51 (25.9%) 
B symptoms 264 (28%) 123 (28%) 402 (29%) 98 (21%) 149 (21%) 166 (36%) 253 (37%) 45 (38.5%) 75 (38.1%) 











Table 3-1B Clinical characteristics of the NHL patient subgroup analysed for IL10 gene variations 
This table shows a comparison of the clinical characteristics of patients from the whole RICOVER-60 trial, the patients from the CHOP and the R-CHOP arms 
and patients from the MInT clinical trial. ”Included” refers to the patients included into our analyses based on availability of respective material and “complete” 
refers to patients included into the original clinical trials. * IPI= International Prognostic Index LDH >N, age >60 years, ECOG >1, stage III/IV, and number of 





























































Age Median (Min.;Max.) 68 (61;80) 68 (61;80) 68 (61;80) 68 (61;80) 68 (61;80) 68.5 (61;80) 46 (18;60) 45 (18;60) 
IPI* 
          low (IPI=0,1) 
          intermediate low (IPI=2) 
          intermediate high (IPI=3) 
































Serum LDH > N 288 (48%) 604 (49%) 148 (50%) 301 (49%) 140 (46%) 303 (50%) 55 (31%) 84 (29%) 
Age Older than 60 y 604 (100%) 1222 (100%) 301 (100%) 612 (100%) 303 (100%) 610 (100%) 0 (0%) 0 (0%) 
Performance status ECOG > 1  78 (13%) 176 (14%) 41 (14%) 87 (14%) 37 (12%) 89 (15%)   
Ann Arbor stage III,IV 303 (50%) 619 (51%) 153 (51%) 312 (51%) 150 (50%) 307 (50%) 54 (30%) 83 (29%) 
No of extranodal sites >1  104 (17%) 216 (18%) 49 (16%) 107 (17%) 55 (18%) 109 (18%) 23 (13%) 38 (13%) 
Bulky tumor (>7,5 cm)  241 (40%) 463 (38%) 123 (41%) 230 (38%) 118 (39%) 233 (38%) 91 (51%) 148 (51%) 
B symptoms 199 (33%) 399 (33%) 102 (34%) 202 (33%) 97 (32%) 197 (32%) 57 (32%) 80 (28%) 
extranodal involvement 336 (56%) 663 (54%) 167 (56%) 335 (55%) 169 (56%) 328 (54%) 77 (44%) 125 (43%) 








 The IL10 gene variations are in strong LD to each other, therefore certain haplotypes 
are formed by these gene variations. Figure 3-1 shows the estimated haplotypes for 




Figure 3-1 Frequency of IL10 haplotypes 
Phase software has been used to estimate haplotypes formed by the analysed IL10 gene variations. 
The respective haplotypes with a frequency higher 3% are shown for healthy blood donors (normal 
population; NP), patients from the RICOVER-60 cohort and patients from the NHL-B cohort. 
Frequencies are given on the left. The human IL10 gene locus from -12.806bp till +6800bp on 
chromosome 1q31/32 is shown as scheme above the haplotypes. Single nucleotide polymorphisms 
(SNP) and the insertion/deletion variation at -7400bp are indicated. The IL10 gene and the position of 
the ATG are shown. UTR (yellow), exons (dark blue) and introns (white) are displayed.  
 
 
Genotype frequencies have been estimated and are shown in table 3-2 for the 
complete patient cohort. All gene variations have been tested for HDW (Hardy-
Weinberg). The HDW test showed no significant differences between observed and 
suspected numbers of genotype frequencies for the complete patient cohort. 




Table 3-2 IL10 Genotype frequency and HDW of 1724 NHL patients analysed within this thesis 
   
Complete (n=1724) 







IL10-12806C/T rs17015865 TT 81 4,7 0,84 
  
CT 588 34,5 
 
  
CC 1037 60,8 
 IL10-11777A/G rs4072227 GG 11 0,6 0,14 
  
AG 201 11,8 
 
  
AA 1493 87,6 
 IL10-11668G/A rs4072226 AA 304 17,8 0,70 
  
AG 823 48,2 
 
  
GG 579 33,9 
 IL10-7400In/Del 7400In/Del DelDel 79 4,6 0,41 
* 
 
InDel 606 35,3 
 
  
InIn 1034 60,2 
 IL10-6752A/T rs6676671 TT 265 15,4 0,94 
* 
 
AT 819 47,6 
 
  
AA 638 37,0 
 IL10-6208G/C rs10494879 CC 299 17,4 0,66 
* 
 
CG 827 48,0 
 
  
GG 597 34,6 
 IL10-3538T/A rs1800890 AA 265 15,4 0,86 
* 
 
AT 815 47,4 
 
  
TT 638 37,1 
 IL10-2812G/A rs6703630 AA 99 5,8 0,70 
  
AG 637 37,3 
 
  
GG 974 57,0 
 IL10-2726C/A rs6693899 AA 236 13,8 0,21 
  
AC 766 44,8 
 
  
CC 708 41,4 
 IL10-1087A/G rs1800896 GG 394 22,9 0,47 
* 
 
AG 844 49,0 
 
  
AA 485 28,1 
 IL10-824C/T rs1800871 TT 73 6,2 0,70 
* 
 
CT 429 36,6 
 
  
CC 670 57,2 
 IL10-597C/A rs1800872 AA 101 5,9 0,81 
* 
 
AC 640 37,1 
 
  
CC 983 57,0 
 IL10+4259A/G rs3024498 GG 99 5,8 0,87 
  
AG 629 36,9 
 
  
AA 977 57,3 
 IL10+5876C/T rs3024505 TT 53 3,2 0,69 
  
CT 473 28,6 
 
  
CC 1129 68,2 
 
 
Survival analyses have been conducted, comparing the genotyping data to OS and 
EFS of the patients in univariate analyses using a log-rank test. In addition, 
multivariate analyses have been done using a cox-model, adjusted to the clinical 
parameters included into the IPI. Thereby, hazard ratios for relative risks for having 
an event (OS or EFS) were calculated. These analyses have been conducted from 







 The analysis of the combined patient cohort of 1724 aNHL patients revealed no 
significant associations between IL10 gene variations and OS or EFS. 
As the general characteristics of patients included into the three different trials differ 
to some extent in terms of general survival rates, age, risk groups defined by IPI, 
histological subtypes of NHL, general survival and treatment regiments they were 
analysed separately (compare clinical characteristics table 3-1A and B, histology 
table A-1A and A-1B as well as (Pfreundschuh et al., 2008; Pfreundschuh et al., 
2004a; Pfreundschuh et al., 2004b; Pfreundschuh et al., 2006)). These analyses will 
be described in detail within the following chapters. 
117 patients with T-NHL (see Material and Methods 2.1.2 and Table A-2) from the 
NHL-B and the RICOVER-60 trial have been analysed separately for associations of 
IL10 gene variations and IL10 serum levels with survival rates. The results are 
described in detail in chapter 3.1.4.  
3.1.1 Association of IL10-7400DelDel with shorter survival in aNHL patients from 
NHL-B could not be validated 
The IL10-7400In/Del gene variation has been found to be associated with shorter OS in 
a representative cohort of 498 aNHL patients from the NHL-B trial, as described in 
the introduction (Kube et al., 2008). Therefore one of the aims of this dissertation was 
to test if this effect could be validated in a larger patient cohort.  
A significant trend for carriers of the IL10-7400DelDel genotype towards shorter OS 
(p=0.032) but not EFS (p=0.088) could be observed compared to carriers of the other 
two genotypes in the NHL-B trial (Figure 3-2A and B). This is not surprising because 
this subgroup (n=942) includes the 498 aNHL patients analysed in the before 
mentioned previous study (Kube et al., 2008). As there was no additive effect of the 
minor allele IL10-7400Del, meaning that carriers of IL10-7400InDel show similar OS and 
EFS to carriers of IL10-7400InIn, only a comparison between homozygous carriers of 
this allele compared to carriers of the other two genotypes together is described here. 
The survival curves of a comparison of all three genotypes are shown in the 





Figure 3-2 Association of IL10-7400DelDel with shorter survival rates could not be validated.   






 Figure 3-2 Association of IL10-740DelDel with shorter survival rates could not be validated. 
Shown are the survival curves (Kaplan-Meier plots) for OS (A,C,E,G) and EFS (B,D,F,H) of aNHL 
patients from the NHL-B cohorts in comparison with IL10-7400In/Del genotypes (IL10-7400DelDel vs         
IL10-7400InIn+IL10-7400InDel). A. OS of patients from NHL-B. B. EFS of patients from NHL-B. C. OS of 
patients from NHL-B1. D. EFS of patients from NHL-B1. E. OS of patients from NHL-B2. F. EFS of 
patients from NHL-B2. G. OS of patients from NHL-B_CCR-excluded. H. EFS of patients from NHL-
B_CCR-excluded. P refers to the log-rank test. Patients at risk represents the number of patients 
which still can develop an event (OS or EFS) at defined time points. Significant values have been 
observed for OS rates for patients from NHL-B (A) and NHL-B1 (C) studies. 
 
Separate analyses of the NHL-B1 (patients ≤ 60 years) and B2 (patients > 60 years) 
cohorts revealed a difference in these two groups with respect to the IL10-7400In/Del 
gene variation. Consistent with the results of the NHL-B cohort a trend towards 
shorter OS (Figure 3-2 C and E) and EFS (Figure 3-2 D and F) was observed for 
both groups. Significant association between IL10-7400DelDel genotype and survival 
could be observed only for the younger patient cohort from the NHL-B1 study for 
shorter OS rates (p=0.019) but not for shorter EFS rates (p=0.090) (Figure 3-2 C and 
D). For the older patient cohort from the NHL-B2 study neither OS (p=0.509) nor EFS 
(p=0.568) rates were significantly associated with IL10-7400DelDel (Figure 3-2 E and F). 
By comparing the OS and EFS rates of patients included in the CCR-excluded cohort 
no trends for shorter survival rates could be observed (Figure 3-2 G and H).  
The respective three-year survival rates reflect the situation visualized by Kaplan-




Table 3-3 Shorter three-year survival rates for carriers of the IL10-7400DelDel genotype for OS and 
EFS in patients from the NHL-B cohorts 
Three-year survival rates for carriers of the different genotypes of IL10-7400In/Del have been estimated 
for OS and EFS of patients from the four NHL-B cohorts. P refers to the log-rank test. Three-year 
survival rates were significantly shorter for OS for patients with IL10-7400DelDel in the NHL-B cohort and 






(95% CI) p* 
3-y rate 
EFS 
(95% CI) p* 








54.3 (38.9; 76)  47.5 (33.3; 67.7)  








64.3 (41.2; 1)  54.4 (32.9; 90.1)  








46.6 (28.1; 77.2)  42.9 (26.2; 70.2)  








67.4 (46.7; 97.3)  55.6 (36.8; 84)  
*log-rank test, significant p-values are italic and bold 
 
Multivariate analyses using a Cox-Model adjusted to the IPI factors revealed an 
enhanced relative risk of 1.58 for shorter OS for carriers of IL10-7400DelDel (p=0.078) 
compared to carriers of the other two genotypes in the NHL-B cohort (see table 3-4). 
This relative risk was comparable to the relative risks of having a higher stage or 
extranodal involvement. The estimated relative risk for the carriers of IL10-7400DelDel 
for shorter OS in NHL-B1 was 1.92 (p=0.170). In this cohort not all IPI factors could 
be included into the analysis, due to the fact that higher age (>60years) and elevated 
LDH levels are not existing in these young patients. The estimated HR was higher 
than that estimated for higher stage. In the older NHL-B2 patient cohort the same 
trend for an enhanced relative risk for shorter OS could be observed but this was only 
1.31 (p=0.390). For EFS the same, but less pronounced, effect of a higher risk for 
shorter survival rates associated with IL10-7400DelDel has been observed for all three 
cohorts (table 3-4). Notably, the confidence intervals of the estimated risks for shorter 
OS in the NH-B1 and NHL-B2 lie on top of each other and both include the value 1, 






 Table 3-4 Enhanced relative risk for shorter OS and EFS for carriers of IL10-7400DelDel gene 
variation in the NHL-B cohorts 
Relative risks for shorter OS and EFS for patients with IL10-7400DelDel were estimated in multivariate 
analysis adjusted to the IPI factors in the NHL-B, NHL-B1, NHL-B2 and NHL-B_CCR-excluded 
cohorts. P refers to the Cox-model. Significant p-values are italic and bold. International Prognostic 
Index (IPI); overall survival (OS); event-free survival (EFS); hazard ratio for relative risk (HR); 
confidence interval (CI); lactate dehydrogenase (LDH); Eastern Cooperative Oncology Group (ECOG). 






OS    
LDH >  N 1.84 (1.38; 2.47) 0.000042 
age > 60 years 2.15 (1.58; 2.91) 0.0000009 
ECOG > 1 2.13 (1.59, 2.85) 0.00000046 
Stage III/ IV 1.53 (1.18; 1.97) 0.0011 
Extranodal involvement > 1 1.13 (0.86; 1.49) 0.380 
IL10-7400DelDel vs. InDel&InIn 1.58 (0.95; 2.62) 0.078 
EFS    
LDH >  N 1.56 (1.20; 2.03) 0.00087 
age > 60 years 1.47 (1.15; 1.87) 0.0019 
ECOG > 1 1.74 (1.33; 2.27) 0.000059 
Stage III/ IV 1.55 (1.25; 1.92) 0.000058 
Extranodal involvement > 1 1.15 (0.91; 1.46) 0.240 







OS    
ECOG > 1 2.68 (1.36; 5.27) 0.0043 
Stage III/ IV 1.28 (0.80; 2.05) 0.300 
Extranodal involvement > 1 2.23 (1.32; 3.77) 0.0028 
IL10-7400DelDel vs. InDel&InIn 1.92 (0.75; 4.91) 0.170 
EFS    
ECOG > 1 1.40 (0.76; 2.60) 0.280 
Stage III/ IV 1.44 (1.03; 2.02) 0.036 
Extranodal involvement > 1 1.32 (0.86; 2.02) 0.210 







OS    
LDH >  N 1.87 (1.39; 2.51) 0.000041 
ECOG > 1 2.11 (1.52; 2.92) 0.0000066 
Stage III/ IV 1.60 (1.18; 2.16) 0.0027 
Extranodal involvement > 1 0.92 (0.66; 1.26) 0.590 
IL10-7400DelDel vs. InDel&InIn 1.31 (0.71; 2.41) 0.390 
EFS    
LDH >  N 1.53 (1.16; 2.00) 0.0022 
ECOG > 1 1.87 (1.37;2.54) 0.000066 
Stage III/ IV 1.64 (1.24; 2.17) 0.00051 
Extranodal involvement > 1 1.05 (0.79; 1.41) 0.720 

















OS    
LDH >  N 1.98 (1.24; 3.17) 0.0042 
age > 60 years 2.40 (1.51; 3.82) 0.00023 
ECOG > 1 2.43 (1.54; 3.83) 0.00013 
Stage III/ IV 1.59 (1.08; 2.32) 0.018 
Extranodal involvement > 1 1.39 (0.92; 2.09) 0.120 
IL10-7400DelDel vs. InDel&InIn 1.16 (0.47; 2.85) 0.750 
EFS    
LDH >  N 1.68 (1.11; 2.54) 0.015 
age > 60 years 1.61 (1.10;2.34) 0.013 
ECOG > 1 1.81 (1.18; 2.77) 0.0064 
Stage III/ IV 1.50 (1.09; 2.07) 0.013 
Extranodal involvement > 1 1.40 (0.98; 2.00) 0.062 
IL10-7400DelDel vs. InDel&InIn 1.33 (0.65; 2.72) 0.430 
Results 
68 
For the NHL-B_CCR-excluded cohort the estimated risks were 1.16 for OS (p=0.750) 
and 1.33 for EFS (p=0.430). Both values are below the estimated risks of any of the 
IPI factors. 
Taken together, a tendency towards shorter survival rates associated with                
IL10-7400DelDel could be observed in the NHL-B, the NHL-B1 and the NHL-B2 cohorts, 
whereby this was most pronounced in the young NHL-B1 cohort. No trends for        
IL10-7400DelDel to be associated with shorter or longer survival could be observed in the 
NHL-B_CCR-excluded cohort. Therefore, the negative predictive effect of                
IL10-7400DelDel, observed in the previously published NHL-B cohort of 498 patients, 
could not be validated in the enlarged patient cohort. 
 
In contrast to NHL-B, in the Ricover-60 cohort the IL10-7400DelDel genotype was 
associated with a better survival of the patients (Figure 3-4 A-F). This will be 
described in more detail in chapter 3.1.2. 
No statement can be done about this gene variation and survival of patients within 
the MInT cohort. The number of homozygous carriers of IL10-7400DelDel was too low 
for survival analysis. 
 
No other IL10 gene variation showed significant associations with survival in the 
NHL-B, the NHL-B1, NHL-B2 or NHL-B_CCR-excluded cohort. Significant values for 
the log-rank test have been observed frequently. The respective gene variations were 
in LD with the IL10-7400In/Del as, for example, the IL10-6752A/T in NHL-B or the       
IL10-2812G/A in NHL-B1. Therefore significant associations are thought to be caused 
by IL10-7400In/Del, as the trend for shorter survival were associated with those variants 
observed only together with IL10-7400Del in one haplotype (compare to figure 3-1). 
 
Taken together, the negative predictive effect of IL10-7400DelDel could not be validated 
in a larger patient cohort, neither in univariate nor in multivariate analyses of             






 3.1.2 Investigation of prognostic relevance of IL10 gene variations and IL10 
serum levels in the RICOVER-60 trial  
3.1.2.1 IL10-11.668AA is associated with better treatment outcome in patients 
from the RICOVER-60 and the R-CHOP cohort 
Univariate analyses of associations between IL10 gene variations and OS or EFS in 
the RICOVER-60 cohort revealed several significant associations. The same was 
true for those patients treated with R-CHOP. None of these associations was 
significant for the patients treated without Rituximab, even though the observed 
trends were consistent with those observed in the other two cohorts. 
After comparing the estimated haplotypes (Figure 3-1) to the results of the univariate 
analyses one could conclude that the IL10-11.668G/A could be the gene variation that is 
causing the observed effects. The A-allele is part of most of the haplotypes with 
significantly associated alleles. Therefore, this gene variation is described here in 
more detail. 
As for the IL10-7400In/Del there was no additive effect of the minor allele IL10-11.668A, 
meaning that carriers of IL10-11.668AG show similar OS and EFS to carriers of         
IL10-11.668GG, only a comparison between homozygous carriers of this allele 
compared to carriers of the other two genotypes together is described here. The 
survival curves of a comparison of all three genotypes are shown in the Appendix 
(Figure A-2). 
The IL10-11.668AA genotype was significantly associated with longer OS and highly 
significantly associated with longer EFS in the whole RICOVER-60 cohort             
(OS: p=0.039; EFS: p=0.010; Figure 3-3 A and B) as well as in the R-CHOP cohort      
(OS: p=0.041; EFS: p=0.007; Figure 3-3 C and D). The same trend for longer survival 
rates associated with IL10-11.668AA could be observed in the CHOP cohort. Albeit 
these differences were not significant within this cohort and the survival curves 
especially for OS but also for EFS overlap within the first month (OS: p=0.340 and 
EFS: p=0.240) (Figure 3-3 E and F). Respective three-year survival rates have been 
estimated (see table 3-5). A trend for longer survival has been observed for carriers 




Figure 3-3 The IL10-11.668AA genotype is associated with longer survival rates for OS and EFS in 
patients from the RICOVER-60 cohort and in patients within the R-CHOP cohort. 
Shown are the survival curves (Kaplan-Meier plots) for OS (A,C,E) and EFS (B,D,F) of aNHL patients 
from the RICOVER-60 cohorts in comparison with IL10-11.668G/A genotypes. A. OS of patients from 
RICOVER-60. B. EFS of patients from RICOVER-60. C. OS of patients from R-CHOP arm of 
RICOVER-60. D. EFS of patients from R-CHOP arm of RICOVER-60. E. OS of patients from CHOP 
arm of RICOVER-60. F. EFS of patients from CHOP arm of RICOVER-60. P refers to the log-rank 
test. Patients at risk represents the number of patients which still can develop an event (OS or EFS) at 
defined time points. Significant values have been observed for OS and EFS rates for patients from 






 Table 3-5 Longer three-year survival rates for carriers of the IL10-11.668AA genotype for OS and 
EFS in patients from the RICOVER-60 cohorts 
Three-year survival rates for carriers of the different genotypes of IL10-11.668G/A have been estimated 
for OS and EFS of patients from the three RICOVER-60 cohorts. P refers to the log-rank test. Three-
year survival rates were significantly longer for patients with IL10-11.668AA in the RICOVER-60 cohort 






(95% CI) p*-value 
3-y rate 
EFS 
(95% CI) p*-value 








81.5 (74.6; 89)  72.2 (64.4; 80.9)  








89.2 (81.3; 97.8)  86.2 (77.7; 95.5)  








74.1 (63.6; 86.4)  58.9 (47.4; 73.2)  
*log-rank test, significant p-values are italic and bold 
 
Multivariate analyses adjusted to the IPI factors revealed a reduced relative risk for 
shorter OS and EFS for carriers of IL10-11.668AA compared to the other two genotypes 
in all three cohorts from the RIVOVER-60 trial (see table 3-6). In the RICOVER-60 
cohort the estimated relative risk was significantly lower for OS (HR=0.6; p=0.030) 
and EFS (HR=0.60; p=0.007) for carriers of IL10-11.668AA. The estimated relative risk 
in the R-CHOP cohort was also significantly lower for OS (HR=0.39; p=0.030) and 
EFS (HR=0.35; p=0.005). In the CHOP arm the same trend for a reduced relative risk 
could be observed but this was not significant for OS (HR=0.78; p=0.400) or EFS 
(HR=0.79; p=0.300). Notably, the confidence intervals of the estimated relative risks 
for IL10-11.668AA for the R-CHOP cohort and the CHOP cohort overlap to some 
extent, whereby the confidence interval of the R-CHOP cohort does not include the 






Table 3-6 Reduced relative risk for shorter OS and EFS for carriers of IL10-11.668AA 
Relative risks for shorter OS and EFS for patients with IL10-11.668AA genotype have been estimated in 
comparison to carriers of IL10-11.668GG or IL10-11.668AG in multivariate analysis adjusted to the IPI 
factors. P refers to the Cox-model. Significant p-values are italic and bold. Reduced relative risks have 
been estimated for all three cohorts, RICOVER-60, R-CHOP and CHOP for OS and EFS. 
Abbreviations see table 3-4. 
 
 










OS    
LDH >  N 2.31 (1.61; 3.32) 0.0000064 
ECOG > 1 1.65 (1.11; 2.46) 0.0130 
Stage III/ IV 1.52 (1.04; 2.23) 0.0320 
Extranodal involvement > 1 1.32 (0.88; 1.98) 0.180 
IL10-11.668AA vs. GG&AG 0.60 (0.38; 0.95) 0.030 
EFS    
LDH >  N 1.57 (1.18: 2.08) 0.002 
ECOG > 1 1.70 (1.21; 2.40) 0.0026 
Stage III/ IV 1.76 (1.29; 2.40) 0.00039 
Extranodal involvement > 1 1.23 (0.88; 1.72) 0.230 







OS    
LDH >  N 2.61 (1.46; 4.67) 0.0013 
ECOG > 1 1.52 (0.81; 2.83) 0.190 
Stage III/ IV 1.60 (0.86; 2.99) 0.140 
Extranodal involvement > 1 1.14 (0.62; 2.10) 0.670 
IL10-11.668AA vs. GG&AG 0.39 (0.17; 0.91) 0.030 
EFS    
LDH >  N 1.95 (1.21; 3.15) 0.0064 
ECOG > 1 1.61 (0.93; 2.78) 0.090 
Stage III/ IV 1.96 (1.15; 3.35) 0.014 
Extranodal involvement > 1 1.20 (0.72; 2.00) 0.490 






OS    
LDH >  N 2.19 (1.37; 3.48) 0.00099 
ECOG > 1 1.71 (1.02; 2.89) 0.043 
Stage III/ IV 1.49 (0.92; 2.41) 0.110 
Extranodal involvement > 1 1.63 (0.94; 2.83) 0.080 
IL10-11.668AA vs. GG&AG 0.78 (0.45; 1.38) 0.400 
EFS    
LDH >  N 1.37 (0.96; 1.95) 0.080 
ECOG > 1 1.81 (1.16; 2.81) 0.0088 
Stage III/ IV 1.64 (1.12; 2.40) 0.011 
Extranodal involvement > 1 1.40 (0.90; 2.19) 0.140 








 Because of the prognostic relevance of the IL10-11.668G/A in the RICOVER-60 cohort 
this gene variation was considered attentively again in the combined cohort as well 
as the NHL-B cohorts. Neither positive nor negative associations with survival could 
be observed in any of the cohorts. 
 
Similar results as for IL10-11.668G/A could be observed in survival analysis of the 
RICOVER-60 cohort for other IL10 genotypes, namely the IL10-7400In/Del (Figure 3-4) 
as well as IL10-2812G/A. In both cases the homozygous carriers of the minor alleles 
IL10-7400DelDel and IL10-2812AA showed a superior OS and EFS compared to carriers 
of the other two genotypes of the respective gene variation. For IL10-7400In/Del this 
was not significant for RICOVER-60 (OS: p = 0.074 and EFS: p = 0.237; Figure 3-4 A 
and B) but for OS in the R-CHOP cohort (OS: p = 0.047 and EFS: p = 0.054, Figure 
3-4 C and D). For IL10-2812G/A the significance was higher in the R-CHOP cohort (OS: 
p = 0.032 and EFS: p = 0.030) compared to the RICOVER-60 cohort (OS: p = 0.048 
and EFS: p = 0.256). In the CHOP arm an insignificant trend for a better outcome 
associated with IL10-7400DelDel was observed for OS (p=0.499; Figure 3-4 E) but not 
EFS (p=0.976; Figure 3-4 F). The same trends were observed for carriers of IL10-
2812AA in the CHOP arm (OS: p=0.385; EFS: p=0.909). Survival curves showing a 
comparison of all three genotypes for IL10-7400In/Del are shown in the Appendix 
(Figure A-3). Again there was no additive effect and therefore, only a comparison of 
survival rates of homozygous carriers of the minor allele with those of carriers of the 
other two genotypes together is described here. 




Figure 3-4 The IL10-7400DelDel genotype is associated with longer survival rates for OS and EFS 
in patients from the RICOVER-60 cohort and patients from the R-CHOP cohort. 
Shown are the survival curves (Kaplan-Meier plots) for OS (A,C,E) and EFS (B,D,F) of aNHL patients 
from the RICOVER-60 cohorts in comparison with IL10-7400In/Del genotypes. A. OS of patients from 
RICOVER-60. B. EFS of patients from RICOVER-60. C. OS of patients from R-CHOP arm of 
RICOVER-60. D. EFS of patients from R-CHOP arm of RICOVER-60. E. OS of patients from CHOP 
arm of RICOVER-60. F. EFS of patients from CHOP arm of RICOVER-60. P refers to the log-rank 
test. Patients at risk represents the number of patients which still can develop an event (OS or EFS) at 
defined time points. A Significant association has been observed for OS rates for patients from the R-






 Table 3-7 Longer three-year survival rates for carriers of the IL10-7400DelDel genotype for OS and 
EFS in patients from the RICOVER-60 cohorts 
Three-year survival rates for carriers of the different genotypes of IL10-7400In/Del have been estimated 
for OS and EFS of patients from the three RICOVER-60 cohorts. P refers to the log-rank test. Three-
year survival rates were significantly longer for patients with IL10-7400DelDel in the R-CHOP cohort. 






(95% CI) p*-value 
3-y rate 
EFS 
(95% CI) p*-value 








87.9 (77.5; 99.8)  68.7 (54.1; 87.2)  








1   93.8 (82.6; 100)  








77 (59.6; 99.6)  47.7 (28.8; 79)  
*log-rank test, significant p-values are italic and bold 
 
Consistent with the univariate analyses, multivariate analyses adjusted to the IPI 
factors revealed a reduced relative risk for OS or EFS (Table 3-8). In the RICOVER-
60 cohort this relative risk was estimated to be 0.36 (p=0.042) for OS and 0.60 
(p=0.120) for EFS. This positive effect was even more pronounced for patients within 
the R-CHOP cohort. The relative risk for OS could in fact not be calculated because 
the number of events was too low. For EFS it was estimated to be 0.15 (p=0.056). In 
the CHOP cohort, where the relative risk for shorter OS was 0.67 (p=0.440) and 0.94 
(p=0.870) for EFS, the effect was less pronounced. However, the respective 
confidence intervals of the R-CHOP and the CHOP cohort still overlap to some extent 
and therefore, the positive prognostic effect of IL10-7400DelDel cannot be ascribed to 
Rituximab. 
 
Taken together, aNHL patients carrying the IL10-11.668AA genotype show a 
significantly better treatment outcome compared to carriers of the other two 
genotypes in the RICOVER-60 cohort and in the R-CHOP cohort, whereby the same 




A follow up study of the RICOVER-60 trial has been conducted in which all patients 
received Rituximab. Genotyping for the most important IL10 gene variations has 
been completed and the data is currently under evaluation in the IMISE in Leipzig. 
 
Table 3-8 Reduced relative risk for shorter OS and EFS for carriers of IL10-7400DelDel 
Relative risks for shorter OS and EFS for patients with IL10-7400DelDel genotype have been estimated in 
comparison to carriers of IL10-7400InIn or IL10-7400In/Del in multivariate analysis adjusted to the IPI 
factors. P refers to the Cox-model. Significant p-values are italic and bold. Reduced relative risks have 
been estimated for all three cohorts, RICOVER-60, R-CHOP and CHOP for OS and EFS. 
Abbreviations see table 3-4. 
 
 










OS    
LDH >  N 2.46 (1.71; 3.53) 0.0000011 
ECOG > 1 1.54 (1.04; 2.28) 0.031 
Stage III/ IV 1.48 (1.01; 2.16) 0.043 
Extranodal involvement > 1 1.46 (0.98; 2.17) 0.063 
IL10-7400DelDel vs. InDel&InIn 0.36 (0.13; 0.97) 0.042 
EFS    
LDH >  N 1.68 (1.26; 2.22) 0.00035 
ECOG > 1 1.57 (1.12; 2.20) 0.0095 
Stage III/ IV 1.72 (1.26; 2.34) 0.00063 
Extranodal involvement > 1 1.31 (0.94; 1.83) 0.110 







EFS    
LDH >  N 2.12 (1.31; 3.41) 0.0022 
ECOG > 1 1.39 (0.81; 2.41) 0.240 
Stage III/ IV 1.79 (1.05; 3.04) 0.032 
Extranodal involvement > 1 1.34 (0.81; 2.23) 0.260 






OS    
LDH >  N 2.28 (1.43; 3.62) 0.00052 
ECOG > 1 1.68 (1.01; 2.79) 0.045 
Stage III/ IV 1.50 (0.92; 2.43) 0.100 
Extranodal involvement > 1 1.75 (1.02; 2.99) 0.041 
IL10-7400DelDel vs. InDel&InIn 0.67 (0.24; 1.84) 0.440 
EFS    
LDH >  N 1.46 (1.03; 2.08) 0.034 
ECOG > 1 1.75 (1.14; 2.71) 0.011 
Stage III/ IV 1.65 (1.13; 2.42) 0.010 
Extranodal involvement > 1 1.46 (0.94; 2.27) 0.089 








 3.1.2.2 High IL10 serum levels are associated with worse treatment outcome 
in the RICOVER-60 trial 
To estimate the effect of elevated IL10 serum levels on the outcome of aNHL patients 
IL10 levels have been determined by ELISA in serum samples of 523 patients from 
the RICOVER-60 trial. Thereof 252 patients were treated with CHOP and 271patients 
were treated with R-CHOP.  
According to the detection limit of 5pg/ml of the ELISA, patients were defined as high 
or low IL10 producers. In Figure 3-5 the respective Kaplan-Meier survival curves are 
shown. The relative risk for shorter OS and EFS rates for the patient group with high 
IL10 secretion levels was estimated using a univariate Cox-model. In addition a 
multivariate Cox-model adjusted for the IPI factors has been used to calculate 
relative risks. Statistical analyses were conducted by Markus Kreuz (IMISE).  
Patients with IL10 secretion levels ≥5pg/ml were characterized by significantly shorter 
OS and EFS in all analysed subgroups from the RICOVER-60 cohort (Figure 3-5). 
Consistently the respective three-year survival rates of those patients with detectable 
and therefore elevated IL10 serum levels were shorter compared to those patients 
without detectable amounts of IL10 in their serum (Table 3-9).  
 
Table 3-9 Shortened 3-year survival rates for OS and EFS of patients from the RICOVER-60 trial 
with elevated IL10 serum levels 
Three-year survival rates have been estimated for OS and EFS of patients from the RICOVER-60 
cohorts. According to the detection limit of 5pg/ml of the ELISA, patients were defined as high or low 
IL10 producers. Three-year survival rates were significantly shorter for patients with IL10 serum levels 







(95% CI) p-value* 
3-y rate 
EFS 
(95% CI) p-value* 
RICOVER-60        
 <5pg/ml 78.9 (74.5; 83.5) 0.0000089 67.3 (62.4; 72.6) 0.00028 
 ≥5pg/ml 61 (53.7; 69.3)  50.3 (43.1; 58.8)  
R-CHOP        
 <5pg/ml 83.5 (78.2;.89.3) 0.0011 76.7 (70.8; 83.1) 0.0091 
 ≥5pg/ml 68.7 (59; 79.9)  59.9 (49.9; 71.9)  
CHOP        
 <5pg/ml 73.5 (66.7; 81.1) 0.0036 56.7 (49.2; 65.2) 0.015 
 ≥5pg/ml 53.3 (43.1; 66)  41.1 (31.6; 53.5)  





Figure 3-5 Elevated IL10 serum levels are associated with shorter survival in patients from the 
RICOVER-60 trial. 
Shown are the survival curves (Kaplan-Meier plots) for OS (A,C,E) and EFS (B,D,F) of aNHL patients 
from the RICOVER-60 cohorts in comparison with IL10 serum levels. According to the detection limit 
of 5pg/ml of the ELISA, patients were defined as high or low IL10 producers. A. OS of patients from 
RICOVER-60. B. EFS of patients from RICOVER-60. C. OS of patients from R-CHOP arm of 
RICOVER-60. D. EFS of patients from R-CHOP arm of RICOVER-60. E. OS of patients from CHOP 
arm of RICOVER-60. F. EFS of patients from CHOP arm of RICOVER-60. Patients at risk represents 
the number of patients which still can develop an event (OS or EFS) at defined time points. P refers to 
the univariate Cox-model. Significant association has been observed for patients with IL10 serum 






 Multivariate analyses adjusted to the IPI factors revealed that the estimated relative 
risks of IL10 serum levels ≥5pg/ml are comparable to clinical factors included into the 
IPI in all the RICOVER-60 subgroups (Table 3-10). The estimated relative risks are 
comparable in all three cohorts and higher for OS than EFS.  
In the RICOVER-60 cohort the relative risk for shorter OS for patients with elevated 
IL10 serum levels was estimated to be 1.72 (p=0.0014), while it was 1.40 (p=0.020) 
for shorter EFS. In both cases it was higher than the estimated risk for extranodal 
involvement or higher ECOG. Notably, in both cases the confidence interval did not 
include the 1, which means that that the probability that the real relative risk is higher 
than 1 is given.  
In the R-CHOP cohort the estimated relative risk for shorter OS was 1.72 (p=0.036) 
and 1.47 (p=0.092) for EFS. For OS this was higher than the estimated relative risk 
for all other IPI factors excluding enhanced LDH levels. The value 1 was not within 
the confidence interval. For EFS it was higher than the risks estimated for extranodal 
involvement and higher ECOG. 
In the CHOP cohort a relative risk for shorter OS of 1.71 (p=0.018) and of 1.33 for 
EFS (p=0.130) was calculated. This estimated relative risk was higher compared to 
the risks calculated for higher ECOG or higher stage in case of OS but not EFS. 
Taken together it could be shown that high IL10 production negatively influences 
treatment outcome in the RICOVER-60 cohort. The addition of Rituximab to CHOP 
therapy does not overcome adverse prognostic features reported here and 




Table 3-10 Enhanced relative risks for patients from the RICOVER-60 cohorts with elevated 
IL10 serum levels 
Relative risks for shorter OS and EFS for patients with elevated IL10 serum levels (≥5pg/ml) have 
been estimated in multivariate analysis adjusted to the IPI factors in the RICOVER-60, R-CHOP and 
CHOP cohorts. Enhanced relative risks have been estimated for all three cohorts for OS and EFS. P 
refers to the Cox-model. Significant p-values are italic and bold. Abbreviations see table 3-4. 
 










OS    
LDH >  N 2.12 (1.46; 3.07) 0.00007 
ECOG > 1 1.37 (0.90; 2.09) 0.140 
Stage III/ IV 1.55 (1.04; 2.3) 0.030 
Extranodal involvement > 1 1.47 (0.98; 2.21) 0.061 
IL10≥5pg/ml 1.72 (1.23; 2.39) 0.0014 
EFS    
LDH >  N 1.52 (1.12; 2.05) 0.0068 
ECOG > 1 1.38 (0.95; 2.00) 0.092 
Stage III/ IV 1.89 (1.35; 2.64) 0.00019 
Extranodal involvement > 1 1.30 (0.92; 1.84) 0.140 







OS    
LDH >  N 2.2 (1.22; 3.94) 0.008 
ECOG > 1 1.39 (0.74; 2.61) 0.310 
Stage III/ IV 1.60 (0.84; 3.05) 0.160 
Extranodal involvement > 1 1.25 (0.68; 2.29) 0.470 
IL10≥5pg/ml 1.72 (1.04; 2.86) 0.036 
EFS    
LDH >  N 1.78 (1.08; 2.94) 0.023 
ECOG > 1 1.27 (0.71; 2.26)) 0.420 
Stage III/ IV 1.75 (0.99; 3.07) 0.053 
Extranodal involvement > 1 1.33 (0.79; 2.27)) 0.290 






OS    
LDH >  N 2.13 (1.31; 3.47) 0.002 
ECOG > 1 1.37 (0.77; 2.42) 0.280 
Stage III/ IV 1.48 (0.89; 2.46) 0130 
Extranodal involvement > 1 2.02 (1.16; 3.53) 0.013 
IL10≥5pg/ml 1.71 (1.10; 2.66) 0.018 
EFS    
LDH >  N 1.40 (0.95; 2.05) 0.088 
ECOG > 1 1.59 (0.96; 2.62) 0.070 
Stage III/ IV 1.93 (1.27; 2.94) 0.002 
Extranodal involvement > 1 1.53 (0.96; 2.46) 0.076 







 3.1.3 No associations of IL10 gene variations with survival of patients within 
the small MInT cohort with superior outcome 
The number of patients (n=178) in the MInT cohort was comparably small. 89 
patients were in the CHOP and 89 patients in the R-CHOP arm of this cohort. For 
gene variations with a low frequency of the minor allele, like IL10-7400In/Del or           
IL10+5876C/T, survival analysis could not be conducted for homozygous carriers of 
these alleles.  
The only significant results were obtained for IL10-824C/T and IL10-597C/A. These gene 
variations are in such strong LD, that the same patients are in each genotype group. 
The minor allele was associated with significantly shorter OS rates (p=0.011). No 
effect of these gene variations was observed for EFS. However, the same effect is 
not seen in any other cohort to this extend. Therefore and due to the very low 
number of homozygous carriers of the minor alleles (n=11) this effect should not be 
over interpreted.  
The MInT trial was similar to the RICOVER-60 trial in terms of tested treatment 
strategies. These two trials differ regarding the age of recruited patients. The three-
year-survival rates for OS were 93% for the R-CHOP arm compared to 84% in the 
CHOP cohort (Pfreundschuh et al., 2006). This means that the general outcome is 
much better in this trial compared to the RICOVER-60 trial (Pfreundschuh et al., 
2008) and overall differences are pretty small. 
Due to the small of patients in this cohort and the general very good treatment 
outcome, the two treatment arms could not be analysed separately.  
 
3.1.4 IL10 gene variations and serum levels do not have significant prognostic 
relevance for treatment outcome in T-NHL patients 
Associations of 13 IL10 gene variations and IL10 serum levels with OS and EFS 
have been analysed to determine if they are of prognostic relevance for treatment 
outcome of T-NHL. We analysed the gene variations IL10-12806C/T, IL10-11777A/G,    
IL10-11668G/A, IL10-7400In/Del, IL10-6752A/T, IL10-6208G/C, IL10-3538T/A, IL10-2812G/A,    
IL10-2726C/A, IL10-1087A/G, IL10-597C/A and IL10+4259A/G but not IL10-824C/T and     
IL10+5876C/T. IL10-824C/T is in strong LD with IL10-597C/A. IL10+5876C/T has been 
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included into our analyses at a later time point of our studies. In addition IL10+5876C/T 
is very rare, therefore its value information in a cohort of only 117 T-NHL patients 
would be rather poor. Genotyping for IL10 gene variations has been done mainly by 
Frederike von Bonin and determination of respective IL10 serum levels via ELISA 
has been done by Dr. rer. nat. Nils Schoof as part of his dissertation. The impact of 
this dissertation was the completion of the genotyping data for IL10 gene variations 
and mainly the evaluation and interpretation of the results obtained from Markus 
Kreuz from the IMISE in Leipzig.  
In addition to IL10 gene variations and serum levels the cytokine receptor genes 
coding for IL4 receptor (IL4R), tumor necrosis factor alpha receptor I (TNFRI) and 
TNFRII as well as the respective circulating levels of soluble receptors have been 
examined in the same patient cohort. This work has been done by Dr. rer. nat. Nils 
Schoof and Dr. med. Irene Stoller as part of their dissertations, assisted by Frederike 
von Bonin. 
A manuscript with the title “Circulating levels of TNF- receptor II are prognostic for 
patients with peripheral T cell Non-Hodgkin lymphoma” resulted from this work and is 
attached to this dissertation. 
The most important finding of the study was a strong association of circulating levels 
of sTNFRII with OS and EFS. T-NHL patients with serum levels of                     
TNFRII >2.16ng/ml had significantly shorter OS (p=0.003) and EFS (p=0.0007). 
The impact of this dissertation was the evaluation of all available data supplied by 
Markus Kreuz and writing of the above mentioned manuscript. During the evaluation 
process, analyses of associations between the respective circulating serum levels of 
soluble receptors and survival have been requested. 
3.1.4.1 Associations of IL10 gene variations with OS or EFS of T-NHL 
patients  
Univariate analyses of OS and EFS in correlation with IL10 gene variations revealed 
shorter survival rates for the IL10-7400DelDel (Figure 3-6 A and B). The respective 
three-year survival rates for patients characterized by IL10-7400DelDel were calculated to 
be shorter compared to the three-year survival rates of carriers of IL10-7400InIn or   








Figure 3-6 IL10-7400DelDel is insignificantly associated with shorter OS and EFS in patients 
suffering from T-NHL. 
Shown are the survival curves (Kaplan-Meier plots) for OS (A) and EFS (B) of T-NHL patients in 
comparison with IL10-7400In/Del genotypes. P refers to the log-rank trend test. Patients at risk represents 
the number of patients which still can develop an event (OS or EFS) at defined time points. Figure is 
taken from the Manuscript “Circulating levels of TNF- receptor II are prognostic for patients with 
peripheral T cell Non-Hodgkin lymphoma” by Heemann et al. 
 
This tendency was comparable to the observations described within the large cohort 
of 942 aNHL patients in the NHL-B. However, the observed differences were not 
significant for T-NHL patients. Table 3-11 shows the results obtained via comparison 
of carriers of all three genotypes and of homozygous carriers of the minor allele with 
carriers of the other two genotypes together.  
 
Table 3-11 Shorter three-year survival rates for carriers of the IL10-7400DelDel genotype for OS 
and EFS in patients with T-NHL 
Three-year survival rates for carriers of the different genotypes of IL10-7400In/Del have been estimated 
for OS and EFS of patients from the T-NHL cohort. P refers to the log-rank test. Three-year survival 
rates were shorter for patients with IL10-7400DelDel. Confidence Interval (CI), Three-year survival rate (3-
y rate). The table is taken and modified from the manuscript “Circulating levels of TNF- receptor II are 














IL10-7400In/Del          
InIn (n=69) 67.2 0.776 51.9 0.934 InIn; InDel 71.2 0.153 57.3 0.139 
InDel (n=42) 78.1  66.3  DelDel 50  33.3  
DelDel (n= 6) 50.0  33.3       




A respective multivariate Cox model for every IL10 gene variation adjusted for the IPI 
factors was estimated. This multivariate analysis showed a 2.2 (OS) or 1.9 (EFS) 
times increased relative risk for carriers of IL10-7400DelDel, which is close to that of 
having elevated LDH, higher ECOG-status or age, but was not significant in our study 
due to the low number of patients carrying this gene variation (Table 3-12).  
 
Table 3-12 Enhanced relative risk for shorter OS and EFS for carriers of IL10-7400DelDel gene 
variation in the T-NHL cohort 
Relative risks for shorter OS and EFS for patients with IL10-7400DelDel genotype have been estimated in 
multivariate analysis adjusted to the IPI factors in the T-NHL cohort. P refers to the Cox-model. 
Significant p-values are italic and bold. Abbreviations are given in table 3-4. The table was taken and 
modified from the Manuscript “Circulating levels of TNF- receptor II are prognostic for patients with 
peripheral T cell Non-Hodgkin lymphoma” by Heemann et al. 
 













OS    
LDH >  N 2.25 (0.95; 5.34) 0.065 
age > 60 years 2.41 (1.07; 5.38) 0.033 
ECOG > 1 2.73 (1.03; 7.20) 0.043 
Stage III/ IV 0.75 (0.35; 1.61) 0.467 
Extranodal involvement > 1 4.64 (2.13;10.08) <0.001 
DelDel vs InDel&InIn 2.21 (0.74; 6.65) 0.157 
EFS    
LDH >  N 1.63 (0.75; 3.51) 0.215 
age > 60 years 1.73 (0.92; 3.28) 0.091 
ECOG > 1 2.16 (0.46; 5.15) 0.083 
Stage III/ IV 0.74 (0.40; 1.38) 0.349 
Extranodal involvement > 1 2.89 (1.51; 5.51) 0.001 
DelDel vs InDel&InIn 1.90 (0.72; 4.97) 0.193 
 
In a previous study of Lee and colleagues a protective effect of the ATA haplotype 
(formed by IL10-1087A, -824T, -597A) has been described (Lee et al., 2007). Therefore, 
this effect was evaluated in our T-NHL cohort focusing on IL10-824C/T representing the 
ATA haplotype best (Figure 3-1). Patients characterized by the presence of at least 
one T-allele (IL10-824TT, IL10-824CT) were compared to homozygous carriers for the C-
allele (IL10-824CC). Thereby shorter survival rates for OS (p=0.178) and EFS (p=0.359) 
could be observed for patients carrying at least one T-allele. However, this was not 
significant. A further detailed analysis revealed that the four T-NHL patients with   
IL10-824TT showed a very short OS and EFS within the first 30 month of follow up. 
Furthermore, no comparable trends for shorter cumulative OS or EFS were detected 






 3.1.4.2 Associations of circulating serum levels of IL10 with survival of        
T-NHL patients  
As circulating levels of certain cytokines are parameters that could, to some extent 
reflect the actual host-lymphoma interaction and thereby influence the prognosis of 
lymphoma patients, the circulating levels of IL10 were determined by ELISA using 
pretreatment sera of T-NHL patients whenever possible. The ELISA was done by Dr. 
Nils Schoof. Statistical analysis was done by Markus Kreuz (IMISE). The evaluation 
of the statistical results was part of this dissertation. 
To define high and low producers, the threshold for IL10 was set on 5 pg/ml, 
according to the detection limit. OS and EFS rates of T-NHL patients were compared 
to high and low serum levels in univariate analyses.  
During the first 40 months patients with IL10 serum levels ≥5 pg/ml seemed to 
relapse more often (have more events for OS or EFS) compared with those patients 
having <5 pg/ml IL10 in their serum. However, at the end of the follow up both groups 
show the same OS and EFS. Due to the low number of patients the curves become 
instable at this point. The overall analysis revealed no statistical significant 
differences according to the IL10 serum levels (OS: p=0.54; EFS p=0.36) (Figure 3-7 
A and B). 
 
Figure 3-7 Overall and Event free survival of patients suffering from T-NHL in relation to IL10 
serum levels. 
The survival curves (Kaplan-Meier plots) show a comparison of the OS (A) and EFS (B) of T-NHL 
patients with IL10 serum levels. Patients with serum levels >5pg/ml are considered as high and 
patients <5pg/ml as low producers. P refers to the log-rank test. Patients at risk represents the number 
of patients which still can develop an event (OS or EFS) at defined time points (here 10 month interval 
monitored). The figure was taken and modified from the Manuscript “Circulating levels of TNF- 




3.2 Investigation of interindividual differences of IL10 production 
capacity in comparison to IL10 gene variations in LCLs 
Interindividual differences in IL10 production capacity have been attributed to genetic 
variations in the IL10 promoter (Gibson et al., 2001; Mormann et al., 2004; Rieth et 
al., 2004). In one of these studies the IL10-7400DelDel genotype has been found to be 
associated with high levels of IL10 secretion in LPS stimulated peripheral blood 
mononuclear cells (PBMCs) (Rieth et al., 2004). The same trend has been observed 
for lymphoblastoid cell lines (LCLs). These are immortalized B lymphocytes, 
established via infection with the EBV strain B95/8 (for detailed information see 
Material and Methods 2.9.2). Due to the fact that the IL10-7400DelDel genotype is 
rather rare only 4 homozygous LCL were included into that study. 
Therefore, this dissertation aimed to enlarge the overall number of LCLs measured 
for IL10 secretion, thereby enhancing the number of LCLs with the IL10-7400DelDel 
genotype and to analyse additional IL10 gene variations compared to the study of 
Rieth et al.(Rieth et al., 2004). 
All IL10 gene variations included into the survival analysis have also been included 
into this analysis. The gene variations IL10-12806C/T, IL10-11777A/G, IL10-11668G/A,    
IL10+4259A/G, IL10+5876C/T, IL10-2812G/A and IL10-2726C/A have been included due to the 
same reasons as they have been included into the survival analysis of aNHL 
patients, their localization within evolutionary conserved regions and their functional 
description relevant for IL10 expression (Gibson et al., 2001; Jones and Flavell, 
2005; Shoemaker et al., 2006). 
Approximately 130 LCLs established in the context of previous studies from Prof. Dr. 
Kube have been cultured, these include the 80 LCLs published within the study of 
Rieth et al (Rieth et al., 2004). Not all these cell lines could be successfully 
recultured. Therefore, attempts were done to establish new LCLs from B cells, 
whereof only 6 were successfully immortalized. In addition to this, 8 LCLs were 
derived from the HapMap project. These have to be evaluated with care due to the 
fact that all available HapMap LCLs with IL10-7400DelDel genotype (n=4) have been 
included into this study, which is no random selection and not correct in terms of 
population genetics. However, the IL10-7400DelDel genotype was of particular interest 







 Table 3-13 Genotype frequencies and HDW of analysed LCLs 
Genotype frequencies and results of the HDW exact test are shown for all analysed LCLs (n=111) in 
comparison to the LCLs excluding all HapMap (HM) LCLs (n=103), which have been chosen without 
random selection. In case of n≠111 or n≠103 respective genotyping analysis was not successful.  
   
 All LCLs (n=111) LCLs without HM (n=103) 














IL10-12806C/T rs17015865 TT 9 8.1 0.320 5 4.9 1.000 
  CT 38 34.2 
 
35 34.0  
  CC 64 57.7  63 61.2  
  total 111   103   
IL10-11777A/G rs4072227 GG 0 0.0 1.000 0 0.0 1.000 
  AG 16 14.4  16 15.5  
  AA 95 85.6  87 84.5  
  total 111   103   
IL10-11668G/A rs4072226 AA 28 25.2 0.057 23 22.3 0.162 
  AG 45 40.5  43 41.7  
  GG 38 34.2  37 35.9  
  total 111   103   
IL10-7400In/Del 7400In/Del DelDel 7 6.4 0.608 3 3.0 0.758 
  InDel 38 34.9  35 34.7  
  InIn 64 58.7  63 62.4  
  total 109   101   
IL10-6752A/T rs6676671 TT 21 19.6 0.226 17 17.2 0.295 
  AT 45 42.1  42 42.4  
  AA 41 38.3  40 40.4  
  total 107   99   
IL10-6208G/C rs10494879 CC 27 24.8 0.059 22 21.8 0.154 
  CG 44 40.4  42 41.6  
  GG 38 34.9  37 36.6  
  total 109   101   
IL10-3538T/A rs1800890 AA 23 20.7 0.118 19 18.4 0.157 
  AT 45 40.5  42 40.8  
  TT 43 38.7  42 40.8  
  total 111   103   
IL10-2812G/A rs6703630 AA 12 10.9 0.148 7 6.9 0.600 
  AG 38 34.5  36 35.3  
  GG 60 54.5  59 57.8  
  total 110   102   
IL10-2726C/A rs6693899 AA 15 13.5 0.677 12 11.7 0.828 
  AC 48 43.2  45 43.7  
  CC 48 43.2  46 44.7  
  total 111   103   
IL10-1087A/G rs1800896 GG 31 28.7 0.056 27 27.0 0.164 
  AG 44 40.7  43 43.0  
  AA 33 30.6  30 30.0  
  total 108   100   
IL10-824C/T rs1800871 TT 6 5.5 1.000 6 5.9 1.000 
  CT 40 36.7  40 39.6  
  CC 63 57.8  55 54.5  
  total 109   101   
IL10-597C/A rs1800872 AA 6 5.5 1.000 6 5.9 1.000 
  AC 40 36.7  40 39.6  
  CC 63 57.8  55 54.5  
  total 109   101   
IL10+4259A/G rs3024498 GG 12 11.0 0.048 7 6.9 0.399 
  AG 34 31.2  33 32.7  
  AA 63 57.8  61 60.4  
  total 109   101   
IL10+5876C/T rs3024505 TT 2 1.8 0.517 2 2.0 0.511 
  CT 34 31.2  33 32.7  
  CC 73 67.0  66 65.3  
  total 109   101   




In the end, 111 LCLs have been successfully cultured. Pellets for DNA and RNA 
(qRT-PCR) preparation as well as supernatants for ELISA (n=107) have been 
harvested. DNA has been used for genotyping analysis using Taqman SNP 
genotyping assays, and the SNaPshot-assay or a fragment length analysis for        
IL10-7400In/Del (for details see Material and Methods 2.11.3 and table 2-9). Genotype 
frequencies and results of the HDW are shown in table 3-13. Only the gene variation 
IL10+4259G/A was not in HDW. This was caused by the HapMap LCLs, because it was 
no longer observed in the group, excluding all these cell lines. However, for statistical 
analysis the complete group of LCLs was used, because in a preliminary analysis 
(data not shown) only IL10-7400In/Del showed significant associations.  
Once sufficient LCLs have been cultured, qRT-PCR and ELISA were conducted (for 
details see Material and Methods 2.10.3 and 2.11.12). As not all samples could be 
measured on the same qRT-PCR plate, linearized plasmids containing PCR products 
of the respective primers used for the qRT-PCR (IL10e1-2 and β2m) have been used 
as standards in order to obtain comparable results for all plates. 
 
Figure 3-8 IL10 expression and secretion of LCLs are comparable. 
LCLs were cultured in a density of 5*10
5
/ml. Pellets for RNA preparation and supernatants were 
harvested after 24h. IL10 expression was measured using qRT-PCR. Linearized plasmids containing 
PCR products of the respective primers used for the qRT-PCR (IL10e1-2 and β2m) have been used 
as standards. Results are shown as ratio marker of number of corresponding standard molecules 
(NSM) IL10/ NSM β2m on the left y-axis. For details see chapter 2.11.8. Supernatants of LCLs were 
used to define IL10 secretion by ELISA and the results are shown in pg/ml on the right y-axis. (for 
details see chapter 2.10.4 and 2.11.8) On the x-axis LCL numbers are shown ordered from the cell 
with the lowest IL10 expression to the highest. The median of IL10 expression and IL10 secretion are 






 The results of qRT-PCR and ELISA measurements are plotted in one graph 
exemplary for 40 LCLs in figure 3-8. Besides some exceptions both measurements 
seem to be comparable. 
All statistical analyses have been conducted supported by Hans Joachim Helms from 
the department of medical statistics. 
 
3.2.1 IL10 expression of LCLs in comparison to IL10 gene variations 
RNA of 111 LCLs has been harvested after 24h cultivation and cDNA has been 
reverse transcribed from these samples for qRT-PCR analysis of IL10 expression of 
the respective LCLs. 
Due to the relative large amount of collected RNA samples, three 384-well plates 
were used for the qRT-PCR analysis. Therefore, each qRT-plate must be thought of 
as an independent experiment. To enhance comparability of the three 
measurements, plasmids, containing the respective PCR-Products of IL10 and the 
housekeeper β2m primers, have been used in different concentrations as a standard. 
This standard was included onto each qRT-PCR analysis (see Material and Methods 
2.11.12). In addition to this, a two-way analysis of variance (ANOVA) has been 
conducted, examining the impact of the two variables IL10 gene variation and     
qRT-PCR plate (independent variables) on IL10 expression, in order to exclude that 
observed associations between IL10 expression level and the respective IL10 gene 
variation were caused by the fact that the samples were measured on different     
qRT-PCR plates. Because the results of the qRT-PCR were not normally distributed, 
all measured values have been ranked before analysis of variance. 
The qRT-PCR plates had no influence on the results as there were no significant 
associations observed between IL10 gene variations and the qRT-PCR plates. No 
interactions between these two variables were found, meaning that none of the gene 
variations differed significantly between plate one, two and three. Significant results 
were obtained for two IL10 gene variations, IL10-7400In/Del and IL10+5876C/T             





Table 3-14 Associations of IL10 gene expression of LCLs with the gene variations IL10-7400In/Del 
and IL10+5876C/T 
111 LCLs were cultivated in a density of 5x10
5
/ml and pellets for RNA preparation were harvested 
after 24h. After reverse transcription into cDNA, IL10 expression has been measured using qRT-PCR 
analysis (for details see Chapter 2.11.12). Shown are the results of a two-way ANOVA, examining 
associations between IL10 expression levels with IL10 gene variations. 
SNP Name rs-number 
IL10 gene variation  
(p-value* ) 
IL10-12806C/T rs17015865 0.2885 
IL10-11777A/G rs4072227 0.0791 
IL10-11668G/A rs4072226 0.9344 
IL10-7400In/Del 7400In/Del 0.0308 
IL10-6752A/T rs6676671 0.5710 
IL10-6208G/C rs10494879 0.9946 
IL10-3538T/A rs1800890 0.7635 
IL10-2812G/A rs6703630 0.1698 
IL10-2726C/A rs6693899 0.4067 
IL10-1087A/G rs1800896 0.3430 
IL10-824C/T rs1800871 0.1362 
IL10-597C/A rs1800872 0.1362 
IL10+4259A/G rs3024498 0.1597 
IL10+5876C/T rs3024505 0.0454 
* two way AVOVA variance analysis, Italic bold p-values are significant   
 
In a last step IL10 gene variations showing significant associations with IL10 
expression (IL10-7400In/Del and IL10+5876C/T) have been examined in a pair 
comparison using the Wilcoxon Test. For the comparisons of the IL10-7400In/Del 
genotypes no significant differences could be observed (Figure 3-9 A). The median of 
IL10 expression is lowest in the group with IL10-7400DelDel but the interquartile range 
of this group is quite big. The number of LCLs with this genotype is rather small 
(n=8). Therefore, the real median IL10 expression of the IL10-7400DelDel group could 
be much higher than in the group of LCLs included into this study.  
The only significant result was obtained for the comparison of IL10+5876CC with       
IL10+5876CT (p=0.020) but not for the comparison of IL10+5876CC and IL10+5876TT 
(Figure 3-9 B). The median IL10 expression of the IL10+5876TT group is higher than 
the median of the other two genotypes. However the interquartile ranges of the other 
two genotypes overlap with the one of the IL10+5876TT group. In addition to this, the 
number of LCLs carrying the IL10+5876TT genotype is only 2 and therefore the 








Figure 3-9 The difference between IL10 expression level of LCLs with different IL10 genotypes 
was significant only for the LCLs with IL10+5876CT compared to LCLs with IL10+5876TT. 
IL10 expression of LCLs was measured using qRT-PCR (see figure 3-8). Shown are the median and 
the interquartile ranges of IL10 expression for each possible genotype of the gene variations            
IL10-7400In/Del and IL10+5876C/T. IL10 expression results are shown as ratio marker of NSM IL10/ NSM 
β2m. P refers to the Wilcoxon test adjusted for Bonferroni used for pair wise comparison of IL10 
expression of LCLs with different genotypes. Significant p-value is shown in italic and bold. 
 
Subsequently, a second kind of statistical analysis has been conducted. According to 
the median IL10 expression (0.000762 NSM IL10/NSM β2m) LCLs were divided into 
two groups; IL10 high expressing LCLs (IL10 expression ≥ median) and IL10 low 
expressing LCLs (IL10 expression < median). In table A-3 in the appendix the 
frequencies of all genotypes are compared between IL10 high and low expressing 
LCLs. A Pearson Χ2 test was used to examine whether significant differences can be 
observed between the two groups associated with any genotype of the analysed     
IL10 gene variations. No significant associations were found. The smallest p-value 
was again observed for IL10+5876C/T, were the minor genotype IL10+5876TT was only 
found in 2 LCLs with high IL10 expression. 
In summary, no associations between IL10 expression and IL10 gene variations 




3.2.2 IL10 secretion of LCLs in comparison to IL10 gene variations  
IL10 secretion of 107 LCLs has been measured using an ELISA assay for the 
detection of human IL10 (see Material and Methods 2.10.3). In accordance to the 
qRT-PCR results, the values measured for IL10 secretion were not normally 
distributed. Therefore, all measured values have been ranked first. After this they 
were used for a Kruskal-Wallis ANOVA. As shown in table 3-15 none of the analysed 
IL10 gene variations showed significant associations with IL10 secretion level. 
In figure 3-10 this comparison is shown in a box-plot for IL10-7400In/Del and              
IL10+5876C/T. These graphs look similar to those obtained for IL10 expression. For 
IL10-7400In/Del the median IL10 secretion is lowest in the group of IL10-7400DelDel but 
the interquartile range of this group includes all values in the interquartile ranges of 
the other two genotypes.  
The plot of IL10+5876C/T shows again the highest median for the group of                
IL10+5876TT. This group includes only two LCLs and the interquartile ranges of the 
other two groups include values much higher than the median of the IL10+5876TT 
group. Therefore, no statement on the influence of the IL10+5876C/T gene variation on 
IL10 secretion can be made. 
 
 
Figure 3-10 No differences between IL10 secretion levels of LCLs with different IL10 genotypes 
IL10 secretion of 107 LCLs was measured using ELISA (for details figure 3-8). Shown are the median 
and the interquartile ranges of IL10 secretion for each possible genotype of the gene variations       







 Table 3-15 No associations between IL10 secretion levels and IL10 genotypes in LCLs 
107 LCLs were cultivated in a density of 5x10
5
/ml and supernatants for determination of IL10 secretion 
via ELISA were harvested after 24h (see 2.10.3). Measured values have been ranked first. Shown are 
the sum of ranks and mean rank values of LCLs with different IL10 genotypes. Associations between 
IL10 secretion levels with IL10 gene variations have been examined using a Kruskal-Wallis ANOVA. In 
case of n≠107 respective genotyping analysis was not successful. 








IL10-12806C/T rs17015865 TT 8 347.0 56.38 0.494 
  CT 37 1935.5 52.31  
  CC 62 3495.5 43.38  
  total 107    
IL10-11777A/G rs4072227 GG 0 0.0 0 0.955 
  AG 16 857.5 53.59  
  AA 91 4920.5 54.07  
  total 107    
IL10-11668G/A rs4072226 AA 26 1417.5 54.52 0.209 
  AG 44 2123.0 48.25  
  GG 37 2237.5 60.47  
  total 107    
IL10-7400In/Del 7400In/Del DelDel 7 295.0 42.14 0.256 
  InDel 36 1742.5 48.40  
  InIn 62 3527.5 56.90  
  total 105    
IL10-6752A/T rs6676671 TT 20 1103.5 55.18 0.231 
  AT 44 2033.0 46.20  
  AA 39 2219.5 56.91  
  total 103    
IL10-6208G/C rs10494879 CC 26 1398.5 53.79 0.494 
  CG 43 2109.0 49.05  
  GG 36 2057.5 57.15  
  total 105    
IL10-3538T/A rs1800890 AA 22 1265.5 57.52 0.330 
  AT 44 2141.0 48.66  
  TT 41 2371.5 57.84  
  total 107    
IL10-2812G/A rs6703630 AA 12 510.0 42.50 0.265 
  AG 36 1837.5 51.04  
  GG 58 3323.5 57.30  
  total 106    
IL10-2726C/A rs6693899 AA 14 835.5 59.68 0.156 
  AC 47 2231.0 47.47  
  CC 46 2711.5 58.95  
  total 107    
IL10-1087A/G rs1800896 GG 32 1598.5 49.95 0.250 
  AG 44 2197.0 49.93  
  AA 29 1769.5 61.02  
  total 105    
IL10-824C/T rs1800871 TT 6 378.0 63.00 0.310 
  CT 38 2180.5 57.38  
  CC 61 3006.5 49.29  
  total 105    
IL10-597C/A rs1800872 AA 6 378.0 63.00 0.310 
  AC 38 2180.5 57.38  
  CC 61 3006.5 49.29  
  total 105    
IL10+4259A/G rs3024498 GG 12 501.0 41.75 0.344 
  AG 32 1667.5 52.11  
  AA 61 3396.5 55.68  
  total 105    
IL10+5876C/T rs3024505 TT 2 113.0 56.50 0.265 
  CT 33 1980.5 60.02  
  CC 70 3471.5 49.59  





In addition to the variance analysis the associations of IL10 secretion and IL10 gene 
variations have been analysed after grouping the LCLs according to the median IL10 
secretion (737pg IL10/ml) into high (IL10 secretion ≥ median) and low (IL10 secretion 
< median) IL10 secreting LCLs, as it was done for IL10 expression in the previous 
chapter. This analysis did not reveal any significant associations between IL10 
secretion and IL10 genotypes (table A-4). The two LCLs with IL10+5876TT are even 
assigned to the two different groups.  
The analysis shown in table A-4 in the Appendix has been done with all LCLs 
cultivated including the HapMap LCLs. However a second analysis has been done 
with a group of LCLs excluding the HapMap LCLs (data not shown). No significant 
associations could be detected. 
 
In conclusion, no associations between IL10 secretion and IL10 gene variations 
could be observed for the analysed LCLs, neither for the ANOVA nor for the grouped 
analysis. 
3.2.3 LMP1 expression in comparison to IL10 production capacities of LCLs 
IL10 production of LCLs is induced by EBV immortalization of B cells. Therefore, the 
interindividual production capacities could as well be caused by differing levels of 
EBV associated proteins like LMP1. This was tested in 15 LCLs with high IL10 
production and 15 LCLs with low IL10 production via immunoblot of LMP1 (for details 
see Material and Methods 2.10.2).  
 
 
Figure 3-11 LMP1 IL10 production of LCLs is not dependent on LMP1 protein level. 
LCLs were cultured in a density of 5x10
5
/ml. Pellets for protein preparation have been harvested after 
24h. The protein level of LMP1 was visualized by immunoblot. The results shown are representative 







 As seen in figure 3-11 the LMP1 level did not differ between LCLs with high or low 
IL10 production. Therefore, one can conclude that the interindividual differences in 
IL10 production of LCLs are not due to differences in LMP1 protein levels. 
3.3 Regulation of IL10 gene expression in B cells 
IL10 is expressed by a diverse set of immune cells, monocytes and macrophages, 
certain T cell subpopulations and also by B cells. Several studies investigated 
mechanisms that contribute to IL10 gene regulation in macrophages and T cells. 
These studies have been mainly conducted in mouse cell lines. Therefore, one of the 
aims of this dissertation was to investigate molecular mechanisms, contributing to 
IL10 gene regulation in human B cells. 
3.3.1 B cell model systems used to analyse mechanisms of IL10 gene 
regulation 
In order to identify a model system that can be used for the analysis of mechanisms 
involved in regulation of IL10 gene expression, different cell lines have been tested 
for their capacity to induce IL10 gene expression. The aim was to find a cell line 
without constitutive but high inducible IL10 expression to be able to see clear 
changes in chromatin modifications and other processes involved in IL10 gene 
regulation. Two different B cell models systems have been identified. The L428 
Hodgkin-Lymphoma cell line stimulated with phorbol-12-myristate-13-acetate (PMA) 
(Figure 3-12) and the Ramos Burkitt’s lymphoma cell line stimulated with CD40-
ligand (CD40L) (Figure 3-13). In addition to this three B cell lines with constitutive   
IL10 gene expression have been identified (Figure 3-14). 
 
The L428 cell line was stimulated with PMA as previously described (Vockerodt 
2001) for different incubation times (see also Material and Methods 2.9.3). 
Unstimulated cells have been harvested at two different time points to exclude an 
influence of cell culture effects on IL10 expression. IL10 expression levels have been 
determined using qRT-PCR (Figure 3-12). The highest expression of IL10 has been 
observed after 30h and was still visible after 48h of stimulation. Because the aim was 
to analyse mechanisms that lead to the induction of IL10 gene expression, like 
histone modifications, L428 cells were stimulated for 12h or 24h in the following 
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experiments. After these incubation times a clearly detectable IL10 expression was 
induced in L428 but the highest level and therefore the plateau of IL10 expression 
was not reached. 
 
 
Figure 3-12 IL10 expression can be induced in L428 Hodgkin cell line using PMA. 
The L428 Hodgkin cell line has been stimulated with 20ng/ml PMA or left untreated. All samples have 
been centrifuged after the first hour of stimulation and pellets have been resuspended in fresh medium 
(for detailed information see Material and Methods 2.9.3). Cells have been harvested for RNA 
preparation after the indicated time points. IL10 expression was analysed using qRT-PCR. As the    
IL10 expression is below detectable levels in unstimulated samples no fold change could be 
calculated. Therefore, results are presented as ΔCt values relative to abl as housekeeper.  
 
To stimulate Ramos with CD40L, baby hamster kidney (BHK) cells, stably transfected 
with a CD40L expression plasmid (BHK-CD40L), were used (see also Material and 
Methods 2.9.4). BHK and BHK-CD40L cells were seeded 24h pre-stimulation.  
Ramos cells were added to the BHK and BHK-CD40L cells and harvested at different 
time points (Figure 3-13). As a control Ramos cells were cultivated without any BHK 
cells (unstimulated). IL10 expression was determined using qRT-PCR. IL10 
expression could be detected already 3h after stimulation with CD40L. The highest 
induction of IL10 expression was detected after 24h of stimulation and was reduced 
again after 32h. No detectable IL10 expression was visible with unstimulated or BHK 









Figure 3-13 IL10 expression can be induced in Ramos Burkitt cell line after CD40 crosslink. 
The Ramos cell line has been co-cultivated with BHK or BHK-CD40L or left untreated (for detailed 
information see Material and Methods 2.9.3). Cells have been harvested for RNA preparation after the 
indicated time points. IL10 expression was analysed using qRT-PCR. As IL10 expression levels are 
below detectable levels in unstimulated samples no fold change could be calculated. Therefore, 
results are presented as ΔCt values relative to abl as housekeeper.  
 
In addition to this, several B cell lines were tested for their constitutive expression of 
IL10 using qRT-PCR (Figure 3-14). Thereby, the cell lines MC116, Balm3 and BJAB 
have been identified as being positive for IL10 expression. All the other tested B cell 
lines (Ramos, Bl2, Karpas422, SuDHL4, OCI Ly3 and OCI Ly6) did not express 
detectable levels of IL10.  
 
Figure 3-14 The cell lines MC116, Balm3 and BJAB express IL10 constitutively. 
Different B cell lines (MC116, Balm3, BJAB, Ramos, Bl2, Karpas422, SuDHL4 OCI Ly3 and OCI Ly1) 
have been tested via qRT-PCR for IL10 gene expression. A. For most of the cell line the Ct-value was 
above 30 and the respective dissociation curves did not have the right Tm of the IL10 primers used, 
meaning that these cell lines do not express detectable levels of IL10. B. The cell lines MC116, Balm3 
and BJAB do express IL10 visualized here using the ΔCt value relative to the housekeeper abl.  
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Two model systems with inducible IL10 expression, L428 stimulated with PMA and 
Ramos stimulated with CD40L as well as 3 cell lines with constitutive IL10 
expression, MC116, Balm3 and BJAB have been identified. 
3.3.2 Characterization of pathways involved in PMA-induced IL10 expression 
PMA-induced IL10 expression in L428 has been further characterized using inhibitors 
against components of certain signaling pathways, protein kinase C (PKC), 
phosphoinositide 3-kinase (PI3K) and extracellular-regulated kinase (ERK).  
PMA is a homolog of Diacylglycerol (DAG). Signaling through the B cell receptor 
leads to activation of phospholipase C-γ2 (PLC-γ2) which hydrolyses phosphatidyl 
inositol-bisphosphate (PIP2) into the second messengers Inositol trisphosphate (IP3) 
and DAG. While IP3 stimulates calcium release from intra- and extracellular sources, 
DAG mobilizes and activates PKC. DAG also regulates RasGRP, a nucleotide 
exchange factor that activates Ras kinase via exchange of GDP for GTP to activate 
the MAP kinase cascade. This finally leads to the activation of ERK1/2. Ras can also 
activate PI3K. 
 
L428 cells were preincubated with specific inhibitors of PKC, PI3K and ERK (for 
details see Material and Methods 2.9.5). DMSO in respective concentrations was 
used as a solvent control. After 3h, cells were stimulated with PMA and treated again 
with inhibitors or DMSO after the washing step with fresh medium. After 24h of PMA 
stimulation pellets were harvested and IL10 expression was determined using qRT-
PCR (Figure 3-15). The IL10 expression of respective DMSO treated cells was set to 
Figure 3-15 Pathways involved in PMA-
induced IL10 expression in L428 
 
L428 cells were preincubated with specific 
pathway inhibitors (for detailed information 
see Material and Methods 2.9.5). 
Subsequently, the cells have been stimulated 
for 12h with 20ng/ml PMA according to the 
procedure described in chapter 2.9.3 and 
3.3.1. IL-10 expression was determined using 
qRT-PCR.  
Results are presented as 2
-ΔΔCt
 relative to the 
housekeeper gene abl. The IL-10 expression 
of respective DMSO (solvent control) treated 







 1. Treatment with all three inhibitors led to a reduction of IL10 expression. Therefore, 
all three signaling components, PKC, PI3K and ERK, seem to be involved in PMA-
induced IL10 expression in L428 cell line. 
3.3.3 Far distal enhancer regions revealed by ChIP  
After adjustment of the ChIP protocol to suspension cells, ChIP was used for the 
analysis of the chromatin modifications acetylated histone 3 (acH3), tri-methylated 
lysine 4 of histone 3 (H3K4me3) and mono-methylated lysine 4 on histone 3 
(H3K4me1). The antibody used for acH3, detects H3 acetylated at Lysine 9 and 14, a 
modification generally observed at actively transcribed genes, often together with 
H3K4me3 (Koch et al., 2007; Peterson and Laniel, 2004). H3K4me3 is a modification 
characteristic for transcription start sites (TSS) and H3K4me1 is found at enhancer 
regions (Heintzman et al., 2007). PMA stimulation induces strong expression of IL10 
in L428 cells, which do not express IL10 without any stimulus (Figure-3-12). 
Therefore, this model was used to analyse changes of chromatin modifications 
associated with the induction of IL10 expression. L428 cells were stimulated for 24h 
with PMA or left untreated (see Material and Methods 2.9.3). Three biological 
triplicates were prepared (3x stimulated and 3x unstimulated). ChIP has been 
performed according to the procedure described in Material and Methods 2.11.9. 
After crosslinking of proteins to the DNA via formaldehyde treatment, the chromatin 
has been sheared into fragments of 200bp-750bp. The sheared chromatin has been 
used for IP with specific antibodies (see table 2-10) and DNA has been purified. For 
the identification of regions, where the respective chromatin modifications are 
localized, qRT-PCR was used (see Material and Methods 2.11.7). Oligonucleotide 
primers were designed spanning the IL10 gene variations of interest, the TSS or 





Figure 3-16 Positions of oligonucleotide primers used for ChIP 
Shown are the positions of PCR products of the designed oligonucleotide primers used for the 
evaluation of ChIP via qRT-PCR relative to the IL10 gene locus and CNS. All primer pairs amplify 
products between 75 and 130bp of length and are optimized for amplification at 60°C. The human 
IL10 gene locus from -16.400bp till +6800bp is shown as scheme. All gene variations of interest are 
indicated. The IL10 gene is shown starting with ATG. UTR (yellow), exons (dark blue) and introns 
(white) are indicated. A comparison of the human IL10 gene locus (x-axis) and the mouse IL10 gene 
locus (y-axis) is aligned to the scheme to visualize CNS. This comparison has been calculated using 
the browser for evolutionary conserved regions (ECR) (http://ecrbrowser.dcode.org). Sequences of 
similarity are marked by the height of the curves. A vertical axis cut-off of 50% to 100% identity is 
utilized to visualize only the significant alignments. Annotated genes are depicted as a horizontal line 
above the graph. ECRs (pink rectangles on top of the plot), coding exons (blue), intronic regions 
(salmon-pink), transposons and simple repeats (green) and intergenic regions (red) are indicated. In 
addition the positions of CNS-12 and CNS+6 are indicated with red horizontal lines. 
 
One representative experiment is shown in figure 3-17. AcH3 is mainly observed 
after PMA stimulation around the TSS, in the beginning of the IL10 coding region and 
at the proximal parts of the 5’-region (to 1000bp upstream of the TSS). A slight 
increase of acH3 could also be observed at the region around CNS-12. 
As expected, H3K4me3 could be detected at regions around the TSS of the IL10 
gene from 1000bp upstream till the beginning of the IL10 coding region after PMA 
stimulation. H3K4me3 could not be detected around CNS-12 or regions further 
upstream, therefore no other TSS is located within this region.  
At the TSS, the more proximal parts of the 5’-region and the 3’region of IL10 gene 
locus, H3K4me1 could be detected. While this was inducible by PMA stimulation in 
the 5’region and 3’ of the IL10 coding region at +6.800bp, it was detected with or 
without PMA stimulation in the coding region as well as in the 3’region of IL10 at 










Figure 3-17 ChIP of histone modifications in PMA stimulated L428 
ChIP has been performed using the L428 Hodgkin cell line stimulated with PMA for 24h (see chapter 
2.11.10 for details). Shown are results for acH3, a general mark for active transcription; H3K4me3, a 
mark generally found at transcription start sites and H3K4me1, a histone modification associated with 
enhancer activity. qRT-PCR has been done using primers amplifying different regions of the IL10 gene 
locus and one primer for the TSS of ACTB as a control. The standard deviation results from three 
biological replicates within the shown experiment. One representative result of 4 independent 
experiments is shown. 
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The region around CNS-12 shows relatively high inducible H3K4me1 and therefore 
enhancer activity after induction of IL10 expression. Already before PMA stimulation, 
a basic enhancer activity is visualized via localization of H3K4me1 to this region.  
 
The histone modifications acH3 and H3K4me3 but not H3K4me1 have been 
observed at the housekeeping gene ACTB-TSS. This was not dependent on PMA 
stimulation.  
As a negative control, an anti-IgG antibody has been used for the IP (data not 
shown). Detected binding of IgG in qRT-PCR was not higher than 0.05% and mostly 
lower or the dissociation curves did not have the right melting temperature, meaning 
the right PCR-product was not amplified and therefore not detected by the 
instrument.  
The same experiment was done after 12h of PMA stimulation to examine whether a 
different histone modification pattern would be observed to an earlier time point. The 
results did not differ between 12h and 24h of PMA stimulation (Data not shown). 
 
The most important finding of the ChIP experiments was the identification of far distal 
enhancer regions, by localization of H3K4me1 to CNS-12 and regions further 
upstream. 
3.3.4 Chromatin modifications in two cell lines with constitutive IL10 
expression 
To address the question whether histone modifications differ between B cells with 
induced and cell lines with constitutive IL10 expression, the same histone 
modifications analysed in the L428 cell line were examined in the cell lines BJAB and 
MC116 (Figure 3-18). Three biological triplicates have been prepared for both cell 
lines. ChIP has been performed as described in the previous chapter (see 3.3.3). 
Again qRT-PCR was used to identify regions, where respective chromatin 
modifications were localized. Oligonucleotide primers spanning the IL10 gene 
variations of interest, the TSS or certain CNS have been used. One representative 







 The region of the IL10 gene locus where acH3 has been detected starts at -1000bp, 
peaks within the beginning of the IL10 coding region and is reduced at the end of this 
region. This observation can be seen in both examined cell lines and is basically in 
line with the localization of acH3 found in PMA stimulated L428. Notably, in BJAB 
there is also acH3 at the CNS+6 (+6000bp), which was not detected in L428 or 
MC116. In the more proximal regions of the IL10 gene locus, low levels of acH3 
where visible. 
As expected, H3K4me3 is only visible around the TSS and in the beginning of the 
coding region of IL10. No differences between the two cell lines could be observed. 
However, strong differences could be detected with respect to H3K4me1, the histone 
modification associated with enhancer activity. This modification is represented to a 
generally higher extend in the BJAB cell line. In BJAB this histone modification can 
be observed around CNS-12, the distal part of the IL10 promoter (-1000 and -597) 
and in the coding region of IL10. The most important regions emphasized here, 
where this modification could be localized, are the region around -4500bp and the 
CNS+6 (+6000bp). Particularly in comparison to the L428, these two regions attract 
attention. Notably, the region around -4500 contains a putative NF-B binding site 
and the CNS+6 contains a putative AP1 binding site. The peak in H3K4me1 at           
-11.668bp was not observed in the following ChIP experiment, whereby the peaks at 
-4500 and +6kb were reproducible. In the MC116 cell line the highest signal for 
H3K4me1 could be observed at the distal IL10 promoter and again at CNS+6 but not 
at -4500bp.  
All three histone modifications were also assessed at the ACTB-TSS. In this case the 




Figure 3-18 ChIP of histone modifications in BJAB and MC116 with constitutive IL10 
expression 
ChIP has been performed using the unstimulated BJAB and MC116 cell lines. Cells were seeded in a 
density of 5x10
5
/ml and harvested after 24h. 1x10
6
 cells were used per IP. Shown are results for acH3, 
a general mark for active transcription; H3K4me3, a mark generally found at transcription start sites 
and H3K4me1, a histone modification associated with enhancer activity. qRT-PCR has been done 
using primers amplifying different regions of the IL10 gene locus and one primer for the TSS of ACTB 
as a control. As the results for ACTB-TSS differ strongly, they were plotted on a separate graph. The 
standard deviation results from three biological replicates within the shown experiment. One 







 Taken together, this experiment showed that histone modification patterns in B cell 
lines with constitutive IL10 expression show similarities but also differ to some extent. 
Some molecular mechanisms involved in the IL10 regulation in these cell lines seem 
to be common, while other are different between the cell lines. In BJAB cells a region 
around a putative NF-B binding site, shown to be important in macrophages and the 
CNS+6, containing a putative AP1 binding site, showed strong enhancer activity. In 
MC116 only the CNS+6 showed this strong enhancer activity. Most importantly, 
enhancer activity could be detected at distal regions around CNS-12 in all three 
examined cell lines. 
 
3.3.5 Transcription of ncRNA from IL10 gene locus in B cells 
In mature Th2 cells it has been shown that ncRNA (non-coding RNA) is transcribed 
from certain CNS. Therefore, the transcription of RNA from regions outside the 
coding region of the IL10 gene has been assessed in the B cell model systems 
introduced in chapter 3.3.1. For details of the procedure used to analyse ncRNA see 
Materials and Methods 2.11.8.  
At first, it has been determined whether ncRNA is transcribed from CNS-12 in L428 
stimulated with PMA (Figure 3-19). The L428 cell line has been stimulated for 
different time points with PMA as described in chapter 3.3.1. The same RNA samples 
as in Figure 3-12 have been used for conventional PCR for the determination of 
ncRNA transcribed from CNS-12 (Figure 3-19 A). RNA has been reverse transcribed 
with or without Reverse transcriptase (RT) as a negative control. DNA from L428 has 
been used as a positive control for the respective PCR, using primers originally 
designed for ChIP. PCR products were obtained for samples using DNA of L428 and 
cDNA from PMA stimulated samples reverse transcribed with RT, while no PCR 
products were obtained for unstimulated samples and cDNA reverse transcribed 
without RT. Therefore, RNA is transcribed from non-coding regions of the IL10 gene 
locus in L428 cells after PMA stimulation. This RNA will be referred ncRNA. 
Next, it was assessed whether this transcription of ncRNA is dependent on the 
duration of PMA stimulation like it has been observed for IL10 transcription (Figure 3-
12). For this purpose, qRT-PCR analysis of transcription of CNS-12 has been done 
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using the same RNA as for Figure 3-12 reverse transcribed with or without RT. As 
seen in figure 3-19 B, in contrast to IL10 transcription the transcription level of ncRNA 
was the same for all analysed incubation times and not enhanced after longer 
stimulation with PMA. In samples reverse transcribed without RT the dissociation 
curves were similar to water samples, representative for primer dimers. Therefore, no 
ΔCt could be calculated.  
 
Figure 3-19 Transcription of ncRNA from IL10 gene locus after PMA stimulation in L428 
The L428 Hodgkin cell line has been stimulated with 20ng/ml PMA or left untreated (see Methods 
2.9.3). Cells have been harvested for RNA preparation after the indicated time points. RNA has been 
reverse transcribed into cDNA with and, as a negative control, without Reverse Transcriptase (RT). A. 
Transcription of ncRNA from the IL10 gene locus has been detected via conventional PCR using 
oligonucleotide primers for the CNS-12 (ChIP_IL10_CNS-12fwd and ChIP_IL10-11668rev; product = 
497bp). PCR products were separated on 1% agarose gel. PCR products were obtained for L428 DNA 
(positive control) and cDNA of PMA stimulated L428 reverse transcribed with RT. B. Transcription of 
CNS-12 was analysed using qRT-PCR (ChIP_IL10_CNS-12). Shown are only the results for +RT, 
because no PCR products were obtained from -RT samples. Transcription of CNS-12 is below 
detectable levels in unstimulated samples and no fold change could be calculated. Therefore, results 
are presented as ΔCt values relative to abl as housekeeper. The level of ncRNA does not increase 
after longer stimulation with PMA. 
 
To further characterize the ncRNA expressed in L428 cells, its transcription was 
determined at different regions of the IL10 gene locus in comparison to the IL10 
transcription using qRT-PCR (see 2.11.8). For this purpose primers were used, 
originally designed for ChIP, spanning several IL10 gene variations and CNS-12 
(Figure 3-20 and table 2-7). As seen in figure 3-20, ncRNA was expressed from all 










Figure 3-20 Several regions of the IL10 gene locus are transcribed into ncRNA (qRT-PCR) 
The L428 Hodgkin cell line has been stimulated with 20ng/ml PMA or left untreated for 24h and 
respective RNA has been reverse transcribed into cDNA (for details see figure 3-19). Transcription of 
IL10 (IL10) as well as transcription of ncRNA from different regions of the IL10 gene locus was 
analysed using qRT-PCR. As the transcription levels are below detectable levels in unstimulated 
samples, no fold change could be calculated. Results are presented as ΔCt values relative to abl as 
housekeeper. From the cDNA reverse transcribed without RT no detectable PCR products resulted. 
 
Subsequently, conventional PCRs have been made using different primer 
combinations spanning the IL10 gene locus according to the examples shown in 
figure 3-19 A (Figure 3-21). PCR products have been obtained for DNA samples 
used as positive controls for the PCR (compare to lane 5, Figure 3-21) and also in all 
examined cases for PMA stimulated L428 RNA samples, reverse transcribed with RT 
(compare to lane 4, Figure 3-21). In one case a PCR product was also obtained for 
unstimulated RNA samples reverse transcribed with RT (compare to lane 3 in Figure 
3-21 A). However, this band is very weak compared to the stimulated sample. In one 
case a second PCR product was obtained for RNA reverse transcribed with RT 
(compare to lane 3 and 4 in Figure 3-21 F-asterisk). This PCR product does not show 
the expected size and is therefore an unspecific amplification product. No PCR 
product was obtained for RNA reverse transcribed without RT. In conclusion ncRNA 




Figure 3-21 Several regions of the IL10 gene locus are transcribed into ncRNA (PCR) 
The L428 Hodgkin cell line has been stimulated with 20ng/ml PMA or left untreated for 24h and 
respective RNA has been reverse transcribed into cDNA (for details see figure 3-19). Transcription of 
ncRNA from the IL10 locus has been detected via conventional PCR using oligonucleotide primers for 
several regions of the 5’- and 3’-region of IL10 and PCR products were separated on 1% agarose gel. 
Primer pairs (see table 2-7) used were A. hIL10-9133_fwd and hIL10-8583_rev; B. ChIP_IL10-
16.400_fwd and ChIP_IL10-14.700_rev; C. hIL10-8583_fwd and ChIP_IL10-7400_rev; D. ChIP_IL10-
7400_fwd and ChIP_IL10-4500_rev; E. ChIP_IL10-3538_fwd and ChIP_IL10-1087_rev; F. ChIP_IL10-
AP1 (+6000)_fwd and ChIP_IL10+6800_rev. Used templates were 1. L428 cDNA unstimulated –RT; 
2. L428 cDNA +24h PMA –RT; 3. L428 cDNA unstimulated +RT; 4 L428 cDNA +24h PMA +RT; 5. 
L428 DNA (positive control) and 6. H2O. PCR products were obtained for L428 DNA (positive control) 
and cDNA of PMA stimulated L428 reverse transcribed with RT. Asterisks= wrong size/unspecific 
amplification product. 
Transcription of ncRNA was observed in all regions shown schematically in Figure 3-
22. Transcription of ncRNA has been detected from all examined regions analysed. 
This means gaps in this scheme represent regions that have not been examined until 
the time of handing in this thesis, and not regions where transcription of ncRNA has 
not been detected.  
 
Figure 3-22 Regions of IL10 gene locus shown to be transcribed into ncRNA 
A scheme of the IL10 gene locus spanning from -16.400bp to +6.800bp (counted from TSS) on 
chromosome 1q32 is shown. All analysed IL10 gene variations examined within this dissertation are 
indicated. The IL10 coding region comprised of 5’- and 3’-UTR (yellow), Introns (white) and exons 
(blue) is shown. The ATG is displayed. Black lines below the scheme represent regions were 







 Transcription of ncRNA has also been assessed in the other model systems 
introduced in chapter 3.3.1. RNA of Ramos cells stimulated with BHK-CD40L, 
MC116, BJAB and Balm3 has been reverse transcribed with or without RT. 
Transcription of ncRNA has been assessed using conventional PCR according to the 
procedure shown for L428 in figure 3-19. 
The result for Ramos stimulated with BHK cells is shown in Figure 3-23. Bands are 
visible only in the lanes with the PCR products obtained from amplification of DNA 
(positive control) and of Ramos cells stimulated with CD40 crosslink, reverse 
transcribed with RT. Therefore, ncRNA is also transcribed in Ramos after CD40 
crosslink for 24h. 
 
 
Figure 3-23 Transcription of ncRNA in Ramos cells stimulated with CD40 crosslink 
The Ramos Burkitt’s lymphoma cell line has been co-cultivated with BHK or BHK-CD40L or left 
untreated (for detailed information see Methods 2.9.4). Cells have been harvested for RNA 
preparation after 24h. RNA has been reverse transcribed into cDNA with (+RT) and, as a negative 
control, without RT (-RT). Transcription of ncRNA from the IL10 gene locus has been detected via 
conventional PCR using oligonucleotide primers for the CNS-12 (ChIP_IL10_CNS-12_fwd and 
ChIP_IL10-11777_rev; product = 387bp). PCR products were separated on 1% agarose gel. 1kb 
ladder has been used. PCR products were obtained for Ramos DNA (positive control) and cDNA of 
Ramos after CD40 crosslink reverse transcribed with RT. 
 
BJAB, MC116 and Balm3 cell lines have been analysed using the same procedure 
as for Ramos. RNA of MC116, BJAB and Balm3 has been reverse transcribed with or 
without RT. Transcription of ncRNA has been assessed using conventional PCR. The 
results are shown in figure 3-24. PCR products were obtained only for the DNA 
samples and the cDNA reverse transcribed with RT (+RT) but not for those cDNA 
samples reverse transcribed without RT (-RT). The only exception was a faint band 
for Balm3 cDNA reverse transcribed without RT. This might be due to a vast amount 
of RNA in the samples used for the PCR, which might results in primer binding on 
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RNA. Contamination with DNA can also not be excluded. As the PCR products 
obtained for the sample after reverse transcription with RT is much stronger, one can 
conclude that ncRNA is transcribed in Balm3. Notably, the transcription of ncRNA in 
BJAB is very weak. However it is still detectable.  
Therefore, these experiments showed that in all three cell lines with constitutive IL10 
gene expression also ncRNA is transcribed from the IL10 gene locus. 
 
 
Figure 3-24 Transcription of ncRNA in cell lines with constitutive IL10 expression 
The BJAB, MC116 and Balm3 cell lines have been cultivated in a density of 5x10
5
/ml. Cells have been 
harvested for RNA preparation after 24h. RNA has been reverse transcribed into cDNA with (+RT) 
and, as a negative control, without RT (Reverse Transcriptase) (-RT). Transcription of ncRNA from the 
IL10 gene locus has been detected via conventional PCR using oligonucleotide primers for the CNS-
12 (ChIP_IL10_CNS-12fwd and ChIP_IL10-11777_rev; product = 387bp). PCR products were 
separated on 1% agarose gel. 1kb ladder has been used. PCR products were obtained for all samples 
amplified from DNA (positive control) and cDNA of cell lines reverse transcribed with RT. A faint band 
has been detected for Balm3 after reverse transcription without RT. 
 
Taken together all B cell model systems and cell lines, introduced in chapter 3.3.1 
with inducible or constitutive IL10 gene expression, do also transcribe ncRNA from 
the IL10 gene locus under the same conditions needed for IL10 transcription. 
3.3.6 Transcription levels of IL10 and ncRNA in LCLs are not comparable 
The transcription of ncRNA has also been assessed in LCLs using qRT-PCR. LCLs 
were cultured in a density of 5x105/ml for 24h. Subsequently, pellets for RNA 
preparation were harvested. RNA was reverse transcribed into cDNA (+RT only) and 
this was used to evaluate IL10 transcription as well as transcription of ncRNA via 







 ncRNA was detected in all LCLs examined. A comparison between IL10 expression 
and the transcription level of ncRNA from CNS-12 did not reveal any correlations. 
 
Figure 3-25 Transcription levels of IL10 and ncRNA transcribed from the IL10 gene locus are 
not comparable in LCLs. 
LCLs were cultured in a density of 5*10^5/ml. Pellets for RNA preparation were harvested after 24h 
(see figure 3-8). Transcription of IL10 and ncRNA from CNS-12 were measured using qRT-PCR. 
Results are presented as 2
-ΔΔCT
 values (fold change) relative to β2m housekeeper. The LCL with the 
lowest IL10 gene expression level (HM2) was set to 1. On the x-axis LCL numbers are shown ordered 
from the cell with the lowest IL10 expression level to the highest.  
 
Taken together EBV immortalization leads to transcription of ncRNA from the IL10 
gene locus in LCLs but the levels of IL10 transcription do not correlate with 
transcription levels of ncRNA from the IL10 gene locus. This means that neither IL10 
gene expression levels depend on transcription of ncRNA nor the other way around. 
Therefore, ncRNA is not the factor that regulates interindividual differences in IL10 
production capacity in LCLs. 
3.4 Investigation of the influence of IL10 on CDC or ADCC of B cells 
In chapter 3.1.2 it was described that several IL10 gene variations have been 
identified that are associated with disease outcome of NHL patients treated with 
Rituximab in addition to conventional CHOP therapy. Rituximab is thought to mediate 
its effects via complement dependent cytotoxicity (CDC) or antibody dependent 
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cellular cytotoxicity (ADCC). Therefore, it has been examined whether exogenous 
IL10 or levels of endogenous IL10 expression influence these mechanisms after 
Rituximab treatment of different B cell lines. 
3.4.1 IL10 does not influence complement dependent cytotoxicity after 
Rituximab treatment  
The effect of endogenous IL10 on CDC has been examined. At first, different B cell 
lines were tested for their responsiveness to IL10 stimulation. Therefore, the B cell 
lines have been stimulated with recombinant human IL10 and the responsiveness to 
this stimulus has been visualized via immunoblot of phosphorylated STAT3 (data not 
shown). The cell lines Balm3, Ramos and Karpas422 responded to IL10 stimulation 
with phosphorylation of STAT3. In OCI Ly3 constitutive activation of STAT3 was 
detected. These four cell lines were therefore used for the following experiments. 
Viability and proliferation of these cell lines have been examined, following treatment 
with different concentrations of Rituximab, representing the induction of CDC. The 
lower the viability and the proliferation of the cells, the higher was the induced CDC. 
CDC needs complement factors, which are usually destroyed via heat 
decomplementation of the serum used for cell culture medium. For this experiment 
human serum was used either heat decomplemented as a negative control or left 
untreated to retain complement factors. Before the treatment with Rituximab and 
complement, the cell lines were treated with IL10 for 3h. However, in none of the 
examined cell lines an influence of IL10 treatment could be observed (Figure 3-26). 
The cell line Balm3 was lysed after treatment with complement and 10µg/ml 
Rituximab, without a difference between those cells that have been pretreated with 
IL10 and those without this treatment. Already the addition of complement seemed to 
reduce proliferation of the cells. Ramos cells reacted similar to Balm3. But for Ramos 
the addition of 0.1µ/ml Rituximab already reduced the proliferation considerably. In 
contrast to Balm3 and Ramos, Karpas422 and OCI Ly3 do not show a reduction of 
viability or proliferation upon Rituximab treatment. For OCI Ly3 a reduction of 
proliferation was observed after the addition of complement as it was seen for Balm3. 
For both cell lines an enhanced viability could be seen after the addition of 
complement. However, this effect has not been observed in other experiments and is 

































































































































Figure 3-26 No Influence of exogenous IL10 on complement dependent cytotoxicity after 
Rituximab treatment 
Viability (left) and proliferation (right) of Balm3, Ramos, Karpas 422 and OCI Ly3 cell lines were 
measured after Rituximab treatment for 24h as a read-out for CDC. Cells were cultured either with 
decomplemented human serum (-complement) or with undecomplemented human serum 
(+complement) with (+IL10) or without (-IL10) preincubation with IL10 for 3h. Viability and proliferation 
of cells cultured without Rituximab and without complement are set to 100%. Rituximab was used in 
three different concentrations (0.001µg/ml, 0.1µg/ml and 10µg/ml). 
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Next, the effect of endogenous IL10 expression levels has been assessed. As seen 
in Figure 3-14, only the B cell lines MC116, Balm3 and BJAB express IL10 in 
detectable amounts. These cell lines have been analysed in comparison to cell lines 
without IL10 expression. All cell lines have been treated with different concentrations 
of Rituximab, with or without complement. Viability and proliferation have been 
measured as a read out for CDC. For some cell lines, namely MC116 and Ramos, 
lysis of the cells could be seen visually after treatment with 10µg/ml Rituximab on the 
94-well plates used for the assays. As seen in Figure 3-27 for proliferation and Figure 
3-28 for viability no influence of IL10 transcription could be observed for CDC. The 
addition of complement already leads to a reduction of proliferation in all examined 
cell lines. All three cell lines with IL10 expression showed a reduction of viability 
(Figure 3-28) after Rituximab treatment and a reduction of proliferation was observed 
for MC116 and Balm3 (Figure 3-27). For those cell lines without endogenous IL10 
expression different results from complete lysis in Ramos and SuDHL4, represented 
by reduction in proliferation and viability, to no effect at all as seen for Karpas422 and 
OCI Ly3 have been observed. If endogenous IL10 expression would influence CDC, 
it would have been expected that cells from the one group would show stronger 
reaction on Rituximab treatment than cells from the other group. This has not been 
observed. Therefore, one can conclude that endogenous IL10 expression does not 































































































Figure 3-27 Endogenous IL10 does not influence complement dependent cytotoxicity after 
Rituximab treatment, visualized by proliferation of cell lines. 
Proliferation of cell lines with IL10 expression (MC116, Balm3, BJAB; upper lane) and cell lines without 
IL10 expression (Ramos, Bl2, Karpas422, SuDHL4 OCI Ly3 and OCI Ly1) was measured after 
Rituximab treatment for 24h as a read-out for CDC. Cells were cultured either with decomplemented 
human serum (-complement) or with undecomplemented human serum (+complement). Rituximab 
was used in three different concentrations (0.001µg/ml, 0.1µg/ml and 10µg/ml). Proliferation of cells 
cultured without Rituximab and without complement was set to 100%. The cell lines are ordered 





















































































Figure 3-28 Endogenous IL10 does not influence complement dependent cytotoxicity after 
Rituximab treatment, visualized by viability of cell lines. 
Viability of cell lines with IL10 expression (MC116, Balm3, BJAB; upper lane) and cell lines without 
IL10 expression (Ramos, Bl2, Karpas422, SuDHL4 OCI Ly3 and OCI Ly1) was measured after 
Rituximab treatment for 24h as a read-out for CDC. Cells were cultured either with decomplemented 
human serum (-complement) or with undecomplemented human serum (+complement). Rituximab 
was used in three different concentrations (0.001µg/ml, 0.1µg/ml and 10µg/ml). Proliferation of cells 
cultured without Rituximab and without complement was set to 100%. The cell lines are ordered 








 Taken together, it has been shown that neither exogenous IL10 nor IL10 expression 
levels influence Rituximab-mediated CDC. 
3.4.2 Rituximab-mediated ADCC of target cells is inhibited by IL10 
The effect of IL10 on Rituximab-mediated ADCC of target cells has been examined 
using Ramos and Karpas422 cell lines. NK cells were (for details see chapter 2.9.11). 
12h prior to the ADCC assay Ramos and Karpas422 were stimulated with 
recombinant IL10 (see 2.9.6) or left untreated. On the next morning, FACS analysis 
of NK cells and target cells has been performed. NK cells had to be CD56+, CD16+, 
CD3- and CD20-. Target cells had to be CD20+. The expression of HLA class I was 
also assessed and target cells were positive. The expression of HLA class I did not 
change significantly after IL10 treatment. 
Subsequently, target cells were stained with 3,3′-Dioctadecyloxacarbocyanine 
perchlorate (DiO) and incubated for 4h with or without NK cells, with or without IL10 
and different concentrations of Rituximab. To determine specific lysis of the target 
cells FACS analysis has been performed after addition of propidium iodide (PI) to 
stain dead cells. Specific lysis has been calculated as the percentage of all PI 
positive cells of all DiO positive cells. ADCC has been calculated as the amount of 
cells, which have been lysed due to Rituximab treatment compared to the amount of 
target cells lysed already without Rituximab. The ADCC assay was performed by 
Christina Kiecke. 
No Rituximab-mediated lysis of target cells could be observed without the addition of 
NK cells for Karpas422 or Ramos (Figure 3-29 A and B). The addition of IL10 alone 
did not lead to any lysis. Karpas422 cells as well as Ramos cells have been lysed by 
NK cells less effectively after pretreatment with IL10. In accordance to this, ADCC 
was lower in cells treated with IL10 in addition to Rituximab (Figure 3-29 C). This was 
most pronounced in Ramos treated with 0.1µg/ml Rituximab. A Student’s t-test was 
used to calculate significance.  
Therefore, IL10 induces changes probably of surface expression of certain proteins 




Figure 3-29 Rituximab-mediated ADCC of target cells is inhibited after IL10 treatment. 
NK cells have been purified according to the method described in 2.9.11 Karpas422 and Ramos cells 
have been treated with 100ng IL10/ ml cells. 12h later these cells have been labeled with DiO, 
followed by 4h incubation with different concentrations of Rituximab, with or without NK cells, with or 
without IL10. Specific lysis of the target cells Karpas422 (A) and Ramos (B) has subsequently been 
determined as the percentage of PI positive cells of all DiO-labeled cells using FACS analysis. ADCC 
has been calculated as the amount of cells, which have been lysed due to Rituximab treatment 
compared to the amount of target cells lysed without Rituximab. Significance of ADCC has been 
determined using Student’s t-test. The mean of two independent experiments is shown. 
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4 Discussion  
This thesis aimed at the elucidation of the role of IL10 gene variations and elevated 
IL10 serum levels for the treatment outcome of aNHL. The prognostic relevance of an 
increased number of IL10 gene variations in independent cohorts of aNHL patients 
was investigated. Furthermore, the influence of so called regulatory gene variations 
within the IL10 gene locus on interindividual IL10 production was examined in LCLs. 
Despite the fact that approximately 90% of aNHL originate from B cells and IL10 acts 
as a potent growth factor for these cells, most studies on IL10 gene regulation were 
implemented in T cells and macrophages. Hence, molecular mechanisms 
contributing to IL10 gene regulation in B cells, including histone modifications, were 
assessed in this thesis. 
4.1 Characterization of elevated IL10 serum levels and IL10 gene variations 
with respect to the clinical outcome of aNHL patients treated with or 
without Rituximab 
Within this thesis associations of high IL10 levels with the treatment outcome of 
aNHL patients treated with or without Rituximab have been assessed in a 
comparably large cohort of 523 patients. High serum levels of IL10 have been shown 
to be significantly associated with worse treatment outcome (Figure 3-5). No 
conspicuous differences could be observed between patients treated with Rituximab 
or CHOP alone. Therefore, at least within the RICOVER-60 trial the addition of 
Rituximab does not overcome adverse prognostic features reported here for high 
IL10 serum levels.  
In line with this, also T-NHL patients with high IL10serum levels showed a trend 
towards shorter survival (Figure 3-7). However, due to the low number of patients at 
the end of the observation time, the survival curves become instable and the results 
should therefore not be over interpreted. 
Our observations that high pretreatment serum levels of IL10 are associated with 
worse treatment outcome are in line with several previous studies (Blay et al., 1993; 
Lech-Maranda et al., 2010; Lech-Maranda et al., 2006). Two of these studies were 
conducted on DLBCL patients by Lech-Maranda and colleagues (Lech-Maranda et 
al., 2010; Lech-Maranda et al., 2006). Patients included into these trials have been 
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treated with anthracyclin-based regimens. The standard therapy today is CHOP 
therapy in combination with Rituximab. Rituximab mediates downregulation of the 
anti-apoptotic protein Bcl-2 via downregulation of autocrine IL10 production, which 
leads to chemosensitization of the B cell lymphoma cells (Alas et al., 2001). 
Therefore, the authors stated that Rituximab treatment may abolish the adverse 
effects of elevated IL10 serum levels on treatment outcome. Furthermore, they 
concluded that studies evaluating the effect of high IL10 serum levels on treatment 
outcome of patients treated with Rituximab would be important (Lech-Maranda et al., 
2010; Lech-Maranda et al., 2006).  
Until very recently, no studies have been published assessing whether high serum 
levels of IL10 would also be a negative predictive factor in patient cohorts treated 
with Rituximab. During the writing process of this thesis, one study was published, in 
which this question was assessed in 70 patients with DLBCL (Gupta et al., 2012). 
Supporting our findings, also this study found high IL10 serum levels to be 
associated with a worse treatment outcome, shown by shorter EFS periods.  
In contrast to the here reported findings, other studies reported no correlation of high 
IL10 serum levels and treatment outcome (Cortes et al., 1995; Ozdemir et al., 2004; 
Stasi et al., 1994). These studies have been conducted in relatively small cohorts. 
Moreover, these patient cohorts differ to ours with respect to general treatment 
outcome. In the study of Ozdemir and colleagues for example 71% of the patients 
experienced a complete remission and 21% a partial remission. This was a much 
better outcome compared to patients from the trails used in this thesis. Stasi and 
colleagues reported that high IL10 levels together with high sIL2R levels are indeed 
of prognostic relevance. No study reported a superior treatment outcome for patients 
with high IL10 levels.  
Taken together, the results indicate that high serum levels of IL10 are most likely an 
adverse prognostic factor in aNHL patients and that these adverse prognostic 
features are not overcome by Rituximab treatment.  
 
So far a potential role of IL10 during the manifestation and progression of lymphomas 
is still debated (Lin and Karin, 2007; Mocellin et al., 2005). IL10 can act as a growth 
factor for normal and transformed B cells, leading to an enhanced proliferation of the 
lymphoma cells and exerts strong immunosuppressive activity, which allows 
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malignant cells to escape from an active immune response (Mocellin et al., 2005; 
Voorzanger et al., 1996). But also the opposite has been reported (Lin and Karin, 
2007; Mocellin et al., 2005). The immunosuppressive properties of IL10 have been 
linked to an inhibition of tumor development and progression, which is supported by 
inflammatory processes. However, as high IL10 serum levels have been found 
repeatedly to be associated with a worse treatment outcome, the probability that IL10 
has cancer inhibiting properties in aNHL is low. 
Tumor progression, invasion, metastasis and angiogenesis are supported by a 
persistent inflammatory tumor microenvironment. Deregulation of certain cytokines, 
released by tumor cells or cells in the microenvironment, can lead to a sustained 
inflammatory response. Even though IL10 inhibits the production of proinflammatory 
cytokines like TNF-, high levels of IL10 have been shown to be associated with an 
adverse prognosis. Therefore, one could speculate that the normal negative feed-
back loop, leading to inhibition of TNF- by IL10 is impaired. Instead of inhibiting 
TNF- production, IL10 contributes to tumor progression by acting as an autocrine 
growth factor. Only recently, IL10 has been reported to activate JAK2 in certain 
DLBCL cell lines, leading to STAT3 activation and upregulation of c-myc expression, 
an important survival factor for DLBCL (Gupta et al., 2012).  
However, it also has to be taken into account that increased IL10 serum levels in 
aNHL patients could solely reflect an active immune response against more 
aggressive disease and the attempt to stop chronic inflammation processes not 
controlled by the host.  
To validate the obtained results, optimally a patient cohort that can be divided into a 
CHOP and an R-CHOP treatment arm should be used. Due to ethical reasons, 
patients are no longer treated only with CHOP nowadays, as R-CHOP has been 
shown to result in a better treatment outcome. The DSHNHL recruited patients for a 
follow up clinical trial of RICOVER-60, the CHOP-R-ESC trial. These patients all 
received R-CHOP. Serum of 258 patients was available. IL10 serum levels of these 
samples have been measured via ELISA and the data are currently evaluated in the 




In addition to this, in vitro analyses revealed a negative effect of IL10 on Rituximab-
mediated antibody dependent cellular cytotoxicity (ADCC) but not complement 
dependent cytotoxicity (CDC) (Figure 3-29). 
The B cell lymphoma cell lines Ramos and Karpas422 were treated for 12h with 
recombinant human IL10 before adding of NK cells together with Rituximab in 
different concentrations. This means that the effect of IL10 on the target cells rather 
than the effect on NK cells was investigated. Natural cytotoxicity of NK cells as well 
as NK cell-mediated ADCC are regulated by HLA/KIR interactions (Borgerding et al., 
2010). An absence or blocking of the inhibitory signal mediated by HLA/KIR 
interactions has been found to cause an enhanced Rituximab-mediated ADCC.  
IL10 expression as well as treatment with recombinant IL10 has been reported to 
induce a reduction of HLA class I expression in different tumour entities (Kundu and 
Fulton, 1997; Kurte et al., 2004; Petersson et al., 1998). The same was found for 
EBV-induced IL10 expression in B cells (Zeidler et al., 1997). The reduction of HLA 
class I expression increased the sensitivity of target cells to natural cytotoxicity of NK 
cells and according to the results of Borgerding et al. should lead to an increased 
Rituximab-mediated ADCC. This was not the case in our experimental set up. HLA 
class I expression has been assessed as a general control prior to the ADCC assay 
in the examined cell lines. IL10 treatment did not lead to conspicuous changes in 
overall surface expression of HLA class I. 
Therefore, the hypothesis that IL10 treatment leads to increased expression of a 
nonclassical HLA class Ib molecule, HLA-G seems more likely. The IL10-induced 
upregulation of HLA-G by tumor cells has been found to inhibit lysis mediated by 
natural cytotoxicity of NK cells (Urosevic and Dummer, 2003). Therefore, it could also 
be associated with a decreased Rituximab-mediated ADCC. Flow cytometric analysis 
of HLA-G expression with and without IL10 treatment would be a useful tool to test 
this hypothesis.  
However, an effect of IL10 on NK cells cannot be excluded, as these have been co-
incubated for 4h during the ADCC assay. Opposing effects of IL10 on NK cells have 
been reported. IL10 has been shown to inhibit production of IFN-ɣ and TNF by NK 
cells in vitro (Moore et al., 2001). Nevertheless, NK cell-mediated cytotoxicity against 
Daudi cells has been enhanced by IL10, albeit to a lesser extent compared to IL2 
(Mocellin et al., 2004). The NK cells used here had been cultivated with IL2 over 
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night before the ADCC assay was performed. Therefore, the addition of IL10 to NK 
cells does not further enhance cytotoxic activity but rather inhibits it. Additional 
assays, with different conditions for overnight culture of NK cells, prior to the ADCC 
might be useful to analyse this. 
Taken together, it could be shown that elevated serum levels are an adverse 
prognostic factor for aNHL treatment outcome. This was still observed in patients 
treated with Rituximab. Furthermore, it was observed that IL10 treatment of B cells is 
associated with a decrease in Rituximab-mediated ADCC. Therefore, Rituximab 
treatment does not overcome adverse prognostic features of elevated IL10 levels 
and in addition an important Rituximab-mediated anti-cancer response seems to be 
decreased by elevated IL10 levels. 
 
Survival analyses have been conducted to assess associations between IL10 gene 
variations and treatment outcome. 
In a previous study, aNHL patients carrying the IL10-7400DelDel genetic variation have 
been found to be characterized by a worse treatment outcome compared to carriers 
of the other two genotypes of IL10-7400In/Del (Kube et al., 2008). However, this 
negative predictive effect of IL10-7400DelDel could not be validated in the extended 
NHL-B cohort (Figure 3-2). 
Moreover, the IL10-7400DelDel gene variation was associated with a better treatment 
outcome in patients from the RICOVER-60 trial (Figure 3-4). This effect was not 
restricted to patients treated with Rituximab. Patients from the CHOP cohort, who 
have been treated similar to patients within the NHL-B trial also showed an 
insignificant trend towards better treatment outcome for carriers of IL10-7400DelDel. 
However, it has to be taken into account that these two cohorts differ to some extent 
in terms of age, IPI risk score, extranodal involvement, general OS as well as period 
of patient accrual (1993-2000 for NHL-B and 2000-2005 for RICOVER-60). General 
treatment conditions within the clinics improved during these years. 
In the RICOVER-60 cohort several IL10 gene variations showed significant 
associations with OS and EFS. Based on haplotype analyses (Figure 3-1) the         




The IL10-11.668AA genotype showed significant associations with a better treatment 
outcome in the RICOVER-60 as well as the R-CHOP cohort. The same trend was 
observed for the CHOP cohort (Figure 3-3). 
The relative risk for shorter OS and EFS periods, estimated in multivariate analyses 
adjusted to IPI factors was lowest in the R-CHOP cohort compared to the other two 
cohorts (Table 3-6). The confidence intervals of the R-CHOP cohort and the 
RICOVER-60 do not include the value 1. However, the trend for IL10-11.668AA 
observed within the CHOP cohort was the same as for the other two cohorts and it 
has to be taken into account that the confidence intervals of the R-CHOP and the 
CHOP cohort overlap to some extent. This means that the “true relative risk” could be 
the same for both cohorts.  
Notably, no association of better or worse treatment outcome with IL10-11.668G/A was 
observed for the NHL-B cohorts. However, as mentioned above, the RICOVER-60 
cohorts and the NHL-B cohorts differ with respect to clinical and histological 
characteristics as well as the period of patient accrual. 
However, before a final conclusion about the prognostic relevance the IL10-11.668G/A 
can be drawn, this effect has to be validated in another patient cohort. DNA was 
available for 258 patients of the above mentioned CHOP-R-ESC trial. Genotyping for 
IL10 gene variations has already been conducted and the data are currently 
evaluated in the IMISE in Leipzig.  
Interestingly, the IL10-11.668G/A gene variation is located within CNS-12, which has 
been shown to possess enhancer activity by ChIP analyses using the H3K4me1 
antibody (Figure 3-17). Even though it still has to be validated that IL10-11.668G/A is of 
prognostic relevance for treatment outcome, this finding raises the possibility that this 
gene variation could be involved in IL10 gene regulation. Based on the results of the 
survival analyses, this would indicate that IL10-11.668AA somehow causes low IL10 
expression. 
IL10-11.668A is in Linkage Disequilibrium (LD) with the A-G/A-A haplotypes (compare 
to figure 1-3 and figure 3-1), formed by IL10-3538A/T, IL10-2812G/A and IL10-2726C/A, 
which is postulated to be associated with low IL10 production in whole blood cultures 
stimulated with LPS (Gibson et al., 2001). However, IL10-11.668A is also observed 
together with the GCC haplotype (IL10-1087G, -824C, -597C) as well as the IL10-7400Del, 
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which have both been described to be associated with higher IL10 production 
capacities (Crawley et al., 1999; Rieth et al., 2004).  
This issue has been assessed within this thesis using LCLs (chapter 3.2). No 
association of an IL10 gene variation could be identified with high or low IL10 
production capacities using this system, even though high number of LCLs was 
analysed. Therefore, it is likely that differences in IL10 production capacities of LCLs 
could be influenced by other factors associated with EBV infection, the “age” of each 
cell line or an interaction of these factors with IL10 gene variations. The level of one 
EBV associated protein, LMP1 was assessed as it was shown to induce IL10 
expression in Burkitt’s lymphoma cell lines (Vockerodt et al., 2001). No association of 
LMP1 expression with IL10 production was found. Maybe other EBV gene products, 
like EBV-encoded small proteins, expressed in LCLs, have a higher influence 
(Samanta et al., 2008). Moreover, it has been observed that LCLs, comprised of 
polyclonal cell populations directly after EBV immortalization, become monoclonal 
over time (data not shown). This could further influence IL10 expression levels. 
However, no conspicuous differences have been observed between old LCLs and 
newly established LCLs.  
Even though LCLs possess different IL10 production capacities, they were found to 
be limited for their utilization as model for the analysis of the influence of IL10 gene 
variations on IL10 production. No answer can be given to the question on how      
IL10-11.668G/A influences IL10 production capacity. However, the fact that IL10-
11.668G/A is located within an important regulatory region in B cells underlines the 
importance of further elucidation of its function for IL10 gene regulation. This could 
be conducted for example by luciferase assays comparing the effect of the A- to the 
G-allele on a basic promoter fragment. In addition PBMCs derived from voluntary 
blood donors might be a better model for the elucidation of the influence of this gene 
variation on IL10 production. Two different stimuli, LPS and cAMP could be used for 
this purpose. 
IL10 gene variations are thought to be predictive for treatment outcome due to the 
fact that they influence IL10 production. Therefore, one might ask why searching for 
these gene variations should be conducted, instead of using IL10 serum levels. Both 
approaches, IL10 gene variations and IL10 serum levels as prognostic factors for 
aNHL outcome, possess important advantages and disadvantages. IL10, as well as 
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other cytokines, is very unstable in serum (van der Linden et al., 1998). Therefore, 
the logistic effort is much higher. Serum has to be kept cool or better frozen. This is 
especially challenging if samples have to be delivered to external institutions for 
diagnosis. Compared to this, DNA in blood samples is stable and the results of 
genotyping assays are more reliable and reproducible. 
Clinical trials for testing new therapeutic regiments conducted in the future should be 
designed in a way that DNA samples and pre-treatment serum samples should be 
collected from all patients. Thereby, the number of patients included into genotyping 
analyses would be enlarged and the validity of respective survival analyses would be 
higher. Validation cohorts should be included into the study design for the validity of 
both, the clinical trial itself and the prognostic relevance of gene variations. 
Furthermore, it would be interesting to analyse IL10 serum levels and IL10 gene 
variations of patients who achieved complete remission and those who relapsed to 
answer the question if these two factors have an impact on the likelihood of an 
relapse. 
In conclusion the here reported results provide evidence that deregulation of IL10, 
leading to elevated IL10 levels, is an important factor for the clinical course of aNHL. 
High serum levels of IL10 have been shown to be an adverse prognostic factor. 
Furthermore, an inherited far distal IL10 gene variations, IL10-11.668G/A could be 
associated with treatment outcome of aNHL. 
4.2 Distal enhancer activity is involved in IL10 gene regulation in B cells 
In this work several B cell lines with inducible or constitutive IL10 expression have 
been used as model systems for the analysis of mechanisms contributing to IL10 
gene regulation in B cells, a goal that received only minor attention in the past. Using 
specific pathway inhibitors the PKC, PI3K and the ERK signalling pathways were 
demonstrated to be involved in IL10 gene regulation in the L428 cell line.  
ChIP experiments revealed certain histone modifications to be associated with IL10 
expression. These histone modifications could be localized to specific regions of the 
IL10 gene locus. Some of these regions are common to all analysed cell lines while 
others are more unique. The most important finding of the ChIP experiments was that 
far distal regions around CNS-12 are characterized by mono-methylation of lysine 4 
at Histone 3 (H3K4me1), an enhancer-specific histone modification in B cells with 
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active IL10 expression. Moreover, a long ncRNA has been shown to be transcribed 
from the IL10 gene locus in all analysed B cell lines. 
 
Tri-methylation of lysine 4 at Histone 3 (H3K4me3) has been detected at the proximal 
promoter regions as well as at the coding regions of IL10 in all three B cell lines with 
active IL10 transcription but not in unstimulated L428 by ChIP (Figure 3-17 and 3-18, 
middle). Acetylation of H3 (acH3) has been observed basically at the same regions 
as H3K4me3 (Figure 3-17 and 3-18, top). These findings are in line with previously 
reported data. H3K4me3 has been found to be associated with RNA polymerase II 
(RNA-Pol II) binding (Guenther et al., 2007). H3K4me3 and RNA-Pol II binding are 
generally detected at promoters and immediately downstream of TSS. Most studies 
found H3K4me3 together with acH3 to be associated with actively transcribed genes 
(Koch et al., 2007; Santos-Rosa et al., 2002; Schneider et al., 2004). The fact that 
this modification could not be detected at regions further upstream indicates that no 
other TSS or active promoters are located within the examined regions. Regarding 
the IL10 gene locus this modification was firstly described here, therefore no 
comparison to other cell types can be made. 
In cells with active IL10 expression acH3 could be detected at the proximal promoter 
and the IL10 coding regions. Almost no acH3 was found in unstimulated L428 cells. 
At the CNS+6, which corresponds to CNS+6.45 in mice, acH3 could only be detected 
in the BJAB cell line. This indicates that mechanisms of IL10 gene regulation even 
differ between B cell lines. 
Interestingly, a slight increase in acH3 was also observed at more distal parts of the 
IL10 gene locus, around CNS-12, indicating that these regions could also be of 
importance for IL10 gene regulation.  
In contrast to H3K4me3, acH3 at the IL10 gene locus was assessed in the past in 
macrophages and T cells. In macrophages acH3 has been observed at the TSS of 
IL10 and at the HSS at -4.5kb, even without the IL10-inducing stimulus IC/LPS 
(Saraiva et al., 2005). However, the level of acH3 changes after stimulation with 
IC/LPS within the proximal IL10 promoter and the time course of acH3 resembles 
that of IL10 mRNA induction (Zhang et al., 2006). This means acH3 is increased 
when IL10 expression is up-regulated in macrophages. In T cells the infection with a 
GATA3 containing retrovirus leads to induction of IL10 expression accompanied by 
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acH3 at three examined regions of the IL10 locus, including CNS+6.4 (Shoemaker et 
al., 2006). Therefore, our data obtained in the three B cell lines, L428, BJAB and 
MC116 are only partially in line with the data obtained in macrophages and Th cells. 
Similarities are found in terms of inducibility of acH3 at the proximal promoter and the 
IL10 coding regions. No acH3 could be seen at the postulated macrophage specific 
HSS-4.5 (Saraiva et al., 2005). 
In addition to acH3 and H3K4me3, H3K4me1 has been assessed at the IL10 locus 
(Figures 3-17 and 3-18, bottom). This modification has been associated with 
enhancer activity (Heintzman et al., 2007). H3K4me1 has been observed at the 
proximal promoter as well as in the coding regions of IL10. In BJAB and MC116 the 
proximal promoter regions show higher enhancer activity than regions within the 
coding region. In L428 this enhancer activity was inducible at the proximal promoter 
but in the coding region it was already detectable in unstimulated cells. Therefore, 
these regions seem to have an intrinsic enhancer activity, which may reflects a 
certain competence rather than activity in unstimulated L428, indicating that an 
enhancer element could be located in Intron 2. Taken together, this implies that these 
proximal promoter regions act as enhancers during active transcription of IL10 in all 
three B cell lines.  
The most interesting observations were made in more distal parts of the IL10 gene 
locus around CNS-12. In all three cell lines H3K4me1 could be observed at CNS-12, 
whereby this was most pronounced in L428 stimulated with PMA. Even though 
H3K4me1 was detected in unstimulated cells, the levels of H3K4me1 increased 
considerably after PMA stimulation. In BJAB and in MC116 low levels of H3K4me1 
could be detected at CNS-12. These findings provide evidence that this region could 
be of high importance for IL10 gene regulation in B cells.  
H3K4me1 could also be detected at the second important CNS, CNS+6, containing a 
putative AP1 binding site. In L428 it could be detected without prior stimulation and 
considerably high levels of H3K4me1 could be observed in BJAB at CNS+6. 
In BJAB, H3K4me1 was also found to be localized HSS-4.5, a putative NF-B 
binding site. This indicates that this region is not only relevant for IL10 gene 
regulation in macrophages but also in some B cells. Notably, NF-B cannot be a 
relevant transcription factor for IL10 expression in L428. In L428 NF-B is 
constitutively active and no IL10 is expressed without additional stimulation with 
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PMA. These results underline once more that even in different B cell lines or B cell 
lymphomas different molecular mechanisms seem to contribute to IL10 gene 
regulation. 
As H3K4 methylation of the IL10 gene locus in immune cells has been observed for 
the first time here, no comparison to other cell types can be made. The only 
publication that addressed was a review about histone modifications in T cells (Lee et 
al., 2009b). The authors mentioned that methylation of H3K4 at several CNS is 
higher in Th2 cells than in Th1 cells as so far unpublished results. But whether they 
assessed mono- and/or tri-methylation was not described (Lee et al., 2009b). 
H3K4me1 was found to be distributed in a cell type specific manner and was 
associated with differences in gene expression (Heintzman et al., 2009; Koch et al., 
2007). In a recent work on different T cell subsets the authors came to a similar 
conclusion and stated that it is likely that transcriptional enhancers are primary 
mediators of cell-type specific patterns of gene expression (Tian et al., 2011). This 
underlines the importance of assessing enhancer regions for elucidating mechanisms 
of gene regulation in different cell types. Future studies should assess these 
modifications also in macrophages and T cells to elucidate cell type specific 
modification patterns. 
As mentioned above (chapter 4.1) the gene variation IL10-11668G/A is located within 
CNS-12. Therefore, the finding that this is an enhancer region in transformed B cell 
lines could also be of clinical relevance. It would be interesting to know whether CNS-
12 also has enhancer activity in B cells derived from primary lymphoma material. 
Luciferase assays would allow a validation of enhancer activity of these regions in B 
cells. Plasmids containing a functional basic IL10 promoter could be used to address 
this question. Furthermore, transcription factor binding at the IL10 gene locus could 
be assessed by ChIP. Computer algorithm-based prediction of transcription factor 
binding sites, as well as the knowledge provided here about the pathways involved in 
IL10 induction in L428 could be used to find suitable candidate transcription factors. 





4.3 A long ncRNA is transcribed from the IL10 gene locus 
Encouraged by the study of Jones and Flavell (Jones and Flavell, 2005), who 
detected transcription of ncRNA from certain CNS and HSS, the transcription of 
ncRNA from the IL10 gene locus was assessed in this thesis. In their study most of 
the sequences transcribing ncRNA have been shown to possess enhancer activity by 
luciferase assays. The actual length of the ncRNA was not described and the 
publication indicated that several small ncRNAs were transcribed from CNS. Until 
now nothing is known about the function of the ncRNA. 
Only approximately 2% of the human genome consist of protein-coding genes even 
though at least 90% are actively transcribed (Gibb et al., 2011). Increasing evidence 
exists that these 90% of human DNA are transcribed into molecules that are 
ncRNAs. This ncRNA can be grouped into small and long ncRNAs. The group of the 
small ncRNAs includes for example the better characterized miRNAs. Little is known 
so far about long ncRNAs, which range between 200nt to 100kb in length, even 
though an increasing attention to this subject is reflected by an increasing amount of 
publications (Gibb et al., 2011). Transcription of the ncRNA from the IL10 gene locus 
in the B cell lines used here was detected from all analysed regions. Therefore, it is 
likely that the ncRNA is one long transcript of at least 23kb. 
Even though some long ncRNAs have been described to mediate gene repression, 
for example during imprinting processes (Saxena and Carninci, 2011), the ncRNA 
detected here was associated with activation of gene expression from the IL10 gene 
locus. In line with this, most genome wide studies suggest that transcription of long 
ncRNA is positively correlated with activity of neighboring genes (Orom and 
Shiekhattar, 2011). These long ncRNAs could mediate their effects though different 
mechanisms. They could solely be a byproduct of transcription, helping to open the 
DNA to activate nearby genes. This has been shown to be a stepwise process during 
which ncRNA is transcribed, leading to an open chromatin configuration as well as 
translocation of RNA-Pol II (Hirota et al., 2008). In contrast to this, it was found that 
knock-down of certain long ncRNAs abolished their enhancer activity and therefore 
the ncRNA itself was important (Orom et al., 2010). One hypothesis how this 
enhancer function is achieved, is that ncRNA mediates the formation of chromatin 
loops between enhancer and promoter region, allowing transcriptional activators to 
be recruited to respective regions. Alternatively, ncRNA could be endowed with 
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enzymatic activity to mediate modifications of chromatin or the DNA (Orom and 
Shiekhattar, 2011). Several other mechanisms have been proposed. 
As an oligo-dT primer has been used for reverse transcription in some assays in the 
L428 cell line during this work, it can be concluded that the ncRNA is polyadenylated. 
This means it is transcribed by RNA-Pol II. This already excludes some kinds of long 
ncRNAs described in the literature, like enhancer RNAs, which are non-
polyadenylated RNAs transcribed from enhancers (Kim et al., 2010). Notably, no 
H3K4me3 could be detected within the examined distal regions by ChIP. As this is 
usually found to be associated with RNA-Pol II binding, it is likely that the 
transcription start of the ncRNA lies even further upstream than -16.400bp or within 
the IL10 coding region, for example in introns.  
In order to further characterize the ncRNA transcribed from the IL10 gene locus, to 
allow conclusions regarding its function, several tools are available. So far, it is 
known that the ncRNA is transcribed from several regions within a 23kb range of the 
IL10 gene locus. Regions further upstream or downstream still need to be included 
into this analysis. Northern Blot analysis could help to estimate its exact length and if 
different splice variants could be involved. Furthermore, it would be useful to analyse 
the 3’ and 5’-end of the ncRNA by RACE-PCR. This would also allow the 
characterization of different splice products, if these exist.  
Even though a final statement about the long ncRNA described herein cannot be 
made, it should be pointed out that deregulation of several long ncRNAs have been 
found to be associated with cancer (Gibb et al., 2011). Moreover, long ncRNAs have 
been shown to be transcribed in a developmental and tissue specific manner. 
Therefore, the elucidation of its function for IL10 gene expression in B cells or B cell 













The identification of biological factors which influence treatment outcome of aNHL is 
an essential tool for the improvement of individual treatment strategies.  
The finding that high serum levels of IL10 are associated with worse treatment 
outcome of aNHL indicates that deregulation of IL10, leading to elevated IL10 serum 
levels, is involved in the progression of this disease. Furthermore, it was shown for 
the first time in a large cohort of 523 aNHL patients, that the observed adverse 
prognostic features of elevated IL10 serum levels are not overcome by Rituximab 
treatment. Therefore, Rituximab-mediated downregulation of IL10 does not seem to 
be a dominant factor for the treatment outcome of aNHL. In addition to this, IL10 
treatment of B cells seems to reduce Rituximab-mediated ADCC, an important 
Rituximab-mediated anti-cancer response. Furthermore, this study provides evidence 
that a far distal IL10 gene variation, IL10-11.668G/A, which is located within CNS-12, 
could be associated with treatment outcome of aNHL patients. It remains to be 
elucidated if and how the IL10-11.668G/A gene variation influences differences in 
interindividual IL10 production. To validate the results obtained here for patients from 
the RICOVER-60 trial, IL10 gene variations and serum levels have been determined 
in 258 patients from a follow-up trial, the CHOP-R-ESC, and are currently evaluated. 
ChIP experiments in different B cell lines revealed for the first time that regions 
around CNS-12 and regions further upstream are characterized by the enhancer-
specific histone modification, H3K4me1. This indicates that far distal regions of the 
IL10 gene locus could be involved in regulation of IL10 expression in transformed B 
cells. These findings underline the importance to include far distal IL10 gene 
variations into survival analyses, to identify gene variations with prognostic 
significance. Moreover, it was shown that active IL10 expression is accompanied by 
transcription of a very long ncRNA from the IL10 gene locus. Further characterization 
of the ncRNA in different B cell lines combined with analyses of enhancer activity by 
luciferase assays or transcription factor binding by ChIP could help to elucidate the 
exact role of the distal regions for IL10 gene regulation.  
Taken together, this study suggests an important role for IL10 in the progression of 
aNHL. Furthermore it provides evidence that far distal conserved regions as well as a 
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843 (89.5%) 1256 (89.9%) 409 (85.7%) 609 (85.8%) 434 (93.3%) 647 (93.9%) 
  Lymphoblastic 1 (0.1%) 2 (0.1%) 0 (0%) 0 (0%) 1 (0.2%) 2 (0.3%) 
  Diffuse large 594 (63.1%) 913 (65.3%) 275 (57.7%) 424 (59.7%) 319 (68.6%) 489 (71.0%) 
    Centroblastic 454 (48.2%) 687 (49.1%) 214 (44.9%) 326 (45.9%) 240 (51.6%) 361 (52.4%) 
    Immunoblastic 72 (7.6%) 114 (8.1%) 23 (4.8%) 35 (4.9%) 49 (10.5%) 79 (11.5%) 
    Anaplastic 20 (2.1%) 28 (2.0%) 13 (2.7%) 17 (2.4%) 7 (1.5%) 11 (1.6%) 
    T-cell rich 13 (1.4%) 24 (1.7%) 7 (1.5%) 16 (2.3%) 6 (1.3%) 8 (1.2%) 
    NOS 35 (3.7%) 60 (4.3%) 18 (3.8%) 30 (4.2%) 17 (3.7%) 30 (4.4%) 
  Mediastinal B cell 17 (1.8%) 25 (1.8%) 16 (3.4%) 21 (3.0%) 1 (0.2%) 4 (0.6%) 
  Follicular 81 (8.6%) 105 (7.5%) 47 (9.9%) 63 (8.9%) 34 (7.3%) 42 (6.1%) 
  Mantle cell lymphoma 9 (1.0%) 16 (1.1%) 7 (1.5%) 10 (1.4%) 2 (0.4%) 6 (0.9%) 
  Burkitt lymphoma 30 (3.2%) 35 (2.5%) 10 (2.1%) 10 (1.4%) 20 (4.3%) 25 (3.6%) 
  Aggressive marginal zone 9 (1.0%) 14 (1.0%) 5 (1.0%) 10 (1.4%) 4 (0.9%) 4 (0.6%) 
  Unspecified for technical reasons* 53 (5.6%) 74 (5.3%) 26 (5.5%) 38 (5.4%) 27 (5.8%) 36 (5.2%) 
  NOS 49 (5.2%) 72 (5.1%) 23 (4.8%) 33 (4.6%) 26 (5.6%) 39 (5.7%) 
T cell 
97 (10.3%) 139 (9.9%) 67 (14.0%) 98 (13.8%) 30 (6.5%) 41 (6.0%) 
  Anaplastic large cell 65 (6.9%) 91 (6.5%) 50 (10.5%) 67 (9.4%) 15 (3.2%) 24 (3.5%) 
  Lymphoblastic 2 (0.2%) 3 (0.2%) 2 (0.4%) 3 (0.4%) 0 (0% 0 (0% 
  Peripheral T, unspecified 23 (2.4%) 31 (2.2%) 11 (2.3%) 18 (2.5%) 12 (2.6%) 13 (1.9%) 
  Angioimmunoblastic 2 (0.2%) 3 (0.2%) 0 (0%)  1 (0.1%) 2 (0.4%) 2 (0.3%) 
  Extranodal NK/T, nasal type 1 (0.1%) 6 (0.4%) 1 (0.2%) 5 (0.7%) 0 (0%)  1 (0.1%) 
  Unspecified for technical reasons* 1 (0.1%) 1 (0.1%) 0 (0%) 0 (0%) 1 (0.2%)  1 (0.1%) 

































B cell 591 (97.8%) 1160 (94.9%) 296 (98.3%) 582 (95.1%) 295 (97.4%) 569 (93.3%) 
  lymphoblastic 1 (0.2%) 1 (0.1%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.2%) 
  DLBCL 499 (82.6%) 949 (77.7%) 253 (84.1%) 475 (77.6%) 246 (81.2%) 474 (77.7%) 
    centroblastic 286 (47.4%) 516 (42.2%) 150 (49.8%) 263 (43%) 136 (44.9%) 253 (41.5%) 
    immunoblastic 35 (5.8%) 63 (5.2%) 18 (6.0%) 36 (5.9%) 17 (5.6%) 27 (4.4%) 
    plasmoblastic (DLBCL) 2 (0.3%) 7 (0.6%) 0 (0.0%) 0 (0.0%) 2 (0.7%) 7 (1.1%) 
    anaplastic large cell 11 (1.8%) 19 (1.6%) 4 (1.3%) 6 (1.0%) 7 (2.3%) 13 (2.1%) 
    T cell-rich 9 (1.5%) 18 (1.5%) 7 (2.3%) 13 (2.1%) 2 (0.7%) 5 (0.8%) 
    DLBC, NOS 149 (24.7%) 313 (25.6%) 68 (22.6%) 147 (24%) 81 (26.7%) 166 (27.2%) 
  primary mediastinal B cell lymphoma 7 (1.2%) 13 (1.1%) 6 (2.0%) 10 (1.6%) 1 (0.3%) 3 (0.5%) 
  Follicular grade III 57 (9.4%) 116 (9.5%) 29 (9.6%) 65 (10.6%) 28 (9.2%) 51 (8.4%) 
  Follicular grade III + DLBCL 32 (5.3%) 55 (4.5%) 16 (5.3%) 32 (5.2%) 16 (5.3%) 23 (3.8%) 
  Burkitt's lymphoma 6 (1.0%) 17 (1.4%) 3 (1.0%) 8 (1.3%) 3 (1.0%) 9 (1.5%) 
  Burkitt-like 4 (0.7%) 8 (0.7%) 2 (0.7%) 5 (0.8%) 2 (0.7%) 3 (0.5%) 
  Mantle cell blastic 3 (0.5%) 17 (1.4%) 1 (0.3%) 6 (1.0%) 2 (0.7%) 11 (1.8%) 
  aggresive marginal 4 (0.7%) 13 (1.1%) 2 (0.7%) 5 (0.8%) 2 (0.7%) 8 (1.3%) 
  Unclassified (technically insufficient) 11 (1.8%) 22 (1.8%) 5 (1.7%) 9 (1.5%) 6 (2.0%) 13 (2.1%) 
  Other lymphoma or no lymphoma 6 (1.0%) 27 (2.2%) 2 (0.7%) 15 (2.5%) 4 (1.3%) 12 (2.0%) 
T cell 1 (0.2%) 2 (0.2%) 0 (0.0%) 1 (0.2%) 1 (0.3%) 1 (0.2%) 
  Angioimmunoblastic T cell lymphoma  1 (0.2%) 1 (0.1%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.2%) 










Table A-2 Clinical and histological characteristics of the T-NHL patients analysed for IL10 gene 
variations in cytokine receptors  
Values in table are expressed as total number of patients and respective percentage are in 
parenthesis (%), unless otherwise indicated. * IPI= International Prognostic Index LDH >N, age >60 
years, ECOG >1, stage III/IV, and number of extranodal sites ≥2.Anaplastic large cell lymphoma 
(ALCL), Anaplastic lymphoma kinase (ALK), Peripheral T cell lymphoma, not otherwise specified 
(PTCL, NOS), Angioimmunoblastic T cell lymphoma (AILT), Natural Killer cell (NK), T cell lymphoma 
not otherwise specified (T cell, NOS) for other than technical reasons.(taken from the Manuscript 
“Circulating levels of TNF-receptor II are prognostic for patients with peripheral T cell Non-Hodgkin 







Patients characteristics (n=117) (n= 197) 
 








Age Median (Min.;Max.) 58 (18;78) 61 (18;78) 
Serum LDH > N 22 (18.8%) 45 (22.8%) 
Age Older than 60 y 50 (42.7%) 99 (50.3%) 
Performance status ECOG > 1  13 (11.1%) 31 (15.7%) 
Ann Arbor stage III,IV 47 (40.2%) 85 (43.2%) 
IPI* 
          low (IPI=0,1) 
          intermediate low (IPI=2) 
          intermediate high (IPI=3) 











No of extranodal sites >1  23 (19.7%) 36 (18.3%) 
Bulky tumor (>7,5 cm)  30 (25.7%) 51 (25.9%) 
B symptoms 45 (38.5%) 75 (38.1%) 
extranodal involvement 51 (43.6%) 88 (44.7%) 
study  
          NHL-B1/B2 








Histology   
ALCL/ALK+ 28 (23.93) 37 (18.78) 
ALCL/ALK- 34 (29.06) 68 (34.52) 
PTCL 28 (23.93) 44 (22.34) 
AILT 9 (7.69) 16 (8.12) 
T/NK 3 (2.56) 8 (4.06) 
Lymphoblastic 2 (1.71) 4 (2.03) 
Intestinal T/NK 0 (0) 1 (0.51) 
Hepatosplenic  1 (0.85) 1 (0.51) 
ALCL/ALK unknown 7 (5.98) 11 (5.58) 
T cell NOS 3 (2.56) 5 (2.54) 






Figure A-1 No significant association of IL10-7400DelDel with shorter survival rates 
Shown are the survival curves (Kaplan-Meier plots) for OS (A,C,E,G) and EFS (B,D,F,H) of aNHL 
patients from the NHL-B cohorts in comparison with all the genotypes of IL10-7400In/Del. A. OS of 
patients from NHL-B. B. EFS of patients from NHL-B. C. OS of patients from NHL-B1. D. EFS of 
patients from NHL-B1. E. OS of patients from NHL-B2. F. EFS of patients from NHL-B2. G. OS of 
patients from NHL-B_CCR-excluded. H. EFS of patients from NHL-B_CCR-excluded. P refers to the 
log-rank test. Patients at risk represents the number of patients which still can develop an event (OS 









Figure A-2 The IL10-11.668AA genotype is associated with longer survival rates for OS and EFS in 
patients from the RICOVER-60 cohort 
Shown are the survival curves (Kaplan-Meier plots) for OS (A,C,E) and EFS (B,D,F) of aNHL patients 
from the RICOVER-60 cohorts in comparison with all three genotypes of IL10-11.668G/A. A. OS of 
patients from RICOVER-60. B. EFS of patients from RICOVER-60.C. OS of patients from R-CHOP 
arm of RICOVER-60. D. EFS of patients from R-CHOP arm of RICOVER-60. E. OS of patients from 
CHOP arm of RICOVER-60. F. EFS of patients from CHOP arm of RICOVER-60. P refers to the log-
rank test. Patients at risk represents the number of patients which still can develop an event (OS or 
EFS) at defined time points. Significant values have been observed for OS and EFS rates for patients 




Figure A-3 The IL10-7400DelDel genotype is associated with longer survival rates for OS and EFS 
in patients from the R-CHOP cohort. 
Shown are the survival curves (Kaplan-Meier plots) for OS (A,C,E) and EFS (B,D,F) of aNHL patients 
from the RICOVER-60 cohorts in comparison with all three genotypes of IL10-7400In/Del. A. OS of 
patients from RICOVER-60. B. EFS of patients from RICOVER-60. C. OS of patients from R-CHOP 
arm of RICOVER-60. D. EFS of patients from R-CHOP arm of RICOVER-60. E. OS of patients from 
CHOP arm of RICOVER-60. F. EFS of patients from CHOP arm of RICOVER-60. P refers to the log-
rank test. Patients at risk represents the number of patients which still can develop an event (OS or 
EFS) at defined time points. A Significant association has been observed for OS rates for patients 








Table A-3 No associations between IL10 genotypes and IL10 high or IL10 low expressing LCLs. 
LCLs have been grouped according to the median IL10 gene expression (0.000762 NSM IL10/NSM 
β2m) into IL10 high and low expressing cells. Number and percentage of LCLs within each group, 
carrying different IL10 genotypes are shown for each analysed IL10 gene variation in a two-way 
summary table. Associations between respective gene variations with low or high IL10 gene 
expression were examined using Pearson X
2
 test. In case of n total ≠111 respective genotyping 
analysis was not successful. 
   
 IL10 low IL10 high total  














IL10-12806C/T rs17015865 TT 6 66.7 3 33.3 9 0.494 
  
CT 17 44.7 21 55.3 38  
  
CC 32 50.0 32 50.0 64  
total 55  56  111  
IL10-11777A/G rs4072227 GG 0 0 0 0,0 0 0.616 
  
AG 7 43,8 9 56,3 16  
  
AA 48 50,5 47 49,5 95  
total 55  56  111  
IL10-11668G/A rs4072226 AA 19 50,0 19 50.0 38 0.572 
  
AG 20 44,4 25 55,6 45  
  
GG 16 57,1 12 42,9 28  
total 55  56  111  
IL10-7400In/Del 7400In/Del DelDel 4 57,1 3 42,9 7 0.856 
  
InDel 19 50,0 19 50,0 38  
  
InIn 30 46,9 34 53,1 64  
total 53  56  109  
IL10-6752A/T rs6676671 TT 21 51,2 20 48,8 41 0.811 
  
AT 21 46,7 24 53,3 45  
  
AA 9 42,9 12 57,1 21  
total 51  56  107  
IL10-6208G/C rs10494879 CC 13 48,1 14 51,9 27 0.978- 
  
CG 21 47,7 23 52,3 44  
  
GG 19 50,0 19 50,0 38  
total 53  56  109  
IL10-3538T/A rs1800890 AA 11 47,8 12 52,2 23 0.801 
  
AT 21 46,7 24 53,3 45  
  
TT 23 53,5 20 46,5 43  
total 55  56  111  
IL10-2812G/A rs6703630 AA 7 58,3 5 41,7 12 0.610 
  
AG 20 52,6 18 47,4 38  
  
GG 27 45,0 33 55,0 60  
total 54  56  110  
IL10-2726C/A rs6693899 AA 7 46,7 8 53,3 15 0.696 
  
AC 26 54,2 22 45,8 48  
  
CC 22 45,8 26 54,2 48  
total 55  56  111  
IL10-1087A/G rs1800896 GG 17 51,5 16 48,5 33 0.876 
  
AG 14 45,2 17 54,8 31  
  
AA 21 47,7 23 52,3 44  
total 52  56  108  
IL10-824C/T rs1800871 TT 2 33,3 4 66,7 6 0.227 
  
CT 35 55,6 28 44,4 63  
  
CC 16 40,0 24 60,0 40  
total 53  56  109  
IL10-597C/A rs1800872 AA 2 33,3 4 66,7 6 0.227 
  
AC 35 55,6 28 44,4 63  
  
CC 16 40,0 24 60,0 40  
total 53  56  109  
IL10+4259A/G rs3024498 GG 20 58,8 14 41,2 34 0.263 
  
AG 7 58,3 5 41,7 12  
  
AA 27 42,9 36 57,1 63  
total 54  55  109  
IL10+5876C/T rs3024505 TT 0 0,0 2 100,0 2 0.083 
  
CT 13 38,2 21 61,8 34  
  
CC 41 56,2 32 43,8 73  




Table A-4 No associations between IL10 genotypes and IL10 high or IL10 low secreting LCLs. 
LCLs have been grouped according to the median IL10 secretion level measured via ELISA (737pg 
IL10/ml) into IL10 high and low secreting cells. Number and percentage of LCLs within each group, 
carrying different IL10 genotypes are shown for each analysed IL10 gene variation. Associations 
between respective gene variations with low or high IL10 secretion were examined using Pearson X
2
 
test. In case of n≠108 respective genotyping analysis was not successful. 
   
 IL10 low IL10 high total  














IL10-12806C/T rs17015865 TT 5 62,5 3 37,5 8 0.518 
  
CT 20 54,1 17 45,9 37  
  
CC 28 45,2 34 54,8 62  
total 53  54  107  
IL10-11777A/G rs4072227 GG 0 0 0 0 0 0.968 
  
AG 8 50,0 8 50,0 16  
  
AA 45 49,5 46 50,5 91  
total 53  54  107  
IL10-11668G/A rs4072226 AA 14 53,8 12 46,2 26 0.400 
  
AG 24 54,5 20 45,5 44  
  
GG 15 40,5 22 59,5 37  
total 53  54  107  
IL10-7400In/Del 7400In/Del DelDel 4 57,1 3 42,9 7 0.464 
  
InDel 20 55,6 16 44,4 36  
  
InIn 27 43,5 35 56,5 62  
total 51  54  105  
IL10-6752A/T rs6676671 TT 9 45,0 11 55,0 20 0.335 
  
AT 25 56,8 19 43,2 44  
  
AA 16 41,0 23 59,0 39  
total 50  53  103  
IL10-6208G/C rs10494879 CC 13 50,0 13 50,0 26 0.570 
  
CG 23 53,5 20 46,5 43  
  
GG 15 41,7 21 58,3 36  
total 51  54  105  
IL10-3538T/A rs1800890 AA 10 45,5 12 54,5 22 0.450 
  
AT 25 56,8 19 43,2 44  
  
TT 18 43,9 23 56,1 41  
total 53  54  107  
IL10-2812G/A rs6703630 AA 8 66,7 4 33,3 12 0.237 
  
AG 20 55,6 16 44,4 36  
  
GG 25 43,1 33 56,9 58  
total 53  53  106  
IL10-2726C/A rs6693899 AA 5 35,7 9 64,3 14 0.078 
  
AC 29 61,7 18 38,3 47  
  
CC 19 41,3 27 58,7 46  
total 53  54  107  
IL10-1087A/G rs1800896 GG 17 53,1 15 46,9 32 0.202 
  
AG 24 54,5 20 45,5 44  
  
AA 10 34,5 19 65,5 29  
total 51  54  105  
IL10-824C/T rs1800871 TT 2 33,3 4 66,7 6 0.379 
  
CT 16 42,1 22 57,9 38  
  
CC 33 54,1 28 45,9 61  
total 51  54  105  
IL10-597C/A rs1800872 AA 2 33,3 4 66,7 6 0.379 
  
AC 16 42,1 22 57,9 38  
  
CC 33 54,1 28 45,9 61  
total 51  54  105  
IL10+4259A/G rs3024498 GG 8 66,7 4 33,3 12 0.420 
  
AG 16 50,0 16 50,0 32  
  
AA 28 45,9 33 54,1 61  
total 52  53  105  
IL10+5876C/T rs3024505 TT 1 50,0 1 50,0 2 0.614 
  
CT 14 42,4 19 57,6 33  
  
CC 37 52,9 33 47,1 70  
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